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Abstract 
 
Pathogens are microbes that infect hosts and cause disease. There are many forms 
of pathogens, including: bacteria, viruses, parasites, and fungi. In particular, fungi are 
found throughout the environment, and as a result, humans are continuously exposed to 
these organisms. While in many cases our immune system provides protection against 
lethal disease, individuals with immune deficiencies are dramatically more susceptible to 
fungal disease. Conversely, fungal exposure causes over half of the pulmonary allergies 
and asthma experienced by otherwise healthy humans with normal immune function. 
The immune system is comprised of innate and adaptive components. The innate 
arm provides rapid and generalized protection to pathogen invasion, whereas the adaptive 
arm acquires specialized functions to combat specific microbes. T cells of the adaptive 
immune system express receptors that recognize molecules (i.e. antigens) uniquely 
produced by the pathogen. This allows T cells to mount highly potent responses against 
invading microbes while avoiding responses directed towards the host. T cells are 
particularly important in response to fungal infection. A selective elimination of T cells 
due to HIV infection results in more frequent and severe fungal disease. However, the 
allergy and asthma symptoms associated with fungal exposure in healthy individuals are 
also a direct result of inappropriate T cell responses.  
T cells come in many flavors and each T cell subset coordinates unique 
components of the immune response. Type-1 Helper (Th1) and Type-17 Helper (Th17) T 
cells generally contribute to protective anti-fungal immunity, whereas Type-2 Helper T 
(Th2) cells produced in response to many fungal infections positively correlate with 
disease severity and allergy symptoms. Another lineage of T cells, regulatory T (Treg) 
cells can inhibit the function of the helper T cells upon resolution of the infection. 
Mechanisms describing Th2 and Treg cell responses underlying fungal disease are ill 
defined. Thus, my thesis research aims to understand the induction, suppression, and 
downstream consequences of Th2 cells using a mouse model of pulmonary infection with 
the fungus, Cryptococcus neoformans. 
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INTRODUCTION 
 
Cryptococcus – a significant human pathogen 
Cryptococcosis is a mycotic disease caused by the basidiomycete, Cryptococcus. 
The saprophytic fungus thrives in the environment by feeding on decaying organic 
matter. Cryptococcus can be isolated from animal excreta and superficial surfaces of trees 
and soil (1-3). When these surfaces are disturbed, aerosolized cryptococcal yeasts or 
spores are inhaled into the lower respiratory tract of terrestrial vertebrates where they can 
cause symptomatic disease.  
Two established cryptococcal species typically cause disease: C. neoformans and 
C. gattii, although recent nomenclature recommendations further sub-divide these into 7 
species (4). Exposure to C. neoformans is quite common in humans, as most individuals 
produce cryptococcal antibodies by school age (5), indicating a history of cryptococcal 
infection and further supporting the ubiquity of C. neoformans in the environment. 
Disease onset after C. neoformans exposure is mainly determined by the competence of 
the adaptive host immune response, while the spectrum of disease severity can be 
additionally ascribed to strain-dependent cryptococcal virulence (6, 7). Consequently, due 
to the high incidence of HIV infections, cryptococcosis is the leading cause of death in 
persons living with AIDS in Sub-Saharan Africa (8). In contrast to C. neoformans, C. 
gattii causes disease in otherwise healthy individuals (9). C. gattii was previously thought 
to be sequestered in tropical or sub-tropical regions of the world but an outbreak and 
subsequent spread in North America has prompted additional analysis of the prevalence 
of this species throughout the Americas, Europe, and Asia (10). The mechanism by which 
C. gattii causes disease in apparently healthy individuals is still under investigation, but 
disease threshold may be driven, in part, by rare exposure to this highly virulent fungus. 
With both species, if the pulmonary immune response does not sufficiently limit fungal 
replication, Cryptococcus eventually escapes into the peripheral circulation, accumulates 
in the brain, and results in semi-occult pneumonia and clinically apparent 
meningoencephalitis. 
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Evolution of cryptococcal virulence 
 C. neoformans is remarkably well suited to survive in a human host. Despite the 
moniker, “opportunistic pathogen,” an immaculate conception of random traits does not 
faithfully explain cryptococcal acrimony in the context of human disease. Rather, its 
virulence is more likely a culmination of traits that evolved in a multilayered process in 
both environmental and animal niches (Figure 1).  
The first layer of evidence for evolved virulence is the capacity of C. neoformans 
to subsist in the environment while also avoiding uptake and killing by organisms (i.e. 
amoeba, nematodes, and insect larvae) with ancestral components of our innate immune 
system (11-13). A unique characteristic among medically important fungi is the thick 
polysaccharide capsule that surrounds C. neoformans. The capsule protects against 
environmental dehydration (14), as well as allowing C. neoformans to resist oxidative 
damage of primordial lysosomal conditions (15). Furthermore, melanin produced by C. 
neoformans absorbs damaging radiation (16) and inhibits the effect of reactive oxygen 
species produced in the lysosome (17). Natural selection driven by primitive features of 
human physiology has likely played a significant role of the evolution of cryptococcal 
virulence.  
Several enzymes and secreted factors produced by C. neoformans also alter the 
adaptive immune response, modulate the lung epithelium, and compromise the blood-
brain barrier (18-21). These actions are required for the establishment of pulmonary 
infection, systemic dissemination, and accumulation in the central nervous system (CNS). 
Only higher vertebrates have analogous anatomy or adaptive immune systems, and 
consequently, C. neoformans probably evolved these properties under the selective 
pressures of reptilian/avian/mammalian hosts within the environment. Further evidence 
supporting non-human mammals as a natural host and reservoir for virulence trait 
selection and maintenance comes from the identification of various animals - from 
aquatic mammals to companion animals - as emergent species affected by the C. gattii 
outbreak (22-24).  
   3 
T cell-mediated immunity is effective at preventing invasive cryptococcal disease. 
Yet, C. neoformans circumvent effector mechanisms of adaptive immunity. As a result, 
the fungus is not always completely cleared from healthy human hosts following 
exposure, resulting in latent infections (25, 26). Perhaps the ability to remain latent 
without perturbing its host is the strongest evidence for host adaptation by C. 
neoformans. Taken together, these observations suggest that interactions with both soil 
microorganisms and vertebrates within the environment likely play a critical role in the 
virulence potential of C. neoformans (Figure 1). 
 
Cryptococcal morphology: spores, yeasts, and titan cells 
C. neoformans has a diverse repertoire of morphologies that impact its ability to 
establish pulmonary infection. Cryptococcal yeasts and spores are capable of generating 
robust pulmonary infections in animal models of experimental cryptococcosis (27, 28). 
Recent studies in mouse models of cryptococcosis revealed that spores and yeast cells 
interact with the host immune system differently and these differences can promote 
development of disease. Giles et al. showed spores were phagocytized more efficiently 
than yeast cells, and these infections readily disseminate to the brain (27, 29). Although 
both forms commonly exist in the environment, the infectious propagule of C. 
neoformans that humans naturally encounter is not empirically testable and consequently, 
remains speculative. 
Whether derived from spores or yeast cells, upon inhalation into a mammalian 
host, all C. neoformans transition to or maintain a yeast form. Recent studies have 
highlighted the unique diversity of cryptococcal yeast cells within the host. When grown 
under laboratory conditions, C. neoformans is a round, budding yeast 5-7 microns in 
diameter. Yet in the host, the cells show dramatic variation in their cell size, structure, 
and characteristics (30, 31). The best studied atypical morphology occurs in the form of 
cryptococcal titan cells (32). Titan cells are greater than 12 microns in diameter 
(excluding capsule), are polyploid instead of haploid, have highly crosslinked capsules 
and a thickened cell wall (33, 34). Titan cell formation is regulated by pheromone-
sensing and G-protein-coupled receptor signaling (35), which is functionally analogous to 
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virulence conferred by quorum sensing in pathogenic bacteria (36). The transcription 
factor, Rim101, controls titan cell production along with many other cryptococcal 
virulence factors, suggesting titan cell formation intersects with a generalized virulence 
program of C. neoformans (35, 37, 38). Finally, infection with C. neoformans mutants 
that are incapable of generating titan cells, yet retain an otherwise normal virulence 
phenotype, results in extended survival of mice (39). Therefore, the collective traits 
associated with titan cell formation enhance cryptococcal virulence. How each of the 
aforementioned titan cell characteristics influence C. neoformans pathogenesis remains  
under active investigation (39). 
  
Pulmonary immune response to cryptococcal infection 
The lung is a primary interface with the external environment and is under 
constant assault from infectious microbes. As a result, innate and adaptive immune cells 
must efficiently coordinate protection against invading pathogens in the lungs (Figure 2, 
Top). Airway resident phagocytes, known as alveolar macrophages, are among the first 
to respond to pulmonary cryptococcal infection (40). In addition, monocytes and 
neutrophils are quickly recruited after infection to the lung mucosa (41, 42). Pathogen 
associated molecular patterns (PAMPs) unique to fungi are found on the fungal cell 
surface. These PAMPs are recognized by receptors on innate immune cells, leading to a 
cascade of innate immune cell activation (43). Despite pattern recognition of fungal cell 
wall carbohydrates, innate immunity may not be sufficient to eliminate C. neoformans 
from the lungs.  
A profound capacity to resist phagocytic killing lies at the core of cryptococcal 
virulence. Several well-studied cryptococcal traits allow the fungus to avoid 
phagocytosis, as well evade destruction within phagocytes. Specifically, the 
polysaccharide capsule blocks complement from opsonizing cryptococcal cells (44) and 
inhibits maturation of dendritic cells and macrophages (45). Anti-phagocytic protein-1 
produced by C. neoformans antagonizes complement receptors on pulmonary 
phagocytes, which prevents C. neoformans uptake (46). Melanin and capsule also act as 
redox sinks to prevent oxidative damage within the phagolysosome, thereby promoting 
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the survival of internalized cryptococcal cells (15, 17). C. neoformans employs potent 
phagocyte evasion strategies and the immune system must rely on additional methods to 
eliminate cryptococcal infection 
The selective depletion of T cells due to HIV/AIDS dramatically enhances 
susceptibility to invasive cryptococcosis (8). This experiment of nature indicates that the 
immune system requires additional help from Th cells to prevent cryptococcal disease. 
Before Th cells can enact their functions, naïve Th cells must undergo priming. Th cells 
are incapable of coordinating their own activation and differentiation. This task is 
performed by professional antigen presenting cells (APC). Microbial peptides are bound 
by major histocompatibility II (MHCII) molecules and presented on the surface of the 
APC. Rare naïve Th cells survey APC, usually within lymphoid tissues, searching for a 
peptide-MHCII complex with high avidity for peptide-specific T cell receptors on the Th 
cell surface. Upon finding the cognate peptide-MHCII, the Th cell undergoes rapid 
proliferation. The APC also provides secondary cues that further promote Th cell 
activation and instruct the Th cell to acquire a stable effector function (e.g. Th1/2/17). 
“The Th1/Th2 Paradigm” has been a useful framework for understanding cell-
mediated immunity, where Th1 cell responses provide protection against intracellular 
microbes and Th2 cell responses confer resistance to protozoan and helminth parasites 
(47). However, the discovery of additional Th cell subsets has forced the revision of this 
idea (e.g. Th9, Th17 and regulatory T cells) (48-52). These Th cell subsets may play an 
important but hitherto incompletely understood role in immunity to C. neoformans (53, 
54).  
Despite the lack of more contemporary knowledge of Th cell subsets pertaining to 
cryptococcal pathogenesis, current evidence suggests Th1 responses are protective and 
Th2 responses are pathologic. The Th1 cytokine, interferon gamma (IFN-γ), positively 
correlates with patient survival and fungal clearance from the cerebrospinal fluid when 
used as adjunct therapy in cryptococcal meningitis patients (55, 56). Conversely, excess 
Th2 cell cytokines, IL-4, and IL-13, as well as a lack of IFN-γ in the peripheral blood and 
CSF are associated with poor clinical outcome in a separate cohort of patients (57, 58). In 
mouse models of cryptococcosis, Th2 cell polarized responses promote disseminated 
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disease (59-62), whereas infection with a modified strain of C. neoformans that produces 
recombinant IFN-γ results in sterilizing primary immunity and protection from fully 
virulent rechallenge. However, the capacity of C. neoformans to modulate the host 
response during human infection is still unknown. Furthermore, the molecular and 
cellular mechanisms underlying Th2 cell differentiation are poorly understood. 
Activated, fully differentiated Th cells instruct several fundamental processes 
during the immune response to pulmonary fungal infection. First, Th cells form an 
immunological synapse with macrophages and exchange signals via co-receptors and 
cytokines. In the case of Th1 cells, IFN-γ instigates a series of changes in macrophages, 
including: phagolysosome fusion, nitric oxide synthase expression, and reactive oxygen 
species production (63). This “classical” activation allows the macrophage to eliminate 
the intracellular cryptococcal cells (Figure 2, Top). Th2 cells similarly interact with 
macrophages, yet the production of IL-5 and IL-13 causes “alternative” activation of 
macrophages and the failure to control intracellular cryptococcal replication (63) (Figure 
2, Top).  
Th cells, along with other lymphocytes, produce cytokines with wide ranging 
effects. More specifically, IL-5 produced by Th2 cells and IL-17A produced by Th17 
cells lead to the differentiation and recruitment of eosinophil and neutrophil granulocytes, 
respectively (Figure 2, Top). There is conflicting evidence showing eosinophils and 
neutrophils are beneficial, detrimental, and dispensable to cryptococcal immunity (64-
68). Perhaps, the discrepancy in the role of granulocytes in response to cryptococcal 
infection arises from a recent but still poorly understood observation of 
eosinophil/neutrophil compensation, where the loss of eosinophils often promotes 
neutrophil accumulation and vice versa (69, 70). In addition to the Th cell subsets, 
several other lymphocytes produce Th cell cytokines, such as: innate lymphoid cells 
(ILC), CD8 T (Tc17) cells, and γδ T cells. Thus, the study of granulocytes is further 
complicated by the existence of an array of lymphocytes with the capacity to coordinate 
granulocyte responses during cryptococcal infection. 
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Exit from the lung and dissemination to the central nervous system  
C. neoformans encapsulation, melanin production, and titan cell formation 
discussed above have clear indications for promoting the establishment of infection. 
However, an important characteristic of cryptococcosis involves the exit of C. 
neoformans from the lungs into peripheral blood circulation and entry into the CNS 
compartment. 
C. neoformans produces several enzymes that modulate the respiratory epithelium 
and promote escape into the periphery. Mannoproteins have been implicated in the 
attachment of cryptococcal cells to the unidentified receptors on pulmonary epithelial 
cells (71). This affords an opportunity for C. neoformans to exert highly localized 
manipulations of epithelial cells. Phospholipase B hydrolyzes phospholipids in epithelial 
membranes and airway surfactants (72, 73), which compromises the integrity of the 
physical barrier defenses in the lung. Finally, urease catalyzes the conversion of urea into 
ammonia, and increased ammonia concentration in the lung could cause epithelial cell 
cytotoxicity, as is the case in other instances of pathogen-derived urease activity (74). C. 
neoformans has well adapted traits that allow it to penetrate the mucosal barrier of the 
lungs. 
Most fungi that resist immune control at the mucosae readily disseminate to distal 
regions of the body, yet very few fungi accumulate in the brain (75). Due to the 
potentially devastating consequences of collateral damage to nervous tissue during a 
robust immune response in the brain, the CNS is both an immune privileged site and a 
highly sterile environment (76). Therefore, C. neoformans must have evolved potent 
methods to traverse the blood-brain barrier (BBB) and subsist in the CNS. There are three 
proposed mechanisms that C. neoformans could utilize to penetrate this impervious 
palisade: paracytosis, transcytosis, and intracellular transport via a “Trojan horse” uptake 
system. 
First, the yeasts could force their way between the tight junctions of the 
endothelial cells in a process known as paracytosis (Figure 2, bottom). This feat is not 
easily accomplished due to the highly regulated claudins and other proteins that impede 
transfer of even small molecules and proteins (77). Recent evidence from Vu et al. 
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indicates C. neoformans produces a metalloprotease, Mpr1 that could disrupt endothelial 
cell junctions to promote transmigration across the BBB (78). Impressively, when the 
mpr1 gene was introduced into S. cerevisiae, a fungus not normally able to penetrate the 
BBB, it gained the ability to cross endothelial cells in an in vitro transwell assay. 
Additional studies utilizing powerful intravital imaging demonstrated that C. neoformans 
crosses the BBB by inducing an embolic event in the microvaculature that lines the brain, 
and this process is dependent on a secreted cryptococcal enzyme, urease (21, 79).  
The second mechanism of BBB penetration is transcytosis (Figure 2, bottom). 
Hyaluronic acid situated on the surface of C. neoformans binds to CD44 on the luminal 
endothelium, allowing the fungus to affix to the host cell, enter the cytoplasm, and escape 
from the basolateral side into the CNS (80-83).  
Finally, C. neoformans is thought to cross the BBB in host phagocytes, analogous 
to the “Trojan Horse” entry mechanism from mythology (Figure 2, bottom). 
Phagocytosis and intracellular killing is central to controlling C. neoformans replication, 
yet depletion of alveolar macrophages significantly reduces cryptococcal dissemination 
to the CNS (84). Furthermore, infecting monocytes in vitro and transferring the cells into 
naïve hosts substantially increased cryptococcal accumulation in the brain compared to 
transferring C. neoformans directly, supporting the role of monocytes as carriers for 
breaching the BBB (85). While paracytosis, transcytosis, and the Trojan Horse models all 
fundamentally differ, elements of each of these models are readily observed and likely 
occur in concert.  
Not much is known about the behavior of C. neoformans once it has traversed the 
BBB. However, a study of the transcriptome of cryptococcal yeasts isolated from clinical 
cerebrospinal fluid samples offers a brief view into this window (86). Most notably, C. 
neoformans is remarkably metabolically active considering CSF is a relatively nutrient 
deplete medium, and this increased activity correlated with elevated expression of 
virulence genes. Prospective studies across independent patient cohorts employing 
similar methods will undoubtedly yield important information regarding the lifestyle of 
C. neoformans within the CNS. 
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The accumulation of C. neoformans in the brain causes meningoencephalitis, also 
referred to as cryptococcal meningitis (CM). The fever, headache, altered mental state, 
and death that accompany CM are direct results of increased intracranial pressure (87). 
Unfortunately, lumbar punctures to reduce intracranial pressure are among the few 
treatment options at this stage of disease (88). If C. neoformans is allowed to disseminate 
to the brain, the ensuing meningitis is often fatal, even with standard anti-fungal therapy 
(57, 58). Advances in early cryptococcal antigen detection (89) afford an opportunity to 
treat infections in the lung before they cause lethal CNS disease. Therefore, my 
dissertation research focused on the early immune response to pulmonary infection 
before the onset of meningitis.  
 
Allergic airway disease 
Another thrust of my thesis research aims to unify the clinical observations of Th2 
cell responses that correlate with invasive disease in immunocompromised individuals 
and the type-2 driven allergic asthma in otherwise healthy individuals. 
Allergic bronchopulmonary Aspergillosis, severe asthma with fungal 
sensitization, and allergic fungal rhinosinusitis account for over half of the 50 million 
people that experience asthma and pulmonary allergy and >10 billion dollars that the 
United States spends annually for treatment of these diseases (90-95). An association 
between fungal exposure and allergic Th2 inflammation is well established (96). 
Hallmarks of these allergic pulmonary diseases include Th2 cytokine secretion, 
eosinophilia, mucus and IgE production, and airway obstruction (97). Undoubtedly, these 
hallmarks reflect induced activation in  both the innate and adaptive immune arms of the 
immune system. Protease activity from exogenous and endogenous sources has profound 
impact on innate immune responses underlying allergic inflammation (98, 99). Likewise, 
pulmonary inoculation with purified chitin has been implicated in eosinophil recruitment, 
alternative macrophage polarization, and lung epithelium activation (100, 101). However, 
durable recall responses to allergen challenge and IgE isotype switching both require 
CD4+ T cell help, underscoring the importance of CD4+ T cells in mediating fungal 
pathology (102). 
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The cellular and molecular events underlying Th2 cell fate determination during 
fungal infection are incompletely known. This information is critically important for the 
development of novel pharmaceuticals that block immunopathologic responses and/or 
promote beneficial immune responses (103, 104).  
Thesis summary 
Pulmonary mycoses, including invasive fungal infections and allergic asthma, 
affect millions of people worldwide. Fungi inhabit a multitude of ecological niches, and 
consequently, humans continuously inhale potentially pathogenic fungi. Adaptive 
immune cells, and in particular, Th cells, are critical to the immune response to fungal 
infection. While Th1 subsets contribute to protective antifungal immunity, Th2 cell 
responses to many fungal infections correlate with increased invasive disease severity 
and allergy symptoms. Yet the cellular and molecular basis for Th2 cell responses is 
poorly known. 
My thesis project aims to understand the fundamental, yet unanswered, question 
of how fungal-intrinsic properties and host determinants influence Th2 cell 
differentiation. Through multilocus sequence typing of clinical isolates from humans with 
cryptococcal disease, I noted a genetic clustering of C. neoformans. Genetically related 
clusters of C. neoformans isolates were associated with differential mortality in the 
patients. Representative isolates from certain clades provoked type-2 cytokine responses 
to ex vivo stimulation of human blood, and this type-2 response directly correlated with in 
vivo virulence. These data suggested pathogen-derived signals altered the host immune 
response to infection. To further define how the host generates this type-2 response, I 
developed novel tools and strategies to analyze Th cell production in a mouse model of 
pulmonary infection. I found that C. neoformans influences detrimental Th2 cell 
generation through the production of chitin. The host additionally contributes to this 
harmful response by promoting chitin recognition via the chitinase, Chit1. Furthermore, I 
elucidated a detailed mechanism that the host employs to resist Th2 cell-mediated disease 
by inducing suppressive Treg cells in the lungs. Lastly, Th2 cells and other lymphocytes 
engage in a competition to drive neutrophil and eosinophil development in the bone 
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marrow and accumulation in the lungs of infected mice. Biasing granulocytes towards 
eosinophil- or neutrophil-dominated responses significantly worsen lethal disease.  
These investigations into both fungal intrinsic factors and host responses may 
eventually guide novel anti-fungal therapies by interrupting the deleterious chitin 
recognition pathway, leveraging Treg cell suppression of Th2 cells, or skewing 
lymphocyte competition to prompt favorable, balanced granulocyte responses. 
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Figure 1. Virulence Evolution of an “Opportunist.” 
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Figure 2. Cryptococcal Behavior and Host Response in the Lung and Brain. BBB, 
blood-brain barrier; Eos, eosinophil; G-CSF, granculocyte-colony stimulating factor; 
GXM, glucoronoxylomannan; Th, helper T cell; IFN, Interferon; IL, Interleukin; M1, 
classically activated macrophage; M2, alternatively activated macrophage, Neu, 
neutrophil;  
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SUMMARY 
 
In sub-Saharan Africa, cryptococcal meningitis (CM) continues to be a 
predominant cause of AIDS-related mortality. Understanding virulence and improving 
clinical treatments remain important. To characterize the role of strain genotype in 
clinical disease, we analyzed 140 Cryptococcus isolates from 111 Ugandans with AIDS 
and CM. Isolates consisted of 107 non-redundant Cryptococcus neoformans var. grubii 
strains and 8 C. grubii/neoformans hybrid strains. Multi-locus Sequence Typing (MLST) 
was used to characterize genotypes, yielding 15 sequence types and 4 clonal clusters. The 
largest clonal cluster consisted of 74 isolates. Burst and phylogenetic analysis suggested 
the var. grubii strains could be separated into three non-redundant evolutionary groups 
(Burst group 1 to group 3). Patient mortality was differentially associated with the 
different evolutionary groups (P=0.04), with highest mortality observed among Burst 
group 1, Burst group 2, and hybrid strains. Compared to Burst group 3 strains, Burst 
group 1 strains were associated with higher mortality (P=0.02), exhibited increased 
capsule shedding (P=0.02), and elicited a more pronounced Th2 response during ex vivo 
cytokine release assays with strain-specific capsule stimulation (P=0.02). These analyses 
suggest that cryptococcal strain variation can be an important determinant of human 
immune responses and mortality.  
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IMPORTANCE 
 
Cryptococcus neoformans is a common life-threatening human fungal pathogen 
that is responsible for an estimated 1 million cases of meningitis in HIV-infected patients 
annually. Virulence factors important for human disease have been identified, yet the 
impact of strain genotype on virulence and outcomes of human infection remains poorly 
understood. Using an analysis of strain variation based on in vitro assays and clinical data 
from Ugandans living with AIDS and cryptococcal infection, we report that strain 
genotype predicts the type of immune response and mortality risk. These studies suggest 
that knowledge of the strain genotype during human infections could be used to predict 
outcomes and lead to improved treatment approaches aimed at targeting the specific 
combination of pathogen virulence and host response. 
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INTRODUCTION 
 
More than 2.7 million new HIV infections and 1.8 million AIDS-related deaths 
occurred in 2010, despite the roll out of antiretroviral therapy (105). Based on community 
cohorts, 13–44% of HIV/AIDS deaths are due to Cryptococcus infections (8). 
Consequently, cryptococcal meningitis (CM) may be the fourth leading cause of death 
due to infectious disease in Africa with estimates of a half million deaths annually (8). 
Even with antiretroviral therapy (ART) access, the 6-month survival remains >40% (8, 
58, 106). Efforts to improve survival of HIV/AIDS patients in sub-Saharan Africa must 
focus on the development of effective treatments for opportunistic infections such as CM. 
One possible approach to improving clinical outcome is to customize the treatment 
based on specific pathogen virulence and host response. A healthy immune response to 
Cryptococcus depends on coordinated interactions between antigen presenting cells 
(APCs) and effector T-cells to generate a type-1 helper T-cell (Th1) response that 
stimulates classical activation of macrophages and destruction of internalized 
cryptococcal cells (44, 107-110). IFNγ induces protective Th1 responses and human 
studies have shown that IFNγ in the CSF is associated with increased fungal clearance 
(111). In contrast, Th2 biased responses to Cryptococcus are not protective and result in 
disseminated, uncontrolled infections in mice (60, 61). IL-10 produced by Th2 and 
regulatory T-cells inhibits synthesis of pro-inflammatory cytokines such as IFNγ and is 
generated in response to purified cryptococcal capsule (112, 113). Finally, IL-4 is a 
powerful inducer of Th2 development, suppresses Th1 development, and compromises the 
ability of IFN-γ to drive protective Th1 responses (112). Therefore, patients exhibiting 
Th2-biased immune responses to cryptococcal infections could be at higher risk for poor 
clinical outcomes. 
Numerous relationships between pathogen genotypes and virulence have been 
demonstrated in bacterial pathogens (114-117) as well as between Cryptococcus gattii 
genotypes and virulence in the Vancouver Island outbreak (118), suggesting that 
cryptococcal strain variation could play a role in determining clinical outcomes. 
However, clinical outcomes in cryptococcosis are multi-factorial – both the pathogen and 
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the host contribute to disease. Epidemiologic characteristics of Cryptococcus 
neoformans, virulence-associated phenotypic traits, and host immune responses have 
been studied as individual factors influencing cryptococcosis outcomes but none of these 
studies have found associations between cryptococcal strain variation and human disease 
(119, 120). We propose that exogenous (pathogen) and endogenous (host) factors 
contribute concurrently to the pathophysiology of cryptococcosis. Consequently, an 
integrated investigation of cryptococcal strain coupled with host immune response could 
provide valuable insight into cryptococcal pathogenesis and potentially lead to custom 
therapies that target the host-pathogen interface. Thus, we hypothesize that differences in 
strain genotype, as determined by Multi-locus sequence typing (MLST), and strain 
phenotype could be responsible for disease severity and clinical outcome in patients. To 
test these hypotheses, we analyzed cryptococcal strains and clinical data from a cohort of 
ART-naive Ugandans with AIDS and CM. We report that the genotype of the infecting 
strain is associated with the type of immune response and clinical outcome. 
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RESULTS 
 
Cohort Demographic Characteristics 
A prospective cohort of 199 HIV-infected, ART-naive Ugandans with a first 
episode of CM was recruited at Mulago Hospital, Kampala, Uganda, over a 26-month 
enrollment period between 2006 to 2009 in order to study immune reconstitution 
inflammatory syndrome and other clinical outcomes after ART initiation (58). Of these, 
111 patients had culture-positive CSF samples stored for subsequent genotypic analysis. 
Detailed clinical and demographic information from 98 of these patients were used for 
comparison of strain genotype to clinical outcome (Table 1). 
 
Cryptococcal Strain Genotypes 
Cryptococcal strains were colony purified from a total of 140 CSF specimens from 
the 111 patients. Genotypes of the Ugandan clinical (UgCl) strains were determined by 
MLST according to a consensus scheme that included eight loci: CAP59, GPD1, IGS1, 
LAC1, PLB1, SOD1, URA5, and TEF1 (121).  
Eight isolates could not be fully genotyped as some loci were recalcitrant to PCR 
amplification upon sequencing with either legacy (122) or consensus (121) MLST 
primers at >1 MLST locus. Loci from these non-genotyped strains showed highest 
similarity to Cryptococcus neoformans var. neoformans (n=4) or var. grubii (n=4) (data 
not shown). None of the strains were C. gattii based on sequencing or CGB agar 
screening. PCR serotyping showed combinations of both var. grubii and neoformans 
gene alleles in the strains (data not shown). Taken together, these data suggest the eight 
strains are grubii/neoformans “hybrids”. 
Colony purification allowed us to analyze the greatest number of clinical isolates 
from the broadest spectrum of patients, but co-infection of patients with multiple strains 
could confound this approach (123). Thus, multiple isolates were collected from 24 
patients. In 20 of 24 persons, no differences in MLST alleles between isolate pairs were 
observed; however, multiple genotypically distinct isolates were identified in four 
patients (17%) suggesting co-infection with ≥2 strains. Subsequent analyses included 
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single isolates from clonally infected patients as well as both isolates from patients 
infected with two genotypes. 
Sequences for each MLST locus were compared, reduced to non-redundant clonal 
sets, and a maximum parsimony analysis of the sequences at individual loci was 
performed (Supplemental Figure 1). Only one strain showed a polymorphism at the 
URA5 locus. The SOD1 locus was completely clonal in our population. Locus allele 
identifiers for each strain were combined to produce a strain sequence type that serves as 
a representation of the strain genotype. A total of 15 sequence types (ST) were identified 
(Table 2). The sequence types consisted of four clonal clusters and 11 singleton sequence 
types (Figure 1A). The largest clonal cluster (UgCl001) contained 74 isolates. The other 
clonal clusters contained n=14, n=5, and n=3 isolates (represented in Table 2 by 
UgCl021, UgCl011, and UgCl057, respectively).  
A single representative strain for each sequence type was used to analyze 
evolutionary relationships between the UgCl strains and further stratify the isolates into 
distinct groups. Phylogenetic analyses including maximum parsimony, maximum 
likelihood, and bootstrap were performed on the concatenated sequences of MLST loci 
for the 15 identified sequence types. Maximum parsimony analysis was performed with 
inclusion of reference strain sequences for the major C. neoformans var. grubii VNI, 
VNII, and VNB clades to place the resulting tree in the context of previously established 
evolutionary relationships (Figure 1B) (122). Maximum parsimony and maximum 
likelihood analyses produced comparable results (not shown). To further stratify the 
isolates, an MLST-specific Burst clustering analysis was performed (124). The Burst 
clustering hypothesized a division of the 15 sequence types into three non-redundant 
Burst groups and four more distant singleton strains (Figure 1C). The more highly 
stratified three Burst groups were used in subsequent clinical and phenotypic analyses. 
For the 4 patients with multiple infections, 2 patients had infections with strains in the 
same Burst group and thus the demographic and clinical comparisons were not repeated. 
Two of the patients had infections with strains in different Burst groups. In these 
instances, the clinical and geographic data were analyzed as part of each respective Burst 
group. 
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Patient Clinical Outcome  
Having identified three distinct Burst groups and a hybrid group, we next asked 
whether cryptococcal genotype could predict disease severity. Patient 1-year clinical 
outcome was available for 98 of the 111 culture-positive patients (Table 1). The overall 
1-year mortality rate was 78%. Patients infected with Burst group 1 & 2 strains had 
higher mortality than Burst group 3 strains (79% (68/86) vs. 38% (3/8), chi-square: 
p=0.05). Survival curves showed patients infected with Burst group 3 strains lived longer 
than patients infected with the other genotypes (Figure 2, log-rank: p = 0.009). None of 
the six patients infected with hybrid strains survived the infection. No other clinical or 
demographic parameter monitored, including CD4 count and HIV-1 viral load, was 
associated with genotype. 
Environmental exposure to specific cryptococcal strains in particular geographic 
regions is a possible explanation for the association between isolate genotype and patient 
death. The majority of patients lived in parishes within the Kampala district but no 
geographic clusters of patients infected with similar genotypes was observed 
(Supplemental Figure 2).  
 
Cryptococcal Strain Phenotypes 
At least three major virulence factors are important for cryptococcal pathogenesis: 
mating type, melanin, and polysaccharide capsule (119, 120). Mating type determination 
and in vitro assays of melanin and capsule production were performed to identify 
association with genotype that could explain differences in lethality. 
Strain mating type was determined by PCR using STE20 primers specific for 
mating type and serotype. The vast majority of the C. neoformans var. grubii strains were 
mating type α (αA); only two were mating type a (aA). Because only 2 out of 132 var. 
grubii strains were mating type a, sufficient variation was not present to allow for 
comparison of mating type to genotype, phenotypes, or patient outcome.  
Melanin production by the clinical isolates was analyzed using media containing 
niger seeds or L-DOPA (L-3,4-dihydroxyphenylalanine). These media provide biphenolic 
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precursors for melanin production along distinct pathways (125). A relative scoring 
method based on similarity to reference strains with weak (JEC20) and strong (KN99α) 
melanization was employed to analyze melanin production over 48 hours (Supplemental 
Figure 3A). K-means clustering analysis for both media types showed separation of the 
melanin production into 10 major clusters on niger seed and 7 major clusters on L-DOPA 
media (Supplemental Figure 3B). The Burst and hybrid groups did not differ significantly 
in their ability to produce melanin on niger seed media (Figure 3A). In contrast, while no 
association between genotype and melanin production on L-DOPA was observed for the 
Burst groups, the hybrid group had significantly higher melanin production on L-DOPA 
media (Tukey-adjusted T-test: p=0.001) (Figure 3B). 
 Capsule production by the UgCl isolates was monitored in two ways for 
comparison to isolate genotype. First, in vivo capsule release into patient CSF at the time 
of presentation with meningitis was measured using a qualitative CRAG agglutination 
assay. No association between clinical CRAG titer and Burst genotype was observed 
(ANOVA, p≥0.32). This result could be confounded by differences in fungal burden 
between patients resulting in inaccurate measures of capsule production. Consequently, 
an in vitro quantitative CRAG assay was performed to more precisely determine the 
capacity of each strain to produce and shed capsule. Burst group 1 strains had the highest 
capacity to produce and secrete capsule (Figure 3C). Importantly, Burst group 1 showed 
elevated capsule release compared to Burst group 3 (Tukey-adjusted t-test: p=0.02) and 
higher (but not statistically significant) capsule release compared to Burst group 2 strains. 
These data implicate elevated capsule production as one potential mechanism by which 
Burst group 1 isolates could cause increased lethality in patients. 
 
Patient/Host Immune Response 
The observation that Burst group 1 isolates were associated with higher mortality 
and shed more capsule than the other Burst groups led us to hypothesize that the capsule 
from these strains could influence the type of immune response during infection. To 
directly test this hypothesis we developed an ex vivo cytokine release assay to measure 
responses to capsule and cell wall preparations obtained from representative Burst group 
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1 and 3 isolates. Blood samples from 18 healthy volunteers were incubated with Burst 
group 1 and 3 antigens, cytokine production was quantified by multiplex assay, and 
differences between each volunteer’s response to the Burst group 1 and 3 antigens was 
determined by paired t-test.  
Release of the Th1 cytokine, IFNγ, was similar between the Burst group 1 and 3 
capsule antigens (paired t-test: p=0.08) (Figure 4A). In contrast, production of the Th2 
cytokines, IL-4 and IL-10, was significantly higher in response to capsule antigens from 
Burst group 1 strains compared to Burst group 3 strains (paired T-test: p=0.02, p=0.003, 
respectively) (Figure 4B,C).  The amount of capsule antigen (measured by CRAG assay) 
was standardized in these assays, and both capsule antigens elicited equivalent dose-
dependent IL-8 chemokine responses (paired t-test: p=0.99) (Figure 4D, Supplemental 
Figure 4B). Thus, the observed differences in immune response to capsule antigen were 
due to intrinsic properties of the capsule and not the quantity of capsule generated by the 
Burst group 1 and 3 isolates.  
The cell wall antigen preparations did not elicit robust cytokine responses, but dose-
dependent IL-8 chemokine responses equivalent to those observed with the capsule 
antigens were still detected (Supplemental Figure 4). These data show that capsule, but 
not cell wall, from Burst group 1 isolates elicits a stronger Th2 cytokine response than 
capsule from Burst group 3 isolates. 
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DISCUSSION 
 
 We report the association between cryptococcal genotype and clinical outcome with 
further determination of the effect of virulence potential on disease severity in a cohort of 
Ugandans with AIDS and culture-positive CM. Our investigation revealed that different 
genotypes are associated with differences in patient survival. Cryptococcal genotypes 
associated with high patient mortality exhibited increased capsule (Burst group 1) or 
melanin (hybrid strains) production, which are two known virulence factors. We showed 
that capsule differences between genotypes also may have affected the host immune 
response, because capsule from genotypes associated with high mortality elicited a 
greater Th2 cytokine response.  
 Previous studies noted genotypic diversity in clinical isolates from Southern Africa 
(e.g. Botswana, South Africa) predominantly in the VNI and VNB clades that show 
evidence of recombination (122, 126, 127). In contrast, clinical isolates from other 
regions of the world show significant clonality and are typically members of the VNI and 
VNII clades (127). The UgCl strains had the same SOD1 locus observed in other African 
cohorts [15, 24]. Yet, the Ugandan cohort had significant clonality and the predominant 
clade has diverged from the VNI, VNII, and VNB reference alleles. These data suggest 
that cryptococcal populations in Uganda are isolated, highly clonal, and that the unique 
Burst group 1 genotypes may be responsible for the unusually high mortality rates 
observed in Ugandan patient cohorts found several sequence types associated with 
specific regions in South Africa (126). Our data showing no geographic distribution of 
the UgCl strains in the Ugandan patient population suggest that patient geographic 
location within Uganda cannot be used to predict infection with the different Ugandan 
genotypes.  
 MLST has been used extensively to analyze both global and regional population 
structures in both C. neoformans and C. gattii (121-123). Yet the ability of MLST to 
resolve clinically relevant differences between strains remained unclear. The data 
presented here show that MLST can be used to distinguish differences in clinical 
outcome and provide insight into factors affecting disease development. The Ugandan 
   25 
isolates were relatively homogenous with extensive clonality by MLST genotyping and 
with few polymorphisms between genotypes. Because of this homogeneity, most var. 
grubii isolates in the cohort could be stratified into one of three sub-populations based on 
Burst analysis. Each Burst group had multiple patients with identical MLST genotypes 
that could be compared. This clustering of the data revealed connections between 
genotype, clinical outcome, and virulence factor production that may not be readily 
apparent in more genotypically diverse populations.  
 Coinfection with multiple strains of C. neoformans has been observed (128). 
Previous studies identified coinfections based on phenotypic traits (128), mating type 
(123), or genotype of serial isolates (129). Desnos-Ollivier estimated coinfections could 
account for 20% of cryptococcal disease based on studies of a French cohort (123). 
Similarly, 17% of the Ugandan patients screened for coinfection were infected with 
multiple strains. The effect of coinfection on clinical presentation and patient outcome 
remains to be determined. In this study only 4 patients had confirmed coinfections and 
only two of the patients had infections with evolutionarily distinct strains in different 
Burst groups. Unfortunately, because the vast majority of the clinical isolates used here 
were colony purified before storage, coinfection could not be controlled in this study and 
the effect of coinfection on clinical outcome remains unknown. If coinfection rates are 
almost 20%, as the available data suggests, then coinfection could lead to a 20% error 
rate in accurately predicting the host response to infection. In this case, our results 
showing associations between genotype and clinical outcome could underestimate the 
differences between genotypes. The differences might be more pronounced if 
coinfections were identified and excluded from the analysis. Future studies in which 
coinfections and single infections are analyzed for their clinical outcome and host 
response will be necessary to define the effect coinfection has and whether the host 
response is cumulative, associated with the predominant strain, or associated with the 
most antigenic strain. Yet, the high prevalence of coinfection suggests single colony 
purified isolates may not accurately represent C. neoformans infections. This has broad 
implications for many types of studies, including assessing anti-fungal susceptibility. 
 Genotype was associated with differences in clinical outcome. Patients infected 
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with Burst group 1 or 2 isolates had higher mortality rates and shorter survival times than 
patients infected with Burst group 3 isolates (p=0.02); though, admittedly, there were few 
subjects with Burst group 3 isolates. One possible explanation for the low prevalence of 
Burst group 3 isolates is that they may be poor pathogens and do not cause severe 
meningitis as frequently. This hypothesis is consistent with our results showing reduced 
capsule production and stimulation of a protective immune response by Burst group 3 
strains that would limit disease progression. 
 To understand the connection between cryptococcal genotype and patient outcome, 
we analyzed virulence factor production by the different genotypes. We focused on three 
widely acknowledged virulence factors of Cryptococcus: mating type, melanin, and 
capsule. While global populations of C. neoformans var. grubii are predominantly α 
mating type, a high prevalence of a mating type strains were observed in strains from 
Botswana (130). Most of the Ugandan isolates were α mating type, consistent with global 
populations, with only 2% a mating type in the Ugandan cohort. Thus, differences in 
mating type are unlikely to explain the higher lethality associated with Burst groups 1/2 
relative to Burst group 3 strains.  
 Our findings suggested that Ugandan hybrid strains were associated with increased 
mortality. Hybrid strains have attenuated virulence in mouse models of cryptococcal 
infection (131) and often produce less severe infections in humans (119). Thus, the 100% 
mortality observed with the Ugandan hybrid strains was surprising. A larger cohort of 
patients infected with hybrid strains compared to C. neoformans var. grubii strains is 
needed to further explore differences between the infections. 
 In assessing melanin production, we found no differences between genotypes when 
cultured on niger seed medium. However, the hybrid strains produced significantly more 
melanin when L-DOPA was provided as the biphenolic precursor. Although we found 
increased melanin production by hybrid strains when growing these isolates on L-DOPA-
containing media in vitro, we cannot draw conclusions about melanin production by these 
strains in human infections in vivo. L-DOPA, however, is prevalent in the central nervous 
system (119); thus, the increased melanin production of the hybrid strains in response to 
L-DOPA could potentially occur in vivo and promote virulence, leading to increased 
   27 
mortality.  
 Capsule production was measured both in vivo and in vitro. The in vitro data 
proved superior for a number of reasons. First, the high degree of variability in the in vivo 
CRAG titers and small cohort made the statistical comparisons underpowered. Second, 
many uncontrolled factors, including duration of infection and amount of fungal 
proliferation, affect the amount of capsule present in the in vivo samples. These factors 
likely resulted in the high variability of the in vivo CRAG titers. Cell number and 
duration of culture were controlled more rigorously in the in vitro assay. Consequently, 
we were able to precisely stratify the Burst groups and hybrids based on capsule 
shedding. Notably, the high lethality Burst group 1/2 strains shed the greatest amount of 
capsule whereas the less lethal Burst group 3 strains shed significantly less capsule. The 
observation that capsule differences between genotypes are statistically associated with 
differences in patient mortality suggests that genetic diversity of the cryptococcal capsule 
may directly influence clinical outcome and immune response in humans. 
 The current study demonstrates that strain genotype may be a significant factor in 
determining the immune response in patients with AIDS and CM. Protective immunity to 
Cryptococcus requires several elements. Innate cells such as macrophages, monocytes, 
and dendritic cells produce TNFα, CCL2 (MCP-1), CCL3 (MIP-1α), and IL-12 to recruit 
and license additional leukocytes to the site of infection (132-134). The innate immune 
system alone is not sufficient to clear cryptococcal infections, as assistance is required 
from adaptive immunity with helper T cells. The priming and differentiation of CD4+ T 
cells to the Th1 lineage is crucial for a protective immune response to cryptococcal 
infection (135). IFNγ produced by Th1 cells not only acts in a positive feedback loop to 
stimulate the production of more Th1 cells, but also classically activates macrophages to 
increase reactive oxygen production and kill internalized cryptococcal cells (136-138). 
Conversely, an IL-4 driven Th2 adaptive response generates alternatively activated 
macrophages, is non-protective, results in greater fungal burden, and allows 
dissemination (62, 126). The Th1/Th2 balance paradigm used to define interactions 
between Mycobacterium tuberculosis and the human host (139, 140) may also apply to 
Cryptococcus. The pathogen competes against the host to shift a protective Th1 response 
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to a pathogenic Th2 response. How Cryptococcus affects this balance is an active area of 
research and capsule production is one potential strategy. 
 An ex vivo antigen stimulation assay was used to determine the effect of genetic 
diversity within the cryptococcal capsule on the Th1/Th2 balance in humans. High 
lethality Burst group 1 isolates stimulated greater IL-4 and IL-10 production compared to 
less lethal Burst group 3 isolates. IL-4 is a powerful inducer of Th2 development, serving 
as a positive feedback signal for more IL-4 production as well as a negative feedback for 
Th1 responses. Similarly, IL-10 is a suppressive cytokine that has antagonistic effects on 
Th1 responses and development (112). These data suggest that the high lethality Burst 
group 1 isolates shift the Th1/Th2 balance in favor of the pathogenic Th2 response. In 
contrast, the less lethal Burst group 3 isolates are unable to elicit a robust Th2 response 
allowing for a Th1/Th2 balance shifted to the more protective Th1 response. 
 The capsule antigen preparations used in this study were a heterogeneous mix of 
microvessicles, proteins, immunogenic lipids, and capsule polysaccharide. Therefore, it is 
likely that T cell antigens, mainly proteins, present in the preparation were processed and 
presented by APCs to generate the Th1 protective immune response observed in all of the 
preparations. In contrast, capsule polysaccharide is widely implicated in host immune 
evasion and can influence host responses in several ways. Capsule can directly inhibit 
opsonization, phagocytosis, and lysosomal degradation within phagosomes (141-143). In 
addition, shed capsule can disrupt cytokine signaling and lymphocytes (108, 144, 145). 
The major component of capsule polysaccharide, glucuronoxylomannan (GXM), can also 
promote secretion of Th2 cytokines by monocytes (146). Burst group 1 strains produce 
more polysaccharide than Burst group 3 strains, yet the amount of polysaccharide used in 
the ex vivo assay was held constant. Thus, the differences in immune response to the 
capsule preparations observed in the ex vivo assay were due solely to genetic differences 
between the Burst group 1 and 3 strains that affect the structure, function, and/or 
composition of the capsule polysaccharide or other components of the preparation. The 
fact that Burst group 1 strains also produce more capsule polysaccharide suggests that the 
actual affect on the Th1/Th2 balance is even greater than observed in the ex vivo antigen 
stimulation assay. A shift of the Th1/Th2 balance in favor of a pathogenic Th2 response 
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results in greater fungal burden, dissemination, and ultimately death in mouse models of 
cryptococcosis (59, 147). Our data show strains capable of shifting the Th1/Th2 balance 
toward a Th2 cytokine response in humans are also associated with high mortality rates.  
 The studies presented here were designed to analyze the effect of two parameters 
on the immune response and clinical outcome: capsule and cell wall. The capsule data – 
both the amount of capsule and the type of capsule – differed between genotypes and 
affected the immune response. In contrast, while melanin production was found to differ 
in the hybrids, no effect of cell wall components on the immune response was observed. 
Thus, the combination of the melanin and cell wall cytokine induction experiments 
suggest that alterations in cell wall and melanin production can differ between strains, but 
the role, if any, cell wall components play in disease outcome remains unclear. 
 The high overall mortality rate in the Ugandan culture-positive cohort resulted in 
too few surviving patients to analyze the effect of strain genotype on subsequent 
development of immune reconstitution inflammatory syndrome following anti-retroviral 
therapy (ART). A larger cohort of culture-positive patients that initiate ART will be 
needed to examine associations between strain genotype and risk for IRIS. IRIS patients 
have an aberrant immune response following reconstitution of their CD4+ T cell 
population. Current theories suggest this aberrant response is due to uncontrolled 
reconstitution of the immune system or continued prevalence of a highly reactive antigen 
(148). Our data show that Burst group 1 strains produce abundant, Th2 reactive, capsule 
antigen. Thus, Burst group 1 strains may also be more likely to elicit IRIS in patients who 
survive the initial infection compared to Burst group 3 strains with lower and less 
reactive antigen. 
 Taken together, the data presented show that strain genotype is associated with 
disease outcome. The observation that strain genotype affects the immune response to 
cryptococcal infections suggests that genotype can be clinically informative and leads to 
interesting possibilities for new treatment strategies in patients with AIDS and CM. 
Treatment regiments targeted at the unique combination of pathogen and host may 
improve clinical outcomes. For example, new treatments such as IFNg (55) or other 
approaches that increase Th1 cytokines in patients infected with those Cryptococcus 
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strains that elicit predominant Th2 responses may restore proper Th1/Th2 balance and 
allow better control of the infection. 
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MATERIALS AND METHODS 
 
Ethical Statement and Data. Clinical samples were collected during an observational, 
prospective study of Ugandan AIDS patients with CM designed to study immune 
reconstitution inflammatory syndrome following ART initiation (57, 58, 149). Each 
patient contributed only one episode of CM. This study was reviewed and approved by 
the institutional review board of the University of Minnesota, Makerere University, and 
the Uganda National Council of Science and Technology. Written informed consent was 
obtained from all subjects, and all data were de-identified. 
 
Strains and Media. C. neoformans clinical isolates (UgCl) collected from cerebrospinal 
fluid (CSF) were colony purified and stored as glycerol stocks. Cryptococcus and 
Candida albicans reference strains (Supplemental Table 1) were also stored as glycerol 
stocks. All strains were grown on yeast peptone dextrose (YPD) medium prior to 
subsequent analysis. Complete Dulbecco’s modified Eagle’s medium (DMEM+C), Niger 
seed, L-DOPA, canavanine glycine bromothymol blue (CGB), and Christensen’s urea 
media were used as previously described (150, 151). 
 
Multi-locus Sequence Typing (MLST). Genomic DNA extraction was performed as 
described previously (152). Eight loci were amplified and sequenced - seven ISHAM 
consensus loci CAP59, GPD1, IGS1, LAC1, PLB1, SOD1, URA5 (121) and the optional 
highly-polymorphic TEF1 locus (122). An additional LAC1Ra primer was developed to 
replace the consensus primer, which was not sufficiently specific for LAC1 amplification 
in our samples. All primers are listed in Supplemental Table 2. MLST PCR products 
were resolved by agarose gel electrophoresis, excised, purified, and sequenced. Sequence 
assembly was performed with Sequencher 4.9 software (Genecodes, Ann Arbor, MI). 
Exported sequences were truncated to the consensus MLST ends (121). Sequences for 
each locus were aligned using ClustalW software (153). All polymorphisms were verified 
using the sequence chromatograms and alignments were manually edited to resolve 
ambiguities. Manual indel coding was performed by collapsing gaps to a single 
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nucleotide gap at the 5’ end. Multiple alignments were processed with PAUP4.0b10 
software to produce maximum parsimony trees using a heuristic algorithm with 1000 
random sequence additions and gaps treated as the fifth base (154). 4430 characters were 
analyzed: 4315 characters were constant, 71 variable characters were parsimony-
uninformative, and 44 characters were parsimony-informative. Sequences for all loci for 
each UgCl sample were concatenated and subjected to maximum parsimony, maximum 
likelihood and bootstrap analyses using PAUP4.0b10 software (Sinauer Associates, 
Sunderland, MA). Non-redundant allelic sets were compiled using the Non-redundant 
databases (NRDB) web tool (http://pubmlst.org). Novel allele sequences were deposited 
in MLST.net, BioloMICS Net, and BLAST public databases. Sequence types were 
identified as combinations of allelic types for individual loci based on NRDB data. 
Sequence types were subjected to Burst analysis (124) to produce a putative evolutionary 
relationship between clusters of closely related sequence types. A minimum spanning tree 
was produced from the sequence types with Prim’s algorithm combined with Burst 
clustering. 
 
Phenotypic analyses. Cryptococcal yeasts were plated onto either Christensen’s urea or 
CGB plates and incubated concurrently with control strains at room temperature for 24-
48 hours. Plates were visually inspected for color changes. Cryptococcus gattii strains 
were used as positive controls for the CGB test and KN99α was used as a positive control 
for Christensen’s urea and a negative control for CGB test. Bright field microscopy with 
a Zeiss Axioplan microscope with an attached AxioCam camera (Carl Zeiss, Germany) 
was used for analysis of cellular morphology.  
Melanin production was measured by comparing pigmentation of UgCl strains 
grown on Niger Seed and L-DOPA media (17) to reference strains with strong (KN99α) 
and weak (JEC20) melanization. Cell suspensions were adjusted to 106 and 107 
yeasts/mL using a hemocytometer, plated onto YPD, grown at 25oC in the dark, and 
examined at 12, 18, 36, and 48 hours. Melanin assays were performed in triplicate. 
Absolute production of melanin was variable between replicates, but relative amounts of 
melanin were highly reproducible. Relative melanization scores of zero (no 
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pigmentation), one (equal to JEC20), two (between JEC20 and KN99α), three (equal to 
KN99α), or four (more than KN99α) were assigned to UgCl strains based on comparison 
with the reference strains grown on the same plate. C. albicans strain SC5314 was used 
as a negative melanization control.  
Cryptococcal antigen assay (CRAG) was performed at time of diagnosis using the 
Murex Cryptococcus latex agglutination assay (Murex Diagnostics, Norcross, GA) 
according to manufacturer’s specifications or following in vitro culture with the Premier 
Cryptococcal Antigen Kit (Meridian Bioscience, Cincinnati, OH) according to 
manufacturer’s specifications with a modified procedure for sample preparation. Briefly, 
DMEM+C was inoculated and incubated at 30oC. Cultures with an optical density 
(OD)600 of 0.90-1.10 were centrifuged at 10,000 rpm and the supernatant serially diluted 
from 1:10 to 1:6,250 with the provided “DIL” solution to obtain an absorbance at 450 nm 
of 0.14 to 1.50. Enzyme Immunoassay value for each sample was calculated from the 
A450 value according to manufacturer’s instructions and normalized to OD600 of 1.0. PCR 
with differential PAK1, GPA1, and Ste20 primers was used for determination of serotype 
and mating type as previously described (155). 
 
Ex vivo Antigen stimulation. Antigens were prepared from the cell wall and culture 
supernatants of six strains that included the control H99 strain and five strains 
representative of the mean CRAG data points within each of the MLST clonal cluster 
genotypic groups. A capsule antigen preparation was prepared from culture supernatant 
from each strain grown in DMEM+C. The supernatant was decanted, frozen at -80oC, and 
lyophilized. The lyophilized sample was reconstituted in phosphate buffered saline 
(PBS), and the CRAG titer measured. A cell wall antigen preparation was prepared from 
the yeasts. Cells were flash-frozen in liquid nitrogen, combined with glass beads, and 
vortexed vigorously for two hours at 4oC to disrupt the cells. The insoluble fraction (i.e. 
cell wall) was analyzed for CRAG and for protein (BCA Protein Assay, Thermo Fisher 
Scientific, Rockford, IL) concentrations. Endotoxin levels in all antigen preparations 
were undetectable (<0.06 U/mL) by Limulus Amebocyte Lysate assay (Associates of 
Cape Cod, MA).  
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Whole blood samples for the cryptococcal cytokine release assay were obtained 
from healthy individuals in North America. Peripheral blood from each subject was 
drawn into lithium heparin tubes, diluted 2-fold with PBS, and dispensed into a tissue 
culture plate. Cell wall and capsule antigens were added to each well to yield a 
physiologically comparable glucuronoxylomannan (GXM) CRAG titer of 1:256. PBS 
was used as the negative control. Plates were incubated at 37°C in 5% CO2 for 20 hours. 
After incubation, the plasma was separated from the cells and stored at 4oC until cytokine 
analysis. Cytokines were quantified in duplicate for Interleukin (IL)-2, IL-4, IL-6, IL-8, 
IL-10, granulocyte macrophage colony stimulating factor (GM-CSF), interferon-gamma 
(IFN-γ), and tumor necrosis factor-alpha (TNF-α) using a Luminex 100 instrument (Bio-
Rad, Hercules, CA). Negative controls incubated in PBS were subtracted from the raw 
data to determine the net response.  
 
Statistics. Means were compared across groups of isolates using ANOVA and t-tests, and 
medians were compared using Kruskal-Wallis rank sum tests and Mann-Whitney U tests. 
Chi-square and Fishers Exact tests were used to evaluate frequencies of categorical 
variables. Tukey adjustments were made to correct for multiple comparisons. Mantel-Cox 
logrank test was used for the survival anaylsys. All analyses were performed with SAS 
(SAS Institute Inc, Cary, NC).  
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Figure 1. Multilocus sequence typing of Ugandan clinical isolates. (A) Pseudo-color 
representation of the allelic structure of the UgCl strain population. Alleles at each locus 
are indicated by different colors. Each row indicates a single strain. Vertical lines on the 
left represent Burst groups. (B) Consensus tree from 1000 bootstrapped replicates of a 
maximum parsimony analysis of the concatenated sequences of all informative loci. 
Bootstrap values over 50% are shown. (C) Analytical separation of UgCl strains into 
non-redundant evolutionary groups based on Burst analysis of the sequence types. Fill 
color represents the 3 Burst groups. Singleton strains are not shaded.
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Figure 2. One-year survival of culture-positive patients presenting at Mulago 
hospital in Kampala, Uganda based on strain genotype. Patients infected with Burst 
group 3 strains lived longer than patients infected with other genotypes (p=0.007, 
Logrank test). No patients infected with hybrid strains survived the infection.  
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Figure 3. Cryptococcal virulence factors and genotype. (A/B) Association between 
Burst groups and temporal melanization as indicated by K-means cluster rank on niger 
seed (A) or L-DOPA (B) medium. (C) Association between Burst groups and shed 
capsule as measured by Cryptococcal Antigen titer. Asterix represents degree of 
statistical significance with * for p<0.05, ** for p<0.005, *** for p<0.0005.  
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Figure 4. Immune response of healthy volunteers to ex vivo stimulation with capsule 
antigens from genetically distinct strains. Production of IFNγ (A), IL-4 (B), IL-10 (C), 
and IL-8 (D) cytokines in response to shed capsule antigen from a representative clonal 
cluster strain within each Burst group. Antigens were standardized to a physiologically 
relevant final assay CRAG titer of 1:1024 as determined by cryptococcal antigen 
agglutination assay. Data are representative of assays from 6 independent strains. Asterix 
represents degree of statistical significance with * for p<0.05, ** for p<0.005, and “n.s.” 
for non-significant with p=0.08, 0.99 for A & D, respectively.  
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Supplemental Figure S1. Maximum parsimony trees of individual MLST loci. 
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Supplemental Figure S2. Geographical distribution of culture-positive patients 
presenting at Mulago hospital in Kampala, Uganda. No association between 
geographic location and strain genotype was observed. (A) Districts within Uganda with 
culture-positive patients. (B) Parishes within the Kampala district with culture-positive 
patients. 
 
   41 
 
Supplemental Figure S3. Melanin production. (A) Melanization of representative 
UgCl strains relative to controls on niger seed and L-DOPA media. (B) Temporal 
representation of strain melanization on niger seed and L-DOPA media using K-means 
clustering of melanin production from 12 to 48 hours. 
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Supplemental Figure S4. Immune response of healthy volunteers to ex vivo 
stimulation with cell wall antigens. (A) Production of IL-4, IL-10, IFNγ, and IL-8 
cytokines in response to cell wall extract antigen from a representative clonal cluster 
strain within each Burst group. Antigens were standardized to a final assay concentration 
of 5ug of protein per well as determined by Bradford protein assay. (B) IL-8 Dose-
response curve to diluted (0.5), undiluted (1.0) and concentrated (2.0) capsule antigen. 
Best-fit linear regression line is red (p<0.0001, R2=0.79, beta=3401). Units are 
fluorescence intensity (FI) as reported by the Luminex multiplex instrument. 
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CHAPTER 2 
 
Chitin Recognition via Chitotriosidase Promotes Pathologic Type-2 Helper T Cell 
Responses to Cryptococcal Infection 
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SUMMARY 
 
 Pulmonary mycoses are often associated with type-2 helper T (Th2) cell 
responses. However, mechanisms of Th2 cell accumulation are multifactorial and 
incompletely known. To investigate Th2 cell responses to pulmonary fungal infection, we 
developed a peptide-MHCII tetramer to track antigen-specific CD4+ T cells produced in 
response to infection with the fungal pathogen Cryptococcus neoformans. We noted 
massive accruement of pathologic cryptococcal antigen-specific Th2 cells in the lungs 
following infection that was coordinated by lung-resident CD11b+ IRF4-dependent 
conventional dendritic cells. Other researchers have demonstrated that this dendritic cell 
subset is also capable of priming protective Th17 cell responses to another pulmonary 
fungal infection, Aspergillus fumigatus. Thus, higher order detection of specific features 
of fungal infection by these dendritic cells must direct Th2 cell lineage commitment. 
Since chitin-containing parasites commonly elicit Th2 responses, we hypothesized that 
recognition of fungal chitin is an important determinant of Th2 cell-mediated mycosis. 
Using C. neoformans mutants or purified chitin, we found that chitin abundance impacted 
Th2 cell accumulation and disease. Importantly, we determined Th2 cell induction 
depended on cleavage of chitin via the mammalian chitinase, chitotriosidase, an enzyme 
that was also prevalent in humans experiencing overt cryptococcosis. The data presented 
herein offers a new perspective on fungal disease susceptibility, whereby chitin 
recognition via chitotriosidase leads to the initiation of harmful Th2 cell differentiation 
by CD11b+ conventional dendritic cells in response to pulmonary fungal infection.  
   45 
AUTHOR SUMMARY 
 
Humans often inhale potentially pathogenic fungi in the environment. While 
CD4+ helper T (Th) cells are required for protection against invasive disease, a subset of 
Th cells, called Th2 cells, are associated with increased mortality and allergy/asthma 
morbidity. Our study aimed to unravel the cellular and molecular basis of pulmonary Th2 
cell induction in response to lethal infection with Cryptococcus neoformans. Antigen-
presenting cells coordinate naïve Th cell priming and differentiation, but the precise 
leukocyte responsible for Th2 cell expansion to pulmonary cryptococcal infection has not 
been determined. Using an experimental mouse model of pulmonary cryptococcosis, we 
show that a subset of lung-resident dendritic cells is uniquely required for Th2 cell 
induction. We additionally sought to identify the molecular signal received by the host 
that allows dendritic cells to selectively induce Th2 cells. Since parasites and fungi elicit 
Th2 cell responses and both produce chitin, a molecule not found in vertebrates, we 
hypothesized that recognition of fungal chitin is a determinant of fungal disease. Here, 
we demonstrate that C. neoformans chitin and the host-derived chitinase, chitotriosidase, 
promote Th2 cell accumulation and disease. These findings highlight a promising target 
of next generation therapies aimed at limiting immunopathology caused by pulmonary 
fungal infection.  
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INTRODUCTION 
 
 Pulmonary mycoses, ranging from invasive fungal infection to severe asthma with 
fungal sensitization, affect millions of people worldwide (75, 90). Fungi inhabit a 
multitude of ecological niches, and consequently, humans continuously encounter 
potentially pathogenic fungi in the environment. Subsequent disease is determined by the 
size of the innoculum, virulence of the microbe, and immune status of the host. In 
particular, CD4+ helper T (Th) cell subsets are critical mediators of the immune response 
to fungal exposure. Interferon-γ from Th1 cells and interleukin (IL)-17 from Th17 cells 
contribute to protective immunity via classical activation of macrophages and neutrophil 
recruitment, respectively (53). Conversely, Th2 cell production of IL-4, IL-5, and IL-13 
impels eosinophilia, alternative macrophage activation, mucus and IgE production, and 
airway obstruction (97). These type-2 responses drive fungal-associated allergies and 
positively correlate with invasive fungal disease severity (97). Although a fair amount is 
known about type-2 responses and their downstream consequences, the basis of Th2 cell 
induction associated with pulmonary mycosis is less well defined.   
 Antigen presentation by an immune cell bearing major histocompatibility II 
(MHCII) is required for naïve Th cell priming and differentiation. Thus, a cellular 
intermediate must coordinate Th2 cell induction. Professional antigen presenting cells 
direct Th cell fate, and inflamed lungs contain several ontologically distinct immune cells 
with this potential capability (156). The precise leukocyte subset responsible for priming 
Th2 cells, as well as the location that this event occurs, whether at the site of infection or 
within secondary lymphoid tissue, has not been comprehensively investigated. 
Furthermore, specific features of the infection that lead to Th2 cell lineage commitment 
remain largely unexplored in the context of pulmonary fungal infection. 
 While some models attribute induction of type-2 responses to protease cleavage 
of host proteins and wound repair of lung injury (157), many microbes that elicit Th2 cell 
responses produce chitin (158). Chitin is a polysaccharide composed of polymeric N-
acetylglucosamine. The rigidity of chitin is utilized in the cell wall of fungi as well as the 
exoskeleton of arthropods and filarial sheath of parasitic worms. Higher organisms rely 
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on keratin for similar structural purposes, and as a result, vertebrates do not synthesize or 
store chitin. These differences allow an opportunity for the vertebrate immune system to 
detect chitin-containing pathogens as foreign (159, 160). While chitin detection may 
prove beneficial to the host in the context of parasitic infection (161), we hypothesize that 
inappropriate or dysregulated Th2 responses instigated by recognition of chitin promotes 
fungal pathogenesis. 
 Chitinases are a pivotal component of the host response to chitinous organisms 
(162). Chitin is positioned beneath layers of mannans and glucans in the fungal cell wall, 
thus secreted host chitinases are needed to penetrate the wall matrix and make chitin 
fragments available to host surveillance (163). Mammals encode two functional 
chitinases, chitotriosidase (Chit1) and acidic mammalian chitinase (AMCase) (162). A 
naturally occurring allele of CHIT1 renders the enzyme inactive (164), and these 
mutations have been associated with susceptibility to parasitic worm infection in humans 
(165). Likewise, AMCase has been linked to eosinophilia (98) and alternative 
macrophage activation (100) in mouse models of pulmonary allergy. Consequently, we 
reasoned that mammalian chitinases could be necessary for efficient host recognition of 
fungal chitin and subsequent Th2 cell priming.  
 Using an inhalation model of Cryptococcus neoformans infection and novel 
reagents to detect Cryptococcus-specific Th cells, we unravel the basis for Th2 cell 
induction in response to pulmonary fungal infection. We report profound accumulation of 
detrimental Th2 cells in the lungs of infected mice. We additionally show that lung-
resident CD11b+ interferon regulatory factor (IRF) 4-dependent conventional dendritic 
cells present antigen to Th cells and drive potent Th2 differentiation at the site of 
infection in the lungs. Surprisingly, our results demonstrate that an excess of fungal 
chitin, as well as digestion of chitin via Chit1, and not AMCase, lead to chitin detection, 
Th2 cell accumulation, and enhanced disease. Lastly, we observed increased Chit1 
activity in humans with confirmed fungal infections, reinforcing the relevance of Chit1 in 
human disease. This study offers novel insights into the cellular source of antigen 
presentation and molecular basis of chitin recognition via Chit1 that underlies deleterious 
Th2 cell formation during pulmonary mycosis.  
   48 
RESULTS  
 
Pulmonary cryptococcal infection results in profound accumulation of antigen-specific 
Th2 cells. 
 We utilized a murine model of pulmonary cryptococcosis to investigate Th cell 
priming during fungal infection. Upon inhalation, Cryptococcus neoformans establishes a 
robust lower respiratory tract infection that causes tissue damage and ultimately leads to 
mortality from pulmonary complications and dissemination resulting in 
meningoencephalitis. To distinguish Th cell responses to infection from non-specific 
wound healing Th2 cell responses, we generated a recombinant peptide-major 
histocompatibility class II (pMHCII) tetramer that enabled identification of C. 
neoformans antigen-specific Th cells. The pMHCII tetramer contains a 13 amino acid 
peptide from an immunodominant cryptococcal protein, chitin deacetylase 2 (Cda2) 
(Table 1) (166). The Cda2-MHCII tetramer labeled a population of antigen-experienced 
(i.e. CD44+) Th cells, but it did not stain non-activated (i.e. CD44-) Th cells from C. 
neoformans infected mice or CD44+ Th cells from naive mice (Fig. 1A, S1 Fig. for flow 
cytometry gating). In addition, mice infected with a C. neoformans mutant (cda2Δ) that 
lacks Cda2 protein expression (167) had marked reductions in Cda2-MHCII tetramer 
binding cells (Fig. 1A). Though Cda2 contains a dominant CD4+ T cell epitope, cross-
reactivity to other closely related cryptococcal proteins likely account for the remaining 
tetramer binding Th cells generated during infection with cda2Δ (Table 1). Taken 
together, these studies show the Cda2-MHCII tetramer reliably identified antigen-specific 
CD4+ T cells produced in response to C. neoformans infection.  
We characterized the immune response in the lung and lung-draining mediastinal 
lymph node (MLN) to determine the relative contributions of each site to CD4+ T cell 
subset differentiation. Pulmonary cryptococcal infection resulted in a progressive 
accumulation of Cda2-MHCII-specific T cells in the lungs that predominately expressed 
the Th2 cytokines IL-5 and/or IL-13 (Fig. 1B-D). In addition, Th2 cytokines IL-5, IL-13, 
and CCL5 were among the most abundant cytokines present in infected lung 
homogenates (Fig. 1E), and eosinophils, a downstream correlate of type-2 cytokines, 
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represented an overwhelming majority of the bulk leukocyte population in the lungs (S2 
Fig. for flow cytometry gating, S3A Fig.). In contrast, the Cda2-MHCII-specific Th2 cell 
response within the MLN (Fig. 1F-H) was significantly lower than the response observed 
in the lungs, and eosinophils comprised an insubstantial component of the lymph node 
resident leukocytes (S3 Fig.). These findings collectively suggest the local inflammatory 
environment in the lung may shape the differentiation and/or promote the selective 
expansion of Th2 cells. 
 
Interleukin-2 cytokine/antibody complexes enhance Th2 cell expansion and disease. 
 Due to the seemingly contradictory roles of Th2 cells in beneficial wound healing 
responses and harmful allergic disease (168), it is not entirely clear whether Th2 cells 
simply correlate with or cause disease associated with fungal infection. To test the causal 
relationship of Th2 cells with disease severity in this model, we augmented the 
endogenous Th2 cell response to fungal infection using IL-2 cytokine/antibody complex 
treatment. IL-2 can be targeted to the high affinity IL-2 receptor to enhance Th cell 
proliferation by conjugating IL-2 cytokine with anti-IL-2 antibody to form IL-2 
cytokine/antibody complexes (169, 170). Since Th2 cells generated during pulmonary 
cryptococcal infection expressed high levels of the alpha chain of the high affinity IL-2 
receptor (CD25) (Fig. 2A), we sought to use IL-2 complexes to boost the Th2 cell 
response. 
 The wildtype strain of C. neoformans, KN99α, induces an extremely aggressive 
infection that leaves little room to increase the Th2 cell response. Consequently, we used 
an attenuated strain of C. neoformans, gpr4Δgpr5Δ (attenuation explained below/Figure 
5; deficient in production of large, chitinous cells). Treatment with IL-2 complexes 
increased Th2 cell numbers compared with similarly infected mice receiving antibody or 
cytokine alone (Fig. 2B). Th2 cells and cytokines were also elevated in lung 
homogenates from infected mice treated with IL-2 complexes (Fig. 2C&D). In addition 
to Th2 cells, Regulatory T (Treg) cells can be expanded by IL-2 complex treatment (169, 
170) (S4A Fig.). This increase of Treg cells in mice treated with the IL-2 complex could 
theoretically suppress protective Th cell responses and allow Th2 cells to predominate the 
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response. However, IL-2 complex treatment did not affect Th1 or Th17 cell numbers 
(Fig. 2B) and only minimal changes in IFNγ cytokine (Fig. 2C) and monocyte 
accumulation (Fig. 2D) were observed, showing IL-2 complex treatment did not 
eliminate the effector activity of protective Th1 cells (Fig. 2D). Instead, Schulze et al. 
(171) showed Treg cells suppress Th2 cells during cryptococcal infection (S4B&C Fig.), 
suggesting the increase in Treg cells due to IL-2 complex treatment would actually limit 
Th2 cell accumulation in this system. Hence, IL-2 complexes can be used to augment the 
Th2 cell response during pulmonary fungal infection and assess the relationship between 
Th2 cells and fungal disease. 
 If Th2 cells promote disease, we hypothesized that increasing the Th2 response 
should accelerate death during infection with the virulence-attenuated strain, 
gpr4Δgpr5Δ. IL-2 complex treatment increased the Th2 cell response to levels even 
higher than the fully virulent KN99α infection (Fig. 2E). Treatment with IL-2 complexes 
also greatly reduced the survival time of infected mice (Fig. 2F) without affecting 
pulmonary fungal burden (Fig. 2G). Uninfected mice treated with the same regimen of 
IL-2 complexes survived more than 30 days and remained healthy (Fig. 2F), indicating 
the IL-2 complex treatment targeted detrimental cells that were only present during 
infection. IL-2 treatment of infected mice also induced obvious lung pathology consistent 
with increased Th2 activity, noted by increased metaplasia of the bronchiolar epithelium 
and mucous obstruction of the airways (Fig. 2H). En masse, these data indicate that Th2 
cells exacerbate pulmonary disease during fungal infection. 
 
Th2 cells are primed at the site of infection by IRF4-dependent conventional dendritic 
cells. 
 The diminished Th2 response in the MLN compared to the lung led us to question 
whether lymphoid priming was required for Th2 cell induction during pulmonary fungal 
infection. Fms-like tyrosine kinase 3 ligand (Flt3L) is a differentiation factor for several 
hematopoietic cell subsets, and genetic deletion of Flt3L causes defects in antigen 
presenting cell traffic between the site of infection and secondary lymphoid organs (172). 
Flt3L deficient mice infected with C. neoformans neither experienced mediastinal 
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lymphadenopathy (Fig. 3A) nor elicited a polyclonal Th2 response in the MLN (Fig. 3B). 
Surprisingly, the Th2 cell response in the lungs after C. neoformans infection was 
unaffected by Flt3L deficiency compared to wildtype animals (Fig. 3C), indicating 
lymphoid priming is not required for pulmonary Th2 cell accumulation. 
 To determine the immune cell intermediate that primes Th2 cells in the lungs, we 
relied on the fact that Th cells are MHCII restricted. Three leukocyte subsets that express 
MHCII exist in the lungs of mice infected with C. neoformans: monocytes, CD11c+ 
cells, and B cells (Fig. 4A). Of these, CD11c+ cells are the most abundant in the lungs 
during cryptococcal infection (Fig. 4A). Consequently, we interrupted the specific 
interaction between CD11c+ cells and Th cells by generating mice with conditional 
deletion of MHCII in cells that express CD11c (CD11c-cre MHCII fl/fl) (Fig. 4B). 
Unlike NOD/SCID/Rag mice that fail to generate mature Th cells, naïve CD11c-cre 
MHCII fl/fl mice produced an equivalent number of Th cells as naïve wildtype mice (Fig. 
4C), showing the peripheral Th cell compartment remained intact in CD11c-cre MHII 
fl/fl mice. Thus, conditional deletion of MHCII on CD11c+ dendritic cells allowed 
specific disruption of the interaction between the dendritic cells and the Th cells in the 
periphery. Pulmonary Th cell expansion during cryptococcal infection was completely 
abolished in CD11c-cre MHCII fl/fl mice (Fig. 4C-D). Consequently, MHCII-bearing 
CD11c+ cells prime antigen-specific Th cells in the lungs of mice infected with C. 
neoformans. 
 CD11c+ cells are a heterogeneous group of macrophages and several dendritic 
cells (DC) subsets in the lungs (173). Therefore, we sought to discern the specific lineage 
of the CD11c+ antigen presenting cell that is responsible for pulmonary Th2 cell 
induction using an unbiased forward genetic screen of mouse lines genetically deficient 
in various CD11c+ subsets or their ability to interact with Th cells via MHCII (S5A Fig.). 
Lysozyme M (LysM)-cre MHCII fl/fl (macrophages and granulocytes (174)), BATF3-/- 
(CD103+ conventional dendritic cells (156)), and CCR2-/- (monocytes and monocyte-
derived dendritic cells (175)) mice generated robust antigen-specific Th2 responses 
during cryptococcal infection (S5-6 Fig.). Only mice deficient in CD11b+ conventional 
dendritic cells, abrogated using CD11c-cre IRF4 fl/fl mice, experienced blunted Th2 cell 
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accumulation with cryptococcal infection (Fig. 4E-H). Therefore, our exhaustive search 
revealed lung-resident CDllc+ CDllb+ IRF4-dependent conventional DC (referred to as 
CD11b+ conventional DC) are uniquely required for Th2 cell induction in response to 
pulmonary cryptococcal infection.   
  
Fungal chitin correlates with Th2 cell induction and subsequent disease. 
 Existing evidence and our data show CD11b+ conventional dendritic cells are 
capable of inducing both Th17 and Th2 cell responses to pulmonary fungal infection 
(176); therefore, these DC are not inherently programmed to specify a single Th cell 
lineage. Determination of Th2 cell fate by these lung resident DC must require higher 
order detection of specific features of the fungal infection. Many chitin-containing 
pathogens, as well as asthma/allergy models using purified chitin, evoke type-2 immunity 
(69, 100, 160). Consequently, the striking Th2 cell response to pulmonary fungal 
infection prompted us to explore the role of chitin as a Th2 cell adjuvant.  
 Maintaining chitin homeostasis is critical for cell wall integrity and microbe 
vigor. Chitin synthases that regulate cell wall chitin deposition are often essential for 
fungal viability or are part of a redundant pathway (177). As a result, studies that attempt 
to correlate loss-of-function mutations in chitin synthesis genes with modulation of the 
host response and attenuation of virulence would be challenging to interpret. Whether 
loss of Th2 cells and alterations in disease were due to a decrease in chitin, a loss of 
cryptococcal fitness/growth, or unmasking of other antigens due to modifications of the 
fungal cell wall or capsule would not be easily distinguishable (178).  
 In lieu of testing the requirement of chitin in Th2 cell induction, we exploited a 
natural property of C. neoformans to determine if increased fungal chitin was sufficient to 
expand Th2 cell formation. Approximately 20% of wildtype cryptococcal cells (KN99α) 
recovered from the lungs of infected mice increase in diameter from <10 μm to 15-100 
μm (32-34). Previous studies have shown these enlarged cells, known as titan cells, 
exhibit increased thickness of the fungal cell wall (33). Using the fluorescent dye 
calcofluor white to measure chitin content in individual cells by epifluorescence 
microscopy (Fig. 5A-B), or at the population level with flow cytometry (S7A Fig.), we 
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found the large C. neoformans titan cells contained more chitin, at a higher density, than 
the typical sized cells. C. neoformans produces several enzymes that deacetylate chitin to 
form chitosan (167, 178). Biochemical analyses additionally revealed that the amount of 
chitosan produced by titan cells and typical size cells did not differ, whereas chitin was 
significantly more abundant in the titan cells (Fig. 5C). Therefore, enhanced chitin 
content accompanied cell size increases during formation of cryptococcal titan cells.  
 To control for the relative effects of cell size and chitin content on Th2-mediated 
disease, we utilized several mutants of C. neoformans. A strain with targeted deletions in 
G protein-coupled receptor (gpr) 4 & gpr5 produces >95% typical sized cells in vivo 
(35), and these cells retain normal amounts of chitin (Fig. 5A). Deletion of the 
transcription factor Rim101 (rim101Δ) abolishes titan cell production (35, 38), yet the 
typical sized cells have increased expression of chitin synthesis genes and elevated chitin 
content (179, 180) (Fig. 5A). Using these mutants, we were able to dissociate 
cryptococcal cell size from cell wall chitin as well as manipulate the total amount of 
chitin present during infection (Table 2). 
 We examined the impact of alterations in chitin content in C. neoformans on Th2 
cell accumulation in the lungs. Antigen-specific Th cell priming and Th2 cell 
differentiation were reduced in mice infected with the low chitin gpr4Δgpr5Δ strain 
compared to infections with both the high chitin KN99α (due to titan cell production) and 
rim101Δ strains (Fig. 5D-E). The Cda2-independent polyclonal Th2 cell response to 
gpr4Δgpr5Δ infection was also significantly lower than the responses to KN99α and 
rim101Δ infections (S7B Fig.), indicating the defect in antigen-specific Th2 cell 
accumulation to gpr4Δgpr5Δ infection was not due to differential expression of cda2 
between the strains. Finally, the secreted Th2 cytokines IL-5, IL-13, and CCL5 present in 
lung homogenates from mice infected with gpr4Δgpr5Δ were significantly reduced 
compared to KN99α and rim101Δ infections (Fig. 5F). Of note, secreted Th1 and Th17 
cytokines, interferon-γ and IL-17A, did not concomitantly increase in response to 
gpr4Δgpr5Δ infection (Fig. 5F). Thus, Th cells not receiving strongly polarizing Th2 
signals in the gpr4Δgpr5Δ infection failed to acquire an alternate Th1 or Th17 cell 
differentiation fate. Since KN99α and rim101Δ strains contribute more total chitin to the 
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infection than the gpr4Δgpr5Δ strain (Table 2, S7A Fig.), these data demonstrate that 
chitin abundance and not cell size positively correlated with Th2 cell response intensity. 
 Uncontrolled factors affected by the gpr4Δgpr5Δ or rim101Δ mutations could 
correlate with chitin levels and independently contribute to Th2 cell accumulation. To 
directly test if purified chitin can increase Th2 cell numbers, mice were infected with 
gpr4Δgpr5Δ, and <10 μm chitin particles were co-administered into the lungs. Chitin 
treatments partially rescued the attenuated Th2 cell response (Fig. 5G). Importantly, this 
effect was observed in the clonal population of antigen-specific cells, and therefore, 
chitin increased the potency of Th2 cell induction during C. neoformans infection. 
 We examined the correlation between chitin, Th2 cell accumulation, and disease 
severity in our experimental model of cryptococcal infection. Infections with the high 
chitin strains, KN99α and rim101Δ, significantly hastened the time to death relative to 
mice infected with gpr4Δgpr5Δ (Fig. 5H).  Interestingly, all strains had equivalent 
pulmonary colony forming units at 14-days post-infection, indicating the differences in 
disease were not simply due to a failure to control the infection (Fig. 5I), but rather 
paralleled the total amount of chitin present during infection (Table 2). In summary, both 
chitin production by C. neoformans and Th2 cell accumulation directly correlated with 
exacerbation of lethal fungal disease.  
 
Chitotriosidase deficiency confers resistance to Th2-mediated fungal disease. 
 We next investigated host intrinsic factors that could influence detrimental Th2 
cell responses to chitin - specifically the mammalian chitinases, AMCase and Chit1. pH-
sensitive differences in enzyme activity allow for an assessment of the contribution of 
each enzyme to chitin cleavage. Consistent with published reports, recombinant AMCase 
cleaved 4-methlylumbelliferone chitotriose across a broad pH range, whereas 
recombinant Chit1 was only active at less acidic pH (Fig. 6A) (181). Chitinase activity in 
lung homogenates from infected mice was significantly elevated compared with 
uninfected animals at pH 2 and pH 5 (Fig. 6A). Furthermore, lung homogenates from 
infected mice genetically deficient in Chit1 or AMCase both showed decreased cleavage 
of the fluorescent chitin substrate (Fig. 6A). These data indicate both chitinase enzymes 
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are active during pulmonary fungal infection, and genetic abolishment of these enzymes 
can be used to understand the effect of chitin degradation on Th2-mediated fungal 
pathogenesis.  
 To test the hypothesis that Th2 cell-associated disease depends on chitinases, we 
infected wildtype, Chit1-/-, and AMCase-/- mice with C. neoformans and quantified the 
Th2 cell response. Despite no differences in pulmonary fungal burden at 14-days post-
infection (S8A Fig.), Th2 cells were 10-fold less abundant in the lungs of infected Chit1-
/- mice compared with wildtype controls (Fig. 6B-C), and this trend was consistent with 
all the strains of C. neoformans tested (S8B Fig.). Conversely, AMCase deficiency did 
not impact Th2 cell quantities after cryptococcal infection (Fig. 6B-C). Furthermore, 
Chit1 deficiency and not AMCase deficiency also significantly extended the survival of 
mice infected with C. neoformans relative to age matched, wildtype animals (Fig. 6D-E). 
The loss of Th2 cell accumulation with Chit1 deficiency was responsible for attenuation 
of disease, because the use of IL-2 complexes to boost Th2 cell numbers (Fig. 6C) and 
associated cytokines (Fig. 6F) also hastened lethal disease in Chit1-/- mice compared 
with infection-matched, untreated Chit1-/- controls (Fig. 6D). Similar to our previous 
studies using the IL-2 complex, Th1 cytokine production in the Chit1-/- mice was only 
minimally affected by the IL-2 complex treatment (Fig. 6F). Thus, the presence of Chit1, 
and not AMCase, positively influences Th2 induction and subsequent disease. 
 
Digestion of chitin via chitotriosidase promotes Th2 cell accumulation. 
 Chitin receptors in plants bind chitin oligomers (182), and chitin polymer size 
also influences the mammalian immune response to chitin (183, 184). Since appropriately 
sized chitin fragments could result from chitin digestion by Chit1, we used 
heterogeneous-length chitin and highly purified chitin heptamers to understand the effect 
of Chit1-associated degradation of chitin on Th2 cell accumulation. Although treatment 
with heterogeneous-length chitin augmented Th2 cell induction in wildtype animals 
infected with gpr4Δgpr5Δ cells (Fig. 5F), it did not increase Th2 cell numbers in Chit1-
/- mice (Fig. 6G). Conversely, inoculation with mass equivalent amounts of chitin 
heptamers boosted the Th2 cell response in C. neoformans-infected animals with Chit1 
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deficiency (Fig. 6G), revealing the requirement for Chit1 in chitin polymer recognition 
can be bypassed by providing exogenous chitin fragments. Therefore, our data 
demonstrate a role for Chit1 in the chitin cleavage pathway that leads to Th2 cell 
accumulation. 
 We next examined how chitin fragments influence the upstream pathway of Th2 
cell induction. To test the hypothesis that DC interact directly with chitin fragments, we 
cultured primary pulmonary leukocytes from infected mice in the presence of R-
phycoerithrin-fluorophore conjugated chitin heptamers (RPE-GN7) or unbound REP-
streptavidin (RPE-SA). While RPE-GN7 labeled a subset of B cells that have been shown 
to bind chitin (160), RPE-GN7 did not adhere to conventional CD11b+ DC (S9A Fig.). 
Thus, we did not detect direct binding of chitin heptamers to the conventional DC. 
Furthermore, conventional CD11b+ DC stimulated ex vivo with PMA + ionomycin 
produced an important Th2 cell differentiation cytokine, IL-4, yet this DC subset did not 
express IL-4 upon stimulation with chitin heptamers (GN7) (S9B Fig.). Combined, these 
data suggest the CD11b+ conventional dendritic cells may not sense chitin levels directly. 
Pulmonary epithelial cells respond to chitin (101) and secrete several Th2-
inducing alarmins, thymic-stromal lymphopoietin (TSLP), IL-25, and IL-33 (69, 185, 
186). As a result, alarmin receptors on DC could potentially mediate the indirect 
recognition of chitin, leading to Th2 cell polarization during pulmonary fungal infection. 
We found CD11b+ conventional DC from the lungs of fungal infected mice expressed 
high levels of TSLP receptor, but not receptors for IL-25 or IL-33 (S9C&D Fig.), 
indicating this DC subset is capable of sensing TSLP generated by epithelial cells. Taken 
together, our data suggest Th2 cell induction by conventional CD11b+ DC appears to 
involve an indirect recognition of chitin oligomers. 
 
Chitotriosidase activity correlates with cryptococcal infection in humans. 
 The importance of Chit1 in promoting Th2 cell-mediated disease in an 
experimental model of cryptococcosis prompted us to investigate the relevance of 
chitotriosidase activity in human fungal disease. Blood samples were collected from 
human donors: 46 Ugandan patients presenting at the hospital for the first time with 
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AIDS and 38 similar AIDS patients experiencing acute cryptococcal disease (S1 Table). 
We analyzed chitotriosidase and AMCase enzymatic activity in plasma from each group 
as described for the mouse lung homogenates. Chitin substrate cleavage at pH=5 was 
significantly elevated in plasma from AIDS patients with cryptococcal infection when 
compared to AIDS patients without cryptococcal infection (Fig. 6H). Comparatively low 
levels of enzymatic activity were detected at pH=2 for each group, indicating that 
chitotriosidase and not acidic mammalian chitinase is the predominate chitinase produced 
by humans with cryptococcal infection (Fig. 6H). 
 To determine if the difference in chitotriosidase activity was due to an inherent 
propensity or deficiency in chitotriosidase expression, we used cryptococcal lysate 
antigens to stimulate chitinase production in whole blood samples from the human 
donors. Stimulation of whole blood from all patients induced robust chitotriosidase 
activity relative to unstimulated samples, and chitinase activity did not differ between the 
groups (Fig. 6H), indicating all human donors had equivalent capacity to produce 
chitotriosidase.  Chitinase activity was not detectable in pure cryptococcal culture 
supernatants or cryptococcal lysate antigens (S10 Fig.), and as a result, the chitinase 
activity detected in the assays with human samples was not due to Cryptococcus-derived 
chitinases. Taken together, we conclude that fungal antigen induces chitotriosidase 
activity in humans experiencing cryptococcosis.  
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DISCUSSION 
 
 An association between pulmonary fungal exposure and allergic Th2 
inflammation is well established (53, 75). Fungal proteases (99) and fungal chitin (187) 
impact the innate immune responses underlying allergic inflammation, but elements of 
Th2 cell induction are enigmatic. Using an experimental model of pulmonary 
cryptococcosis, we demonstrated that inhalation of C. neoformans establishes a robust 
pulmonary infection, and the potent antigen-specific Th2 cell accumulation required lung 
resident CD11b+ conventional DC. Since these CD11b+ conventional DC can stimulate 
Th2 or Th17 cell differentiation in response to C. neoformans and Aspergillus fumigatus 
exposure respectively (176), these DC must interpret specific features of the infection to 
direct Th2 cell fate. To this end, we found cryptococcal chitin and exogenous 
administration of chitin particles correlated with increased Th2 cell accumulation. We 
further showed that chitotriosidase activity was highest in mice and humans infected with 
C. neoformans, and Chit1 was necessary for efficient Th2 cell induction and disease in 
our murine model of cryptococcosis. Taken together, these data indicate the host response 
to fungal chitin is an important factor that enhances Th2 cell production during 
pulmonary fungal infection. 
Our findings narrow an important gap in the mechanism of pattern recognition of 
fungal chitin in the lungs (Fig. 7). We have shown Chit1 functions as a “gatekeeper” in 
making chitin fragments available to host surveillance, thereby promoting Th2 cell 
accumulation and disease. Additionally, the use of pharmaceutical grade chitin heptamers 
to augment Th2 cell responses establishes a new minimum component for chitin 
recognition in vertebrates. While we did not detect direct interactions between the 
CD11b+ conventional DC and labeled chitin ex vivo, other systems have shown chitin 
binding to the mannose receptor and subsequent recognition by TLR9 and/or NOD2 
(188). Alternatively, pulmonary allergy models demonstrate that lung epithelial cells 
recognize chitin fragments and produce the necessary alarmins for Th2 cell induction: 
TSLP, IL-25, and IL-33 (185, 186, 189). In our model, CD11b+ conventional DC express 
high levels of TSLPR. Finally, natural IgM has been shown to bind fungal carbohydrates, 
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including chitin, and facilitate the interaction of DC and fungal carbohydrates (160). 
Signals, such as alarmins or antibody-chitin complexes, could be received by CD11b+ 
conventional DC to direct Th2 cell differentiation via IL-4 or another novel pathway. 
 A major impediment in understanding Th cell responses to pulmonary fungal 
infection has been the lack of reagents to detect antigen-specific Th cells. Antigen-
specific reagents are particularly important when examining Th2 responses, because Th2 
cells can be induced by the wounding that occurs during infection. Our ability to track 
endogenously derived, antigen-specific Th cells with pMHCII tetramers (190) allowed us 
to present for the first time that Th2 cells produced in response to fungal pathogens are 
not part of a generalized wound healing response but are fungal-antigen specific. Unlike 
T cell receptor transgenic approaches, pMHCII tetramers permitted us to monitor the 
population of infection-specific Th cells in the polyclonal repertoire, while maintaining 
physiologic precursor frequency and clonal expansion. Thus, we are able to examine the 
Th cell response during the natural course of infection and keep all other variables 
constant. The availability of these pMHCII tetramers will undoubtedly empower 
cryptococcal researchers and accelerate the field of fungal immunology. 
 The use of IL-2 complexes allowed us to conveniently and reliably augment the 
Th2 cell response to further understand unappreciated elements underlying Th2-mediated 
disease. This strategy is amenable to any host or microbial genetic model, which 
facilitates direct comparisons. Also, this gain-of-function approach permitted us to test 
the sufficiency of Th2 cells to exacerbate disease. These data, combined with loss-of-
function studies by other groups (62, 191), alter the longstanding paradigm that 
susceptibility to lethal fungal disease is traditionally viewed as a breakdown in protective 
immunity. This paradigm is supported by the higher prevalence of invasive fungal 
disease in immunosuppressed individuals, including people living with HIV/AIDS, 
cancer patients undergoing chemotherapy, and solid organ transplant recipients. 
However, we propose that in addition to the lack of a protective response, an independent 
development of a harmful Th2 cell response further exacerbates disease. This is 
particularly important in the the case of human cryptococcocosis were a compromised 
immune system not only lacks sufficient quantities of lymphocytes to resolve the fungal 
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infection, but the residual Th cell repertoire is plastic and detrimentally influenced by the 
microbe (6, 57, 58, 148). 
 A subset of innate lymphoid cells (ILC) produce the Th2 cytokines, IL-5 and IL-
13 (192), and these so-called ILC2 have been shown to contribute to allergic airway 
disease (97). While IL-2 complex treatment dramatically increases Th2 cell accumulation 
and enhances pulmonary disease, ILC numbers are not affected by IL-2 complex 
treatment in our model. Likewise, CD25+ ILC2 exist in the lungs under homeostatic 
conditions (193), yet uninfected mice exhibit no ill effects of IL-2 complex treatment. 
However, the developmental relationship of ILC2 to lymphocytes, combined with the 
lack of lineage markers expressed by ILC, make it challenging to separate the relative 
effects of Th2 cells and ILC2 in driving immunopathology. Thus, our conclusion that 
Th2 cells are vital mediators of disease does not categorically exclude the participation of 
ILC2 in this process. 
 CD11b+ conventional DC are an ontologically distinct mononuclear phagocyte 
subset that require IRF4 for maturation (156). Although it has been suggested that this 
subset is also functionally unique in programing specific Th cell differentiation, building 
evidence seems to indicate a plastic role of these cells in Th cell induction. CD11b+ 
conventional IRF4-dependent DC have been shown to coordinate Th2 cell priming 
following protease inoculation and worm infection in the skin (194), as well as house 
dust mite extract installation in the lungs (195). However, several research groups have 
found the same DC subset, using identical host genetic systems, can control Th17 cell 
differentiation in the gut under homeostatic conditions (196) and the lungs after fungal 
infection (176). While these observations infer that CD11b+ conventional DC are plastic, 
these cells may have different functions in the skin and gut compared to the lungs that 
could explain their role in priming Th17 and Th2 cell responses.  Our findings showing 
Th2 priming by C. neoformans, combined with work by Schlitzer et al. showing IRF4-
dependent DC are capable of priming Th17 cells in response to A. fumigatus to 
pulmonary fungal infection, highlight a fatal flaw in the notion that DC subsets are 
inherently specialized to control Th cell lineage fate. As a result, we explored an 
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alternative hypothesis that higher order signals (e.g. chitin recognition) are required for 
pulmonary CD11b+ conventional DC to promote Th2 cell priming to fungal infection.   
 Gene deletions in microbes can cause pleiotropic phenotypes, as seen in the 
rim101Δ strain (35) that can complicate interpretation of the effects of these mutations on 
host responses. However, the data obtained from the mutants utilized in this study 
support the conclusion that fungal chitin promotes Th2-mediated disease for several 
reasons. First, equivalent fungal burden in the lungs at 14 days post-infection indicates 
these mutations do not confer an inherent survival advantage or disadvantage for the 
fungus, and any effect the mutants have on leukocyte accumulation or disease is not 
simply driven by antigen load. Second, Rim101 transcriptionally controls many elements 
associated with cryptococcal virulence, including pH responses, encapsulation, cell 
enlargement, and iron sequestration (37). While individual mutations in each of these 
pathways should result in a loss of virulence, the rim101Δ mutants paradoxically exhibit 
equivalent or accelerated disease (179). Altered expression of cell wall synthesis genes 
combined with unmasking of the cell wall has been posited (179, 180), and in particular, 
our data implicate cell wall chitin in enhancing fungal pathogenesis associated with 
rim101 deficiency. More importantly, we view rim101Δ as an essential control for the 
effect cryptococcal cell size has on Th2 cell formation more than an independent test of 
the hypothesis that fungal chitin drives Th2 cell priming. Thus, we needed a strain of C. 
neoformans that produces mostly small cells but retained elevated chitin density to offset 
the loss of elevated chitin density with titan cell deficiency. At a minimum, these data 
prove that large cryptococcal cell size is not driving robust Th2 cell accumulation. 
Finally, due to the structural similarities, as well as the interdependent synthetic 
pathways, it is extremely challenging to decouple how chitin and chitosan separately 
impact a complex biological system. Although we cannot rule out immunomodulatory 
effects of chitosan in our experiments with C. neoformans mutants, we have confirmed 
chitin alone, when provided as an adjuvant, is sufficient to augment Th2 cell 
accumulation. Interpretation of the Cryptococcus chitin mutant data in the context of our 
additional data regarding host recognition of exogenous chitin builds a compelling 
argument that fungal chitin promotes detrimental Th2 cell induction. 
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 Acidic mammalian chitinase has been previously implicated in innate type-2 
responses (197).  However, a head-to-head comparison of the effect of both mammalian 
chitinases, chitotriosidase and acidic mammalian chitinase, has never been performed in 
any model, much less in the context of Th2 cell responses to fungal infection. 
Surprisingly, chitotriosidase, and not acidic mammalian chitinase, influenced Th2 cell 
accumulation and disease during pulmonary fungal infection. While no direct explanation 
exists, the different patterns of expression of AMCase and Chit1 could explain our 
results. AMCase is produced by a number of cells including several leukocyte subsets 
and pulmonary epithelial cells, whereas Chit1 expression is restricted to mononuclear 
phagocytes, including DC (181, 198). Since these DC are the main coordinators of 
antigen presentation to CD4+ T cells, the close proximity of chitin degradation and 
recognition likely allows the DC to efficiently influence the fate of CD4+ T cells during 
pulmonary fungal infection.  Furthermore, the varying pH-dependent enzymatic activity 
of Chit1 and AMCase suggest these enzymes may function in disparate anatomical and 
subcellular compartments that may bias their participation in response to pulmonary 
fungal infection.  
 Considering Th2 cell responses likely evolved to resist parasitic infection (161), 
the asymmetric global distribution of CHIT1 alleles (199) combined with the data 
presented herein offers a unique perspective on why individuals from tropical regions 
with endemic parasites tend to experience frequent and severe mycosis (8, 200-203). 
Ethnic groups historically residing in regions with highly prevalent parasites like 
Strongyloides tend to maintain functional CHIT1, whereas populations from more 
temperate climates with lower endemic parasitic burdens frequently possess 
enzymatically inactive CHIT1 alleles (199). Perhaps continuous fungal exposure in the 
absence of parasitic encounters provides sufficient negative selection pressure to 
eliminate functional CHIT1 alleles from these populations (e.g. Europe). Conversely, 
ethnic groups historically residing in tropical areas (e.g. Africa) that maintain functional 
CHIT1 alleles may have enhanced protection against common parasitic exposures, while 
these same individuals experience exacerbation of Th2-mediated fungal disease (8, 202, 
203). 
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 In conclusion, we elucidated a novel mechanism of Th2 cell induction during 
fungal infection. CD11b+ DC, and importantly recognition of chitin via Chit1, drives the 
generation of deleterious Th2 cells responding to pulmonary fungal infection. Next 
generation anti-fungal treatments should not only block fungal growth, but should also 
target the host immune response.  A recent trial used IFNγ in combination with 
traditional anti-fungal therapy to promote beneficial immune responses. This treatment 
improved cryptococcal clearance, yet it had no significant impact on patient survival (55). 
Our study suggests treatments that additionally aim to suppress the pathologic Th2 
response, perhaps through chitotriosidase inhibition, may be necessary to improve 
clinical outcomes. Ultimately, the coordinated efforts of microbiologists, immunologists 
and infectious disease physicians will enable personalized medicine approaches that 
effectively combat lethal fungal infections by inhibiting fungal growth, promoting 
beneficial host responses, and dampening pathologic inflammation.   
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MATERIALS AND METHODS 
 
Ethics Statement.  This study was approved by the institutional review boards of the 
University of Minnesota, Makerere University, and the Uganda National Council of 
Science and Technology. Written informed consent was obtained from all human 
participants prior to inclusion in the sutdy, and all data were de-identified (204). All 
animal experiments were done in concordance with the Animal Welfare Act, U.S. federal 
law, and NIH guidelines. Mice were handled in accordance with guidelines defined by 
the University of Minnesota Institutional Animal Care and Use Committee (IACUC) 
protocol numbers 1010A91133 and 1207A17286 and University of Massachuesets 
IACUC protocol number A-1802.  
Mice. All mice used in this study were derived from a C57BL/6 background. C57BL/6J, 
LysM-cre (B6.129P2-Lyz2tm1(cre)Ifo/J), CD11c-cre (B6.Cg-Tg (Itgax-cre) 1-1Reiz/J), 
MHCII loxP (B6.129X1-H2-Ab1tm1Koni/J), Batf3 -/- (B6.129S(C)-Batf3tm1Kmm/J), CCR2 -/- 
(B6.129(Cg)-Ccr2tm2.1Ifc/J), B6.129(Cg)-Foxp3tm3(DTR/GFP)Ayr/J) mice were purchased from 
Jackson Laboratories (Bar Harbor, ME) and Flt3L -/- (C57BL/6-flt3Ltm1Imx) were 
purchased from Taconic (Hudson, NY). Crosses were performed when necessary to 
generate the mouse strains used in this study, as indicated in S2 Table. Chit1 -/- (205) 
mice were infected and processed in the laboratory of Kirsten Nielsen. AMCase -/- (206) 
mice were infected and processed in the laboratory of Stuart Levitz per MTA stipulations. 
All mice were housed in specific pathogen–free conditions. 
Cryptococcus. Cryptococcus neoformans var. grubii strains were streaked on yeast 
peptone dextrose (YPD) agar plates and incubated for 2 days at 30°C. YPD broth was 
inoculated with colonies from the aforementioned plate and incubated for 16 hours at 
30°C with gentle agitation. The inoculum was prepared by pelleting the culture, washing 
3 times with phosphate buffered saline (PBS), and resuspending in PBS at a 
concentration of 2x106 cells/mL. All strains used in this study were on a KN99α genetic 
background, and the complemented strains have wildtype phenotypes (35, 38, 167). 
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Infection. A well established intranasal pulmonary aspiration model of cryptococcosis 
was used for this study (207). 6-8 week old, sex-matched mice were anesthetized with 
pentobarbitol or isoflurane. 5x104 cryptococcal cells in 25 μL of PBS was placed on the 
nares of each mouse, and the mice aspirated the inoculum into the lower respiratory tract. 
Finally, the mice were suspended by their incisors for 5 minutes and subsequently placed 
upright in their cage until regaining consciousness. For survival studies, ten mice per 
group were infected as described above. Animals were monitored for morbidity and 
sacrificed when endpoint criteria were reached. Endpoint criteria were defined as 20% 
total body weight loss, loss of 2 grams of weight in 2 days, or symptoms of neurological 
disease. 
 
Tetramer Production. Nine amino acid peptides from Cda2 were selected using a 
MHCII loading algorithm (208). pMHCII tetramers were produced as previously 
described (209). In short, biotinylated pMHCII monomers were expressed in Drosophila 
melanogaster S2 cells and isolated from culture supernatants by affinity chromatography. 
Streptavidin-Phycoerythrin (Prozyme) was added to pMHCII monomers at a 4:1 molar 
ratio. Finally, tetramer formation was assessed by western blot analysis. 
 
Pulmonary Leukocyte Preparation. Lung leukocytes were isolated as previously 
described (210). Briefly, lungs were excised and minced to generate approximately 1 
mm3 pieces. The lung mince was incubated in HBSS (Invitrogen, Grand Island, NY) + 
1.3 mM EDTA solution for 30 min at 37°C with agitation, and then transferred to RPMI-
1640 (Invitrogen) medium supplemented with 5% Fetal Bovine Serum (FBS) 
(Invitrogen) and 150 U/ml type I collagenase (Invitrogen) and incubated for 1 h at 37°C 
with agitation. The cells were passed through a 70 μm filter, pelleted, and resuspended in 
44% Percoll-RPMI medium (GE Life Sciences, Pittsburgh, PA). A Percoll density 
gradient was created (44% top, 67% bottom), and the samples were centrifuged for 20 
min at 650 x g. The leukocytes at the interface were removed, washed 2 times with RPMI 
medium, and resuspended in PBS + FBS at a concentration of 107 cells/ml. CD4+ T cells 
were enriched using a Dynabeads CD4+ T Cell Negative Isolation Kit (Life 
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Technologies, Grand Island, NY) per manufacture’s instructions. After enrichment, ~106 
cells were suspended in 200 μL of restimulation buffer (RPMI + 10% FBS + 1% 
Penicillin/Streptomycin + 5 μg Brefeldin A) with (stimulated) or without (unstimulated) 
10 ng phorbol myristate acetate (PMA) and 50 ng ionomycin. After 6 hours, the cells 
were washed and immediately prepared for flow cytometry. 
 
IL-2 Complexes. 5 μg of murine IL-2 cytokine (Biolegend) and 25 μg of clone JES6-
1A12 anti-IL-2 antibody (Bio X Cell, West Lebanon, NH) were added to 100 μL of PBS 
at room temperature. Each mouse received intraperitoneal injections of IL-2 complexes 
every other day beginning at 5 days post-infection. 
 
Flow Cytometry. Samples were incubated for 5 minutes with CD16/32 antibody 
(Biolegend) to block the Fc receptor and prevent nonspecific antibody binding. 25nM 
Cda2-tetramer was added to the sample and incubated at 25°C for 1 hour in the dark. 
Samples were surface-stained at 4°C for 30 minutes with the following antibodies (see 
gating S1 Fig.): CD4 (RM4-5, BV605, Biolegend), CD8 (53-6.7, APC-eFluor 780, 
eBioscience, San Diego, CA), CD11b (M1/70, PE-Cy5, eBioscience), CD11c (N418, PE-
Cy5, eBioscience), B220 (RA3-6B2, PE-Cy5, eBioscience), and CD44 (IM7, Alexa Fluor 
700, Biolegend). The cells were then incubated in Foxp3 Transcription Factor Buffer 
(eBioscience) at 4°C for 30 minutes. The cells were labeled with antibodes against the 
following intracellular antigens: Foxp3 (FJK-16s, FITC, eBioscience), IL-5 (TRFK5, 
APC, Biolegend), IL-13 (eBio13A, eFluor 450, eBioscience), IL-17A (TC11-18H10.1, 
BV650, Biolegend), and IFNγ (XMG1.2, PE-Cy7, eBioscience). 1:200 antibody 
concentrations were used for surface staining, and 1:100 antibody concentrations were 
used for intracelluar staining. For data acquisition, events from the entire sample 
(500,000-1,000,000) were collected on a BD FACSCanto II flow cytometer (BD 
Biosciences, San Jose, CA), and the data were analyzed with FlowJo X (Tree Star Inc., 
Ashland, OR).  
 To account for cell loss during CD4+ T cell enrichment and mitogen 
restimulation, several calculations were performed. Total leukocyte numbers were 
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determined by hemacytometer count after Percoll density gradient separation. 2.5% of the 
sample was stained with the following antibodies: Ly6G (RB6-8C5, APC-eFluor 780, 
eBioscience), Ly6C (HK1.4, eFluor 450, eBioscience), CD11b (M1/70, BV650, 
Biolegend), CD11c (N418, BV605, Biolegend), NK1.1 (PK136, AF700, Biolegend), 
CD3 (17A2, PE-Cy5, Biolegend), CD4 (RM4-5, FITC, Biolegend), CD19 (6D5, PE-Cy7, 
Biolegend), Sca1 (D7, APC, Biolegend), and Siglec F (E50-2440, PE, BD Biosciences). 
Cells were identified as the following (see gating S2 Fig.): Th cells = CD11b- CD3+ 
CD4+. Eosinophils = CD11b+ CD11c- Siglec F+. Innate lymphoid cells = lineage- 
Sca1+. Dendritic cells and macrophages = CD11b+ CD11c+ Siglec F-. B cells = Siglec 
F- CD11b- CD11c- CD19+. Natural killer cells = Siglec F- CD11c- NK1.1+. Neutrophils 
= CD11b+ CD11c- Ly6G+. Monocytes = CD11b+ Ly6C+ Siglec F-. CD8+ T cells = 
Siglec F- CD11b- CD3+ CD4-. The proportion of CD4+ T cells was determined by flow 
cytometry, and this percentage was multiplied by the total number of lung leukocytes to 
calculate the number of CD4+ T cells per pair of lungs. The number of CD4+ T cells in 
the unstimulated, CD4+ T cell enriched sample was calculated after flow cytometric 
analysis, as described in the previous paragraph. The number of CD4+ T cells recovered 
in the unstimulated, enriched sample was divided by the total number of CD4+ T cells to 
calculate the CD4+ T cell isolation efficiency. Cell death due to mitogen restimulation 
was calculated by dividing the number of CD4+ T cells recovered in the stimulated 
sample by the number of CD4+ T cells recovered in the unstimulated sample. The 
number of Cda2+ Th2 cells was determined by dividing the number of Cda2+ IL-5 
and/or IL-13+ positive cells by the CD4+ enrichment and cell viability indices. 
 Dendritic cell subsets were determined using the following antibodies and gating 
strategy. CD3 (17A2, PE-Cy5, Biolegend), CD19 (6D5, PE-Cy5, Biolegend), Siglec F 
(E50-2440, APC, BD Biosciences), CD64 (X54-5/7.1, PE, Biolegend), MHCII 
(M5/114.15.2, AF700, Biolegend), CD11c (N418, BV605, Biolegend), CD11b (M1/70, 
BV650, Biolegend), CD103 (2E7, e450, eBioscience), FcεRI (MAR-1, PE-Cy7, 
Biolegend), TSLPR (PE, R&D Systems), IL-25R (9B10, PE, Biolegend), IL-33Rα 
(DIH9, PE, Biolegend), IL-4 (BVD6-24G2), PE, Biolegend), and GN7-PE (211). See 
gating S5B Fig. Dump = CD3+, CD19+, Siglec F+. Monocyte-derived DC = Dump-, 
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CD64+, CD11c+, MHCII+, CD11b+, CD103-, FcεRI+. CD103+ cDC = Dump-, CD64-, 
CD11c+, MHCII+, CD103+, CD11b-. CD11b+ cDC = Dump-, CD64-, CD11c+, 
MHCII+, CD11b+, CD103-. While CD103, CD11b, FcεRI, and CD64 surface markers 
allow convenient detection of each DC subset, it is unclear whether other 
developmentally and/or functionally unrelated cells can express similar markers. 
Consequently, genetic blockade in the developmental pathways of each DC subset were 
assumed to be completely penetrant, notwithstanding the persistence of cells expressing 
surrogate markers for each ontological subset.  
 
Lung Cytokines. Lungs from mice 14-days post-infection were excised, snap frozen in 
liquid nitrogen, and homogenized in 3 mL of T-PER (Thermo Fisher Scientific) with 
Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN). The lung homogenate 
was pelleted, and the supernatant was collected and stored at -80°C until analysis. 
Samples were diluted 1:4 in assay buffer immediately before processing. Cytokines were 
quantified using Luminex technology according to manufacturer instructions (Bio-Rad, 
Hercules, CA). 
 
Lung Histology. Lungs were removed from mice 14 days post-infection, perfused via the 
right ventricle with cold PBS, inflated with 10% formalin (Thermo Fisher Scientific, 
Rockford, IL), and placed in a container of 10% formalin. Tissues were dried with 
organic solvent, embedded in parafin, sectioned, and stained with hematoxylin and eosin, 
before images were captured. 
 
Fungal Chitin/Chitosan Quantification. Cryptococcal cells were isolated from the 
lungs after enzymatic digestion and density gradient separation, as described above. Cells 
were fixed with 3.7% formaldehyde and stored at 4°C until analyzed. The cells were 
standardized to 1x106 cells/mL and stained for 2 minutes at 25°C with 1 μg/mL of 
Calcofluor White (Sigma Aldrich, St. Louis, MO) (212). Cells were washed and 
immediately processed with an epifluorescence microscope (Axio Imager M1, 40X/0.6 
lens, Zeiss Filter Set 02, Axio Cam MRc5, Axiovision 4.8; Carl Zeiss, Inc., Munich, 
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Germany). ImageJ software (NIH.gov) was used to calculate fluorescence intesity per 
pixel. For flow cytometry, large and typical sized cells were first gated by forward scatter 
properties to distinguish size. Chitin/chitosan content was then determined by 405 nm 
laser excitation and fluorescence detection at ~450 nm. 
 Biochemical chitin/chitosan quantification was adapted from Banks et al. (178). 
Purified titan cell (>15 μm) and typical sized cell (<15 μm) samples collected from 
infected mice were each divided into two aliquots: one treated with acetic anhydride to 
fully acetylate the chitin/chitosan polymer and the other was left untreated. 5 µl of 
purified Streptomyces griseus chitinase (5 mg/ml in PBS) was added to hydrolyze chitin 
to N-acetylglucosamine (GlcNAc) and samples were incubated for 3 days at 37°C. For 
colorimetric determination of GlcNAc, the Morgan-Elson method was adapted for 
microplate readers. Chitinase-treated samples were incubated with 0.27 M sodium borate 
(pH 9.0) and heated at 99.9°C for 10 minutes. Immediately upon cooling to room 
temperature, freshly diluted 10X DMAB solution (10 g p-dimethylaminobenzaldehyde in 
12.5 ml concentrated HCl and 87.5 ml glacial acetic acid) was added, followed by 
incubation at 37°C for 20 minutes.  Absorbance at 585 nm was recorded for each sample. 
Standard curves were prepared from stocks of 0.2 to 2.0 mM of GlcNAc (Sigma). The 
amount of GlcNAc was calculated as mol/g cells (dry weight). The acetylated samples 
contained chitin plus chitosan, and the untreated sample contained chitin. The difference 
between the two measurements estimated the amount of chitosan. 
 
Exogenous Chitin. Chitin was prepared as previously published (101). Chitin from 
shrimp shells (Sigma Aldrich) was pulverized with a mortar and pestle. 12.5N HCl was 
added, and the slurry was incubated at 40°C for 30 minutes. Chilled 10N NaOH was 
added until a neutral pH was attained. The sample was centrifuged at 2x104 g for 5 
minutes, the supernatant was decanted, and the sample was suspended in deionized water 
(dH2O). This step was repeated 3 times followed by a wash in ethanol. The sample was 
pelleted, suspended in dH2O, and filtered through a 10μm membrane (EMD Millipore, 
Billerica, MA). The solution containing <10 μm chitin was dried with a SpeedVac 
(Thermo Scientific, West Palm Beach, FL). The powder was weighed and resuspended in 
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PBS to make a concentration of 50 mg/mL (i.e. 10X). Endotoxin was measured by 
Limulus amebocyte lysate assay (Associates of Cape Cod, East Falmouth, MA) and was 
found to be less than 0.03 EU/mL. Chitin heptamers were purchased from Carbosynth 
(Berkshire, UK).  Mice were anesthetized and allowed to aspirate 125 μg of chitin 
suspended in 25 μL of PBS into the lungs at 0, 5, and 10 d.p.i. Pulmonary leukocytes 
from wildtype mice 14 days post-infection with KN99α were cultured and stimulated ex 
vivo for 5 hours with PMA + ionomycin (as previously described for Th cells) + 125 μg 
of chitin heptamers + golgi stop, or golgi stop alone (unstimulated) before processing by 
flow cytometry.  
 
Chitinase Activity. CycLex Acidic Mammalian Chitinase (AMCase) and Chitotriosidase 
(Chit1) Fluorometric Assays (MBL International, Woburn, MA) were used to detect 
chitinase activity. In brief, each of the following were added to pH 2 and pH 5 buffers 
containing 4-Methylumbelliferyl Chitotriose: 25 ng of recombinant AMCase, 25 ng 
recombinant Chit1, 10 μL of mouse lung homogenate, 10 μL of human plasma, 10 μL of 
lysate antigen, or 10 μL of culture supernatant of KN99α grown in YPD. The samples 
were incubated at 37°C in a Synergy H1 Microplate Reader (Biotek, Winooski, VT) and 
360 nm excitation/450 nm emission readings were obtained every 2 minutes. The relative 
fluorescent units (RFU) at 1 hour of incubation were compared to the RFU of serial 
dilutions of 4MU standard, and the molar concentration of cleaved chitin was calculated. 
 
Antigen Stimulation of Whole Blood. The assay was performed as previously described 
(6). Cell wall antigens were prepared from Cryptococcus neoformans, strain KN99α. The 
cells were flash frozen in liquid nitrogen, combined with glass beads, and vortexed 
vigorously for 2 hours at 4°C to disrupt the cells. The insoluble fraction (i.e., cell wall) 
was analyzed for protein concentrations (bicinchoninic acid protein assay; Thermo Fisher 
Scientific, Rockford, IL). Endotoxin levels in all antigen preparations were undetectable 
(<0.06 U/ml) by Limulus amebocyte lysate assay (Associates of Cape Cod, East 
Falmouth, MA). Whole-blood samples were obtained from AIDS patients at screening 
for the Cryptococcus Optimal Timing of Anti-retroviral Therapy Trial in Sub-Saharan 
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Africa (204). Peripheral blood samples from each subject were drawn into lithium 
heparin tubes, diluted 2-fold with PBS, and dispensed into a tissue culture plate. Cell wall 
antigens containing 5 μg of protein were added to the wells, and PBS was used as the 
“unstimulated” control. The plates were incubated at 37°C in 5% CO2 for 20 hours. After 
incubation, the plasma was separated from the cells and stored at 4°C until chitinase 
activity analysis. 
Statistics. P-values for pairwise comparisions were by Mann-Whitney U with Bonferroni 
adjustments for multiple comparisons. Global tests were by Kruskal-Wallis ANOVA. 
Surival curves were compared with Mann-Whitney tests. Power calculations were 
performed to assess appropriate sample size for all experiments. P-values ≤ 0.05 were 
considered statistically significant. All statistics and graphs were processed with Prism 6 
(GraphPad Software, La Jolla, CA). 
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Figure 1. Type-2 Helper T Cells Accumulate in the Lungs of Mice Infected with C. 
neoformans. (A) Cda2-MHCII tetramer identifies C. neoformans-specific helper T (Th) 
cells from mice 14 days post-infection with strain KN99α, cda2Δ, or age-matched, naïve 
mice. Flow cytometry plot (B) or graphs (C&D) from lung digests showing CD4+, 
Foxp3-, CD44+ Cda2+ Th cells expressing Th1 (IFNγ), Th2 (IL-5 & IL-13), or Th17 
(IL-17A) cytokines. (E) Cytokines from lung homogenates 14 days post-infection with 
KN99α or age-matched, naïve mice. Flow cytometry plot (F) and graphs (G&H) from 
mediastinal lymph node suspensions of Th cells expressing Th1, Th2, or Th17 cytokines. 
Data are presented as mean +/- standard error with 2 independent experiments of at least 
5 mice per group. Cda = Chitin deacetylase, CCL = chemokine ligand, IFN = interferon, 
IL = interleukin, MLN = mediastinal lymph node, TNF = tumor necrosis factor
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Figure 2. IL-2 Complexes Augment Type-2 Helper T Cells and Enhance Fungal 
Disease. (A) CD25 expression by naïve (CD4+, CD44-), Th2- (CD4+, CD44+, IL-5-, IL-
13-), and Th2+ (CD4+, CD44+, IL-5+, IL-13+) cells. (B) Cda+ Th cell numbers in the 
lungs of gpr4Δgpr5Δ infected mice treated with 5 μg IL-2, 25 μg anti-IL-2 antibody 
(JES6-1A12), or both (IL-2 Complex). Th1, Th17, and Th2 cells were identified by 
production of IFNγ, IL-17A, and IL-5/13, respectively. (C) Cytokines from lung 
homogenates of mice infected with gpr4Δgpr5Δ or age-matched naïve animals, with or 
without IL-2 complex treatment. (D) Pulmonary leukocytes from mice infected with 
gpr4Δgpr5Δ, with or without IL-2 complex treatment. (E) Cda2+ Th2 cells from lungs of 
mice infected with fully virulent KN99α, attenuated gpr4Δgpr5Δ, or mice infected with 
gpr4Δgpr5Δ and treated with IL-2 complex. (F) Survival of naïve mice or mice infected 
with gpr4Δgpr5Δ either with or without IL-2 complex treatment. P-value represents log-
rank test comparing each survival curve with 10 mice per group to: gpr4Δgpr5Δ vs. 
gpr4Δgpr5Δ + IL-2 complex, P<0.0005; gpr4Δgpr5Δ vs. KN99α, P<0.0005; gpr4Δgpr5Δ 
+ IL-2 complex vs. KN99α, P=0.23. (G) Fungal burden within lungs of mice with or 
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without IL-2 complex 14 days post-infection with gpr4Δgpr5Δ. (H) Hematoxylin and 
eosin staining of lungs from mice infected with gpr4Δgpr5Δ or similarly infected and 
treated with IL-2 complexes. A = brochial airway, E = epithelial cell layer. Data are 
presented as the mean +/- standard error with at least 2 independent experiments per 
group. * = P < 0.05, ** = P < 0.005, *** = P < 0.0005 by Mann-Whitney U. Cda = chitin 
deacetylase, CCL = chemokine ligand, DC = Dendritic Cells, IFN = interferon, IL = 
interleukin, ILC = Innate Lymphoid Cells, MΦ = Macrophages, NK = Natural Killer. 
TNF = tumor necrosis factor. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Lymphoid Priming is Dispensable for Pulmonary Th2 Cell Induction 
during Cryptococcal Infection. (A) Lymphadenopathy of mediastinal lymph nodes 
(MLN) after 14 days post-infection with strain KN99α. (B) Quantification of IL-5+ IL-
13+ polyclonal Th2 cells from the MLN in wild-type and Flt3L-/- mice. (C) 
Quantification of IL-5+ IL-13+ antigen-specific Th2 cells contained in the lungs of wild-
type and Flt3L-/- mice.   
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Figure 4. Interferon Regulatory Factor 4-Dependent Conventional Dendritic Cells 
Coordinate Th2 Cell Induction. (A) Antigen-presenting cells as a proportion of total 
MHCII+ cells in the lungs of infected mice. (B) MHCII expression by CD11b/c+ cells 
from mice 14 days post-infection with KN99α. Isotype refers to CD11b/c+ cells from 
wildtype mice stained with a rat IgG2b antibody of irrelevant specificity. (C) 
Quantification of pulmonary CD4+ Foxp3- CD44+ pulmonary Th cells. (D) 
Biexponential plot of CD4+ Foxp3- cells, indicating the absence of antigen-specific 
(CD44-, Cda2-) cells in the lungs of CD11c-cre MHCII mice infected with KN99α. (E) 
IRF4 expression by CD11b+ cDC from lungs of CD11cre IRF4 fl/fl or wildtype mice 14 
days post-infection with KN99α. Isotype refers to CD11b+ cDC from wildtype mice 
stained with a rat IgG1 antibody of irrelevant specificity. (F) Geometric mean 
fluorescence intensity of CD11b+ cDC in from the lungs of infected CD11c-re IRF4 fl/fl 
mice. (G) Quantification of monocytes and dendritic cell subsets from the lungs of 
mutant or wildtype mice infected with KN99α. (H) Quantification of IL-5+ IL-13+ 
antigen-specific Th2 cells contained in the lungs of mutant or wildtype mice 14 days 
post-infection with KN99α. Data are presented as mean +/- standard error. * = P < 0.05, 
*** = P < 0.0005, and n.s. = not significant by Mann-Whitney U. Cda = chitin 
deacetylase, Flt3L = fms-like tyrosine kinase 3 ligand, MHC = major histocompatibility 
complex, cDC = conventional dendritic cells, IRF4 = interferon regulatory factor 4. 
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Figure 5. C. neoformans Chitin Correlates with Type-2 Helper T Cell Response and 
Subsequent Disease. (A&B) Cryptococcal cells isolated from lungs at 14 days post-
infection and stained with Calcofluor White. Cells were either imaged with 
epifluorescence microscopy (A) or analyzed by flow cytometry with fluorescence 
intensity calculated per pixel to determine chitin density within the cell wall (B). (C) 
Total chitin and chitosan content normalized to dry weight of cryptococccal cells. (D) 
Flow cytometry plots of CD4+, Foxp3-, CD44+ Cda2+ Th cells expressing Th2 
cytokines, IL-5 & IL-13, at 14 days post-infection and (E) the quantification of these 
plots. (F) Cytokines from lung homogenates of mice 14 days post-infection. (G) IL-5+ 
IL-13+ antigen-specific Th2 cells from lungs of mice 14 days post-infection without and 
with intranasal chitin particle treatment. (H) P-value represents log-rank test comparing 
each survival curve with 10 mice per group to: gpr4Δgpr5Δ vs. KN99α, P<0.0005; 
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gpr4Δgpr5Δ vs. rim101Δ, P<0.0005; KN99α vs. rim101Δ, P<0.0005. (I) Fungal burden 
in the lungs at 14 days post-infection. Data are presented as the mean +/- standard error 
with at least 2 independent experiments per group. ** = P < 0.005, *** = P < 0.0005 by 
Mann-Whitney U or Kruskal Wallis ANOVA. Cda = chitin deacetylase, CCL = 
chemokine ligand, GlcNAc = N-acetylglucosamine, IFN = interferon, IL = interleukin. 
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Figure 6. Chitotriosidase Promotes Chitin Recognition and Th2 Cell-mediated 
Disease. (A) Chitinase enzyme activity of recombinant enzymes or lung homogenates 
from 14 days post-infected or naïve mice. (B) Flow cytometry plots of CD4+, Foxp3-, 
CD44+ Cda2+ Th cells expressing Th2 cytokines, IL-5 & IL-13, at 14 days post-infection 
and (C) the quantification of these plots. (D&E) Survival of mutant or wildtype mice 
infected with KN99α either with or without IL-2 complex treatment. Logrank test 
comparing each survival curve relative with 10 mice for each group to: Chit1 -/- vs. 
wildtype, P<0.005; Chit1 -/- vs. Chit1 -/- + IL-2 complex, P<0.0005; Chit1 -/- + IL-2 
complex vs. wildtype, P=0.07. (F) Cytokines from lung homogenates of naïve or 
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wildtype and Chit1-/- mice 14 days post-infection with KN99α or age-matched, naïve 
Chit1-/- mice. (G) IL-5+ IL-13+ antigen-specific Th2 cells from lungs of Chit1-/- mice 
14 days post-infection and mice treated with intranasal chitin particles or chitin heptamer 
fragments (C7). (H) Chitinase enzyme activity of human plasma without (LEFT) or with 
(RIGHT) cryptococcal lysate antigen stimulation. Data are presented as the mean +/- 
standard error with at least 2 independent experiments per group. * = P < 0.05, ** = P < 
0.005, *** = P < 0.0005 by Mann-Whitney U or Kruskal Wallis ANOVA. AMCase = 
Acidic Mammalian Chitinase, C7 = chitin heptamer, CCL = chemokine ligand, Cda = 
chitin deacetylase, Chit1 = Chitotriosidase, IFN = interferon, IL = interleukin, TNF = 
tumor necrosis factor. 
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Figure 7. Model of Th2 Cell-mediated Disease during Pulmonary Fungal Infection. 
(1) Chitotriosidase is released by the host and degrades fungal chitin to generate small 
chitin fragments, such as chitin heptamers. (2) Chitin recognition occurs by an unknown 
mechanism that could involve either epithelial cell production of alarmins, such as 
thymic stromal lymphopoietin (TLSP) [9] or antibodies that bind chitin (160). (3) These 
chitin-based signals are recognized by lung-resident CD11b+ conventional dendritic cells 
that are capable of producing IL-4, an essential Th2 cell differentiation factor. (4) The 
adaptive Th2 cell response results in enhanced disease in the absence of significant 
changes in pulmonary fungal burden. 
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Supplemental Figure 1. Helper T Cell Flow Cytometry Gating Strategy.  Single cell 
suspension isolated from lungs of wildtype mice 14 days post-infection with strain 
KN99α. Red or blue gate contains the entirety of the the subsequent plot below. “Th2” 
gate is drawn based on sample not incubated with PMA + ionomycin. 
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Supplemental Figure 2. Bulk Leukocyte Flow Cytometry Gating Strategy.  Single 
cell suspension isolated from lungs of wildtype mice 14 days post-infection with strain 
KN99α. Red arrows and words indicate leukocyte subset. 
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Supplemental Figure 3. Eosinophils Predominate in the Pulmonary Leukocyte 
Response to Cryptococcal Infection. Leukocytes harvested from (A) lungs or (B) 
mediastinal lymph nodes of mice 14 days post-infection with KN99α. Each subset is 
identified by non-redundant gating per Supplementary Figure 2. 
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Supplemental Figure 4. Foxp3+ Regulatory T Cells Specifically Suppress Type-2 
Helper T Cells During Pulmonary Fungal Infection. (A) Proportion of Th cells that 
express Foxp3 in wildtype mice infected and treated with IL-2, IL-2 antibody (JES6-
1A12), or IL-2 complex. (B-C) Foxp3-Diptheria Toxin (DT) Receptor mice received DT 
every other day beginning at 5 days post-infection. Single cell suspensions isolated from 
lungs of wildtype and Foxp3-DTR mice at 14 days post-infection with KN99α were 
analyzed as the proportion of CD4+ cells expressing Foxp3 to monitor Treg depletion 
(B), or CD4+, Foxp3-, CD44+ Cda2+ Th cells expressing Th1 (IFNγ), Th2 (IL-5 & IL-
13), or Th17 (IL-17A) cytokines to determine effector T cell differentiaion (C). Data are 
presented as mean ± standard error of the mean. * P < 0.05 and ***P < 0.0005 by Mann-
Whitney U. 
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Supplemental Figure 5. Analysis of CD11c+ Cell Subsets. (A) Diagram depicting the 
relationship between various CD11c+ cell subsets and mice used to delete/inhibit the 
subsets [5]. (B) Flow cytometry gating gtrategy.  Single cell suspension isolated from 
lungs of wildtype or mutant mice 14 days post-infection with strain KN99α. 
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Supplemental Figure 6. Macrophages, granulocytes, CD103+ Conventional 
Dendritic Cells, Monocytes, and Monocyte-derived Dendritic Cells are Dispensable 
for Th2 Cell Priming. (A) Eosinophils and neutrophils do not express MHCII during 
Cryptococcal infection. MHCII expression in eosinophils or neutrophils from lungs of 
mice 14 days post-infection with strain KN99α. Isotype refers to similar cells stained 
with a rat IgG2b antibody of irrelevant specificity. (B-G) Cells from wild-type, LysM-cre 
MHC fl/fl, CCR2-/-, or BATF3-/- mice 14 days post-infection with KN99α. (B) 
Representivive biexponential flow cytometry plot indicating the loss of macrophages in 
the lungs of LysM-cre MHCII fl/fl mice. (C) Quantification of antigen-specific Th2 cells 
in LysM-cre MHCII fl/fl infected mice. (D) Representative biexponential flow cytometry 
plot indicating the loss of monocytes (Ly6C+, CD11b+) and monocyte-derived DC 
(CD64+, CD11c+, MHCII+, FcεRI+) in the lungs of CCR2 -/- mice.  (E) Representative 
biexponential flow cytometry plot indicating the loss of CD103+ conventional dendritic 
cells in BATF3-/- mice. (F) Quantification of monocytes and dendritic cell subsets from 
the lungs of mutant or wildtype mice. (G) Quantification of antigen-specific Th2 cells in 
wild-type, CCR2-/-, and BATF3-/- infected mice.  
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Supplemental Figure 7. Cryptococcal Chitin Promotes Polyclonal Type-2 Helper T 
Cell Accumulation. (A) Cryptococcal cells isolated from lungs at 14 days post-infection. 
Cryptococcal cells stained with Calcofluor White, and analyzed with flow cytometry. (B) 
CD4+ Foxp3- IL-5+ IL-13+ polyclonal Th2 cells in the lungs of mice infected with high 
chitin (KN99α, rim101Δ) or low chitin (gpr4Δgpr5Δ) cryptococcal strains. Data are 
presented as the mean +/- standard error with at least 2 independent experiments per 
group. *** = P < 0.0005 by Mann-Whitney U. 
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Supplemental Figure 8. Chitotriosidase Promotes Th2 Cell Accumulation without 
Altering Fungal Burden. (A) Fungal burden in the lungs of wildtype, Chit1-/-, and 
AMCase-/- mice 14 days post-infection. (B) IL-5+ IL-13+ antigen-specific Th2 cells 
from lungs of mice 14 days post-infection. Data are presented as the mean +/- standard 
error with at least 2 independent experiments per group. ** = P < 0.005, *** = P < 
0.0005 by Mann-Whitney U or Kruskal Wallis ANOVA. 
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Supplemental Figure 9. CD11b+ Conventional Dendritic Cells Respond to Chitin 
Indirectly. Pulmonary leukocytes from wildtype mice 14 days post-infection with KN99 
α. (A) CD19 (B cells) or CD11c (dendritic cells) co-labeled with R-phycoerithrin 
conjugated to streptavidin with biotinylated chitin heptamers (RPE-GN7) or without 
biotinylated chitin heptamers (RPE-SA). (B) IL-4 expression of CD11b+ conventional 
dendritic cells after 5 hours of stimulation with PMA + ionomycin, 125 μg of chitin 
heptamers (GN7) or left unstimulated. Histogram (C) and quantification of alarmin 
receptor expression (D) by CD11b+ conventional dendritic cells. Data are presented as 
the mean +/- standard error with at least 2 independent experiments per group. ** = P < 
0.005, *** = P < 0.0005 by Mann-Whitney U. gMFI = geometric mean fluorescence 
intesity, TSLP = thymic stromal lymphopoietin. 
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Supplemental Figure 10. Cryptococcus Antigens and Culture Supernatants Do Not 
Possess Chitinase Activity. Chitinase activity at pH=2 and pH=5 as measured in 
Cryptococcus lysate antigens and YPD supernatant from overnight cultures.  
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Table 1. CD4+ T Cell Cda2-MHCII Tetramer Peptide Sequence and Putative Cross 
Reactive Peptides from Other C. neoformans Chitin Deacetylases. 
 
Gene Amino Acid Sequencea 
MHCII 
Scoreb 
cda1 WSHPALTTLTNEEIVAELG 36 
cda2c WSHQYMTALSNEVVFAELY 74 
cda3 WSHPYMTTLTNEQVVGELG 56 
fpd1 WSHADLTQLDESGINDELS 13 
 
The bold sequences indicate regions that align with the P1-P9 residues within the Cda2-
MHCII tetramer core. The underlined sequences correspond to the total peptide included 
in the Cda2-MHCII tetramer. 
a Homologous amino acid sequences within the catalytic domain of chitin deacetylases. 
b Peptide loading score on MHCII I-A
B (74). 
c Cda2-MHCII tetramer made from this gene and amino acid sequence.   
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Table 2. Differences in total chitin due to cell morphology 
 
Strain 
Proportion 
Titan Cellsa 
Chitin Per Cell 
(GMFI)b 
Titan Cell 
Chitin 
(GMFI) 
Typical 
Cell Chitin 
(GMFI) 
Relative Total 
Chitinc 
KN99α 20.4% 
47609 (Titan) 
3060 (Typical) 
9712 2436 4.0 
gpr4Δgpr5Δ 5.3% 
43590 (Titan) 
3102 (Typical) 
2310 2938 1.7 
rim101Δ 0.5% 
45708 (Titan) 
13112 (Typical) 
2235 12456 4.8 
 
a Proportion of cryptococcal titan cells in the lungs, as reported by Okagaki et al. 
2011(35). 
b Mean fluorescence intesity of calcofluor white in size-fractionated cryptococcal cells 
analyzed by flow cytometry. GMFI = geometric mean fluorescence intensity 
c Estimated total chitin calculated uising the folowing equation: Relative Total Chitin = 
[(Proportion Titan Cells × Titan GMFI) + (Proportion Typical Cells × Typical 
GMFI)]/KN99α Typical Cell GMFI 
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CHAPTER 3 
 
Regulatory T Cell Induction and Retention in the Lungs Drives Suppression of 
Detrimental Type-2 Helper T Cells During Pulmonary Cryptococcal Infection. 
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SUMMARY 
 
 Lethal disease caused by the fungus, Cryptococcus neoformans, is a consequence 
of the combined failure to control pulmonary fungal replication and immunopathology 
caused by induced type-2 helper T (Th2) cell responses. In order to gain insight into 
immune regulatory networks, we examined the role of regulatory T (Treg) cell 
suppression of Th2 cells, using a mouse model of experimental cryptococcosis. Upon 
pulmonary infection with Cryptococcus, Treg cells accumulated in the lung parenchyma 
independently of priming in the draining lymph node. Using peptide-MHCII molecules to 
identify Cryptococcus-specific Treg cells combined with genetic fate-mapping, we noted 
that a majority of the Treg cells found in the lungs were induced during the infection. 
Additionally, we found that Treg cells utilized the transcription factor, Interferon 
Regulatory Factor 4 (IRF4), to dampen harmful Th2 cell responses, as well as mediate 
chemokine retention of Treg cells in the lungs. Taken together, induction and IRF4-
dependent localization of Treg cells in the lungs allow Treg cells to suppress the 
deleterious effects of Th2 cells during cryptococcal infection.
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INTRODUCTION 
 
Cryptococcosis is an emerging infectious disease of humans caused by the fungus,  
Cryptococcus neoformans (8). Yeasts or spores are inhaled from the environment and 
enter the lower respiratory tract. Robust CD4+ helper T (Th) cell-mediated immunity 
controls this initial pulmonary infection, and as a result, immune replete individuals 
rarely experience overt disease. However, Th cell deficiencies associated with solid organ 
transplantation, cancer chemotherapy, and HIV/AIDS dramatically increases 
susceptibility to invasive cryptococcosis. In the absence of immune control, C. 
neoformans emigrates from the lung, enters the bloodstream, and traverses the blood-
brain barrier to cause cryptococcal meningitis. Despite access to standard antifungal and 
antiretroviral therapies, patients receiving treatment for cryptococcal meningitis exhibit a 
wide range of adverse clinical outcomes, including: infection relapse, immune 
reconstitution inflammatory syndrome (IRIS) due to excessive reaction to persistent 
antigen, and/or death (148). The reasons why some individuals recover without 
experiencing complications and others perish remains enigmatic. 
Differences in the quality of the impaired Th cell responses in HIV patients 
stratify the spectrum of clinical outcomes (58, 213, 214). Interferon-γ production by 
Type-1 helper T (Th1) cells defends against invasive cryptococcal disease and promotes 
fungal clearance (55, 215, 216). Dysregulated reconstitution of protective immunity in 
patients with recent cryptococcosis can also cause harmful inflammation (204). In 
addition, C. neoformans (serotype A) subverts protective immunity and exacerbates 
disease by driving Th2 cell production of interleukin (IL)-4, IL-5, and IL-13 (217, 218). 
Therefore, therapies that dampen detrimental Th cell responses could be used to 
ameliorate disease. 
One mechanism the immune system uses to dampen Th cell responses is by 
employing regulatory T (Treg) cells. Treg cells are a distinct subset of Th cells that 
uniquely express the transcription factor forkhead box P3 (Foxp3), which stabilizes the 
suppressive function of Treg cells. Genetic aberrations in Foxp3 (i.e. IPEX syndrome) 
cause fatal Th cell-driven autoimmunity in humans, highlighting the importance of Foxp3 
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in immune homeostasis (219). Treg cells also inhibit effector Th cell responses to 
microbial infections (220). In particular, conditional depletion of Foxp3+ Treg cells in 
mice infected with C. neoformans increases Th2 cell abundance in the lungs, indicating 
Treg cells limit the proliferation of Th2 cells primed by cryptococcal infection (221, 
222). Beyond these initial observations, little is known about the mechanism of Th2 cell 
suppression by Treg cells during cryptococcal infection.  
Since Treg cell suppression of effector Th cells is contact dependent (223), Treg 
cells must colocalize with effector cells in order to function in tissues such as the lung 
(224). To accomplish this, Treg cells express chemokine receptors (CCR) and integrins 
that allow them to home to and to be retained at sites of inflammation (225). Separate 
evidence indicates Treg cells that restrain mucosal Th cell responses exhibit highly 
specialized control of distinct Th cell subsets by expressing the same lineage-defining 
transcription factors as their effector Th cell counterpart (226-228). In particular, 
interferon regulatory factor 4 (IRF4) expression by Treg cells has been implicated in the 
suppression of Th2-driven autoimmunity (228). 
Here, we utilized a mouse model of experimental cryptococcosis to investigate 
Treg cell responses to pulmonary fungal infection. Specifically, we explored the 
hypothesis that Treg cells utilize IRF4 and chemokine receptors to colocalize with Th2 
cells in the lungs. While in proximity with Th2 cells, Treg cells are able to inhibit the 
expansion of deleterious Th2 cell responses to cryptococcal infection. 
   97 
RESULTS 
 
Regulatory and effector Th cells coexist in the lung parenchyma. 
Upon pulmonary infection with the pathogenic fungus, Cryptococcus neoformans 
(KN99α), mice develop lethal disease that results from a combination of unabated fungal 
replication and Th2-driven immunopathology. Importantly, these detrimental Th2 cells 
are primed and accumulate in the lungs (222). Since Treg cell suppression of effector 
cells requires these cells to be in close proximity (223), we hypothesized that 
Treg/effector cells colocalize within Cryptococcus-infected lungs. 
Th cells are highly heterogeneous with respect to their T cell receptor and cognate 
functions. Thus, the use of Cryptococcus-specific reagents to track antigen-specific Th 
cells within a polyclonal repertoire facilitates direct comparisons of Th cell subsets 
responding to infection. We used a peptide from chitin deacetylase 2 (Cda2), an 
immunogenic cryptococcal protein (166), to construct a recombinant peptide-MHCII 
tetramer to track Cryptococcus-specific Th cells by flow cytometry (222). The Cda2-
MHCII tetramer not only identified Cda2+ Foxp3- effector Th cells in the lungs of 
infected mice, but the tetramer also labeled a sizable population of Cda2+ Foxp3+ Treg 
cells (Figure 1A).  
The lung consists of three physically separate compartments that may contain Th 
cells: blood vessels, airways, and lung parenchyma. To determine whether the lung 
Treg/effector cells were circulating in the blood vasculature or residing in the 
airways/lung parenchyma, we performed intravital antibody staining. Anti-CD45 
antibody administered intravenously (IV) was used to label polyclonal Foxp3+ Treg cells 
and Foxp3- effector Th cells retrieved from the peripheral blood (Figure 1B). The 
complete labeling of all Foxp3+ and Foxp3- cells in the blood indicates that the antibody 
completely penetrated the entirety of the blood vasculature (Figure 1B, left). Cells 
collected from whole lung digests had a mixture of IV stained and unstained cells, 
showing the lung was composed of circulating and lung-resident Treg/effector Th cells 
(Figure 1B, middle). In contrast, nearly all antigen-specific cells were unstained, 
indicating that infection-induced Th cells resided outside of the blood vasculature 
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(Figure 1B, right). To distinguish Treg/effector Th cells in the lungs from the airways, 
we sedated infected mice and instilled fluorescent-coupled antibodies into the nares. A 
majority of polyclonal and antigen-specific Treg/effector Th cells obtained from lung 
digests did not stain with this inhaled antibody (Figure 1C), thus most of the 
Treg/effector Th cells were not resident in the airways. These data collectively indicate 
that Treg and effector Th cells responding to infection coexist in the lung parenchyma. 
 
Treg cell induction does not depend on lymphoid priming. 
We next sought to determine the location of Treg cell induction. The mediastinal 
lymph node (MLN) is the principle origin of Th cell priming to most microbes that 
breech the airway mucosa. However, we previously showed that effector Th cells gather 
in the lungs in the absence of dendritic cell trafficking and subsequent T cell activation in 
the lung-draining lymph node (222). Thus, we compared the presence of Treg cells at the 
location of traditional Th cell priming in the MLN and the site of C. neoformans infection 
in the lungs. Foxp3-expressing Treg cells increased as a proportion of total CD4+ Th 
cells in the lungs throughout the course of infection (Figure 2A). Yet, Treg cell 
proportions remained unchanged, if not slightly reduced, in the MLN (Figure 2A).  
The relatively small Treg cell response in the MLN suggests that either Treg cells 
immediately migrate after activation in the lymph node to the site of infection or Treg 
cell induction occurs autonomously in the lungs. We used CCR7 -/- mice to answer this 
question. CCR7 is required for naïve T cell entry into lymph nodes, thus CCR7 
deficiency expectedly inhibited naïve Th cells (i.e. CD44 low) from accumulating in the 
MLN (Figure 2B). Likewise, the MLN of infected CCR7 -/- mice exhibited decreased 
swelling compared to wildtype mice (Figure 2C), further indicating dysfunctional Th cell 
priming in the MLN of CCR7-deficient mice. Despite the aberrant MLN response, Treg 
cells accumulated in the lungs of CCR7 -/- mice similar to levels in wildtype mice after 
C. neoformans infection (Figure 2D). Thus, Treg cell induction and accumulation in the 
lungs does not require mediastinal lymph node priming during pulmonary cryptoccocal 
infection. 
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Cryptococcus-specific Treg cells are induced in the lungs upon pulmonary infection. 
Treg cells develop along two ontologically distinct lineages: “peripheral” Treg 
(pTreg) cells and “thymic” Treg (tTreg) cells. Upon receiving secondary cues of 
excessive inflammation, naïve Th cells can differentiate in the periphery into pTreg cells. 
Conversely, tTreg cells become regulatory cells during thymic selection based on T cell 
receptor affinity for self-antigens (229). Of note, tTreg cells emigrate from the thymus 
with full suppressive potency and do not need to undergo further activation in lymphoid 
tissues (230). Therefore, we asked whether the Treg cells in cryptococcal infected lungs 
are tTreg cells that populate the lungs independently of lymph node priming or pTreg 
cells autonomously induced in the lungs.  
Cryptococcus-specific tTreg cells must exist in the pre-immune, naïve Th cell 
repertoire, if these cells are the dominant source of Treg cells in the lungs of infected 
mice. Therefore, we examined the thymus or secondary lymphoid organs of uninfected 
mice for the presence of Cda2+ Foxp3+ Treg cells. Cda2-specific Treg cells were present 
in the pre-immune repertoire contained in the thymus or secondary lymphoid organs, 
albeit at lower Treg/effector proportions compared with polyclonal Th cells (Figure 3A). 
Therefore, a small number of Cryptococcus-specific tTreg cells can be found in 
uninfected mice, and these cells could migrate to the lung and proliferate in response to 
cryptococcal infection. 
To further address the question of whether the Treg cells accumulating in lungs of 
infected mice migrated from the thymus or were induced in the lungs, we developed a 
genetic fate-mapping system to distinguish where these cells developed. Mice containing 
a Foxp3-cre Estrogen Receptor 2 (ERT2) transgene were crossed with mice that had a 
Rosa26 stop codon-floxed tdTomato allele to make Foxp3-i-cre tdTomato mice. 
Effectively, the combination of these transgenes allows for inducible fluorescent marking 
in vivo of Treg cells and all of the progeny of these cells. Similarly, when tamoxifen is 
removed, Treg cells produced de novo will not have any detectable fluorescence reporter 
activity. Ultimately, this allowed us to label tTreg cells (and all cells derived from this 
progenitor) within the pre-immune repertoire, halt new reporter induction by stopping 
tamoxifen administration, and determine whether the lung-resident Treg cell progenitors 
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existed prior to infection (i.e. tdTomato+) or were produced post-infection (i.e. 
tdTomato-) (Figure 3B). Less than 1% of Treg cells from Foxp3-i-cre tdTomato mice 
that did not receive tamoxifen were fluorescent (Figure 3B), and tamoxifen administered 
during the peak Th cell response, 9-14 days post-infection, induced fluorescence in more 
than 90% of the Treg cells (Figure 3B). Thus, the genetic fate-mapping system is not 
leaky and suitably penetrant. When tamoxifen was given 12-7 days prior to infection to 
label the pre-immune Treg cells, a minor fraction of Treg cells retained fluorescence 
when harvested at 14 days post-infection (Figure 3B). Therefore, a small proportion of 
Treg cells in the lungs came from tTreg cells in the pre-immune repertoire, and instead, 
the majority were pTreg cells that acquire a regulatory phenotype as a consequence of 
fungal infection. 
 
Interferon Regulatory Factor 4 expression by Treg cells is required to efficiently 
suppress the pathologic Th2 cell response to pulmonary fungal infection. 
Treg cells generated during cryptococcal infection are poised to uniquely suppress 
Th2 cells (221, 222). Additionally, our data indicating that Treg cells are induced and 
reside in the lungs of infected mice led us to investigate features consistent with Treg 
cells that develop extrathymically, accumulate at mucosal surfaces, and target Th2 cells 
for suppression (231-233). A prominent feature of pTreg cells that suppress distinct Th 
cell subsets in mucosal tissues is the expression of transcription factors that mirror the 
lineage of the effector Th cell populations targeted for suppression (226, 228). Therefore, 
we examined the expression kinetics of the Th2 cell transcription factor, IRF4, by both 
antigen-specific Foxp3+ Treg cells and cognate Foxp3- effector Th2 cells from mice 
infected with C. neoformans. As hypothesized, IRF4 expression increased in Treg cells 
and effector Th cells throughout the course of infection (Figure 4A). This raised the 
possibility that IRF4 is utilized by Treg cells to suppress the Th2 cell response to 
pulmonary fungal infection. 
To test whether IRF4 expression by Tregs was important for Th2 suppression, we 
bred Foxp3-cre mice with IRF4 floxed mice to generate mice with a conditional IRF4 
gene deletion in Treg cells (Foxp3-cre IFR4 fl/fl) (Figure 4B). Cryptococcus-specific 
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Th2 cells increased >5-fold in the lungs of Foxp3-cre IRF4 fl/fl mice, and this impaired 
suppression of Th2 cells resembled the situation observed with complete Treg abrogation 
(Figure 4C&D). Consistent with the increase in Th2 cell numbers, Foxp3-cre IRF4 fl/fl 
mice also had significantly elevated amounts of IL-5 and IL-13 from infected lung 
homogenates compared with both wildtype animals and Treg cell depleted mice (Figure 
4E).  
The failure to efficiently suppress Th2 cell proliferation and effector function in 
mice with IRF4-deficient Treg cells also correlated with exacerbation of Th2-mediated 
disease. IRF4-deficiency in Treg cells enhanced pulmonary accumulation of 
macrophages, multinucleate giant cells, and polymorphonuclear cells (Figure 4F), as 
well as accelerated lethal cryptococcal disease (Figure 4G). While lethal disease onset 
appeared to be accelerated in Foxp3-DTR mice relative to Foxp3-cre IRF4 fl/fl mice, 
naïve Foxp3-DTR mice receiving DT experienced fatal autoimmunity (Fig. 4G). DT 
treatment also negatively impacted the survival of infected wildtype mice independently 
of Treg cell ablation (Fig. 4G). Thus, DT treatment and autoimmunity additionally 
contributed to the more rapid disease experienced by Foxp3-DTR mice. Taken together, 
IRF4-deficient Treg cells exhibited a profound Th2 suppression defect that was 
comparable to complete Treg cell deficiency. 
 
Interferon Regulatory Factor 4 is needed for localization of Treg cells in cryptococcal 
infected lungs. 
How Treg cells utilize IRF4 to suppress Th2 cells remains incompletely 
understood. Existing evidence suggests that IRF4 may dictate expression of suppressive 
factors employed by Treg cells. For example, IRF4 interacts with Blimp-1 to mediate 
transcription of the suppressive cytokine, IL-10 (234). Chromatin immunoprecipitation of 
IRF4 confirms that IRF4 binds to the IL-10 locus, and IRF4 has been shown to mediate 
IL-10 production by Th2 cells (235, 236). However, IL-10 in lung homogenates of 
cryptococcal infected mice was unaffected by IRF4-deficiency in Treg cells and actually 
increased in mice with complete Treg cell abrogation (Figure S1A). Furthermore, 
blockade with substantial quantities (i.e. 2 mg/mouse over the course of 9 days) of anti-
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IL-10R antibody did not alter Th2 cell production (Figure S1B) or IL-5 and IL-13 
secretion in lungs of infected mice (Figure S1C). Finally, in other systems, IRF4-
deficient Treg cells still suppress effector Th cells in an in vitro assay, indicating that 
IRF4 is dispensable for the direct suppression of effector Th cells by Treg cells (228).  
An alternative hypothesis is IRF4 promotes the retention of Treg cells at the site 
of inflammation. Although IRF4-deficiency in Treg cells did not alter the proportion of 
Foxp3+ Treg cells among total CD4+ Th cells in the spleen and MLN (Figure S2), it 
significantly decreased Treg cell proportions in the lungs of infected mice (Figure 5A). 
Furthermore, Foxp3-cre IRF4 fl/fl mice had substantially fewer antigen-specific Treg 
cells in the lungs in comparison to wildtype mice (Figure 5B). However, these studies 
could not determine whether the decreased Treg cell proportions were due to biased 
effector Th cell accumulation or defective Treg cell retention in the lungs.  
To directly test the hypothesis that IRF4 promotes Treg cell localization in the 
lungs, we performed a set of adoptive transfers. Naïve CD4+ Th cells from Foxp3-cre 
IRF4 fl/fl mice were transferred into congenic wildtype recipients, as well as the 
reciprocal transfer of wildtype Th cells into Foxp3-cre IRF4 fl/fl mice. After resting in 
infected mice for 5 days (9-14 days post-infection of recipient), the donor cells were 
identified using the congenic markers. Transferred Th cells from Foxp3-cre IRF4 and 
wildtype mice parked equivalently in the lungs of their respective hosts (Figure 5C). 
However, the proportion of Foxp3-cre IRF4 fl/fl Th cells that expressed Foxp3 was 
significantly lower than similarly transferred wildtype cells (Figure 5C), indicating Treg 
cells lacking IRF4 were inefficiently retained in the lungs. Finally, Treg cells from 
Foxp3-cre IRF4 fl/fl mice were over-represented in the blood vasculature of infected 
lungs (Figure 5D), correlating the decrease in pulmonary retention of Treg cells with the 
diffusion of these cells into the local bloodstream. These data demonstrate that IRF4 
intrinsically regulates Treg cell localization in the lungs of cryptococcal infected mice. 
 
Treg cell accumulation in the lungs is dependent on Chemokine Receptor 5. 
Th cells follow chemokine gradients to traffic to the site of inflammation (225). 
Therefore, we investigated chemotactic signals that may influence pulmonary localization 
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of Treg cells. Chemokine ligands (CCL)3, CCL4, and CCL5 are involved in type-2 
immunity (237), and these chemokines increased 5-100-fold in the lungs of infected mice 
compared with naïve controls (Figure 6A). To determine if the Treg cells could 
recognize these chemokines, we examined expression of the cognate chemokine 
receptors by Treg cells in the lungs of infected mice (Figure 6B). CCR4 and CCR5 were 
highly expressed by Treg cells, and expression of these receptors decreased in IRF4-
deficient Treg cells (Figure 6B). In contrast, CCR3 was minimally expressed by Treg 
cells (Figure 6B), and instead appeared to be associated with eosinophils in the blood 
and lungs of infected mice (Figure S3). Thus, CCL3, CCL4, and CCL5 were highly 
abundant in the lungs of infected mice, and the ability to detect these chemokine signals 
by Treg cells would require IRF4-dependent expression of CCR4 and CCR5. 
Due to the elevated expression of CCR5, abundance of cognate chemokine 
ligands, and the high dependence of CCR5 on IRF4, we tested the causal relationship 
between CCR5 and pulmonary retention of Treg cells during fungal infection. Maraviroc 
is a selective inhibitor of CCR5 that is used in HIV patients to block CCR5-mediated 
entry of HIV into leukocytes (238). Mice that received 500 micrograms of maraviroc 
every day from 9 days to 14 days post-infection had significantly reduced accumulation 
of pulmonary Treg cells compared to similarly infected, vehicle treated controls (Figure 
6C). To further test the requirement of CCR5 for Treg localization in the lungs. 
CD45.1/CD90.2 congenic Foxp3-DTR mice were infected, and Treg cells were 
eliminated at 7 days post-infection by administering DT. 1 million naïve CD4+ Th cells 
from uninfected CD45.2/CD90.1 wildtype and CD45.2/CD90.2 CCR5 -/- mice were 
transferred into the Foxp3-DTR mice. At 14 days post-infection the lungs were harvested 
and analyzed for Treg accumulation in the lungs. Strikingly, while wildtype Tregs readily 
accumulated in the lungs, the Tregs transferred from CCR5 -/-, mice were absent from 
the lungs of infected mice (Figure 6D). Thus, Treg cell induction and retention in the 
lungs requires CCR5.
   104 
DISCUSSION 
 
Th cells are central to immunity and immunopathology associated with 
cryptococcal infection. While Th1 cells correlate with protection, Th2 cells exacerbate 
cryptococcal disease. Therefore, a deeper understanding of how the diseased host 
regulates Th cell responses could lead to development of interventions that ameliorate 
disease in predisposed individuals. One promising target of immune modulation is the 
Foxp3+ Treg cell population. Previously, Treg cells were found to counterbalance 
pathologic Th2 cell inflammation following pulmonary cryptococcal infection (221, 222). 
Yet, the mechanism behind this suppression was largely unexplored. Herein, we tracked 
Cryptococcus-specific Th cell responses with multi-parameter flow cytometry and 
manipulated host immune responses to unravel the mechanism of Treg-mediated 
suppression of Th2 cells during cryptococcal infection. We showed that Treg cells are 
induced in the tissues and utilize CCR5 and IRF4 to colocalize with and suppress Th2 
effector cells in the lung parenchyma. 
 Many fungal pathogens elicit Treg cell responses. In most cases, Treg cells 
control the axis of Th17 cell responses and fungal clearance (239-242). In contrast, the 
primary function of Treg cells generated during cryptococcal infection is Th2 cell 
suppression. This clearly benefits the host, as disease is enhanced when Tregs fail to 
adequately control Th2 cell proliferation. The signals the host uses to detect host damage 
and elicit Treg cell induction are unknown in the case of pulmonary cryptococcal 
infection. Additional insight into these processes could lead to the identification of potent 
biomarkers to predict immune dysfunction in patients stricken with cryptococcal disease. 
Furthermore, therapeutic targeting of these pathways could be used to prompt the host to 
dampen harmful Th2 cell production. 
Collectively, our data unify several emerging concepts regarding Treg cell 
suppression of Th2 cells. Peripherally induced Treg cells inhibit Th2 cells at mucosal 
surfaces (233), and Treg cells utilize effector cell programs like IRF4 to mediate specific 
suppression of Th2 cells (228). IRF4 functions as a rheostat for T cell receptor signaling 
(243), and TCR signaling is required to maintain a portion of the suppressive program of 
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Treg cells (244). Additionally, chemokines promote the migration and retention of Treg 
cells in inflamed tissues (225), and CCR5 is important for Treg cells to suppress Th cell 
responses to pulmonary fungal infections (245). In our model, Treg cells were induced in 
the periphery and IRF4 expression by Treg cells was required for efficient Th2 
suppression. Treg cells in the lungs of cryptococcal infected mice expressed high levels 
of CCR5, and the few remaining IRF4-deficient Treg cells in the lungs had significantly 
decreased expression of CCR5. IRF4 does not directly interact with the promoter region 
of CCR5 (236) and does not likely influence CCR5 gene transcription. Thus, we favor a 
model where diminished T cell receptor signaling in Treg cells due to IRF4 deficiency 
reduces CCR5 expression. This prevents Treg/effector cell colocalization and hinders 
Treg suppression of Th2 cells. Thus, our data provide a logical connection between the 
hitherto disjointed observations of extrathymically induced Treg cells, IRF4-dependent 
suppression, chemokine-mediated localization, and Th2-specific inhibition. 
Skewed type-2 cytokine responses in the peripheral blood and cerebral spinal 
fluid of patients with cryptococcal meningitis are associated with early mortality and 
onset of immune reconstitution inflammatory syndrome (57, 58). CCR5+ T cells are 
recruited to the CSF of patients experiencing cryptococcal meningitis and increased 
presence of CCR5+ T cells is associated with poor clinical outcome (246). HIV infects 
and lyses CCR5+ and CXCR4+ Th cells equally (247), and the in vivo evolution of 
CXCR4-tropic virus is assisted by efficient elimination of CCR5+ Th cells (248). 
Moreover, maraviroc treatment selectively eliminates Treg cells in HIV patients (249). 
Taken together with our findings that Treg cells require CCR5 to colocalize and suppress 
detrimental Th2 cell responses, these findings unveil a novel potential etiology of 
cryptococcal pathogenesis. Perhaps, HIV-directed lysis of CCR5+ Treg cells and/or 
therapeutic targeting of CCR5 in patients could exacerbate Th2-driven disease.
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MATERIALS AND METHODS 
 
Host. All mice used in this study were derived from a C57BL/6 background. 
B6.129P2(C)-Ccr7tm1Rfor/J, B6.129P2-Ccr5tm1Kuz/J, B6.Cg-Foxp3tm2Tch/J, B6.129(Cg)-
Foxp3tm3(DTR/GFP)Ayr/J, Foxp3tm9(EGFP/cre/ERT2)Ayr/J, B6.129S1-Irf4tm1Rdf/J, B6.Cg-
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J, B6.PL-Thy1a/CyJ mice were purchased from Jackson 
Laboratories (Bar Harbor, ME). Foxp3-cre/GFP mice were a kind gift from Calvin 
Williams. Foxp3-eGFP mice were crossed with Thy1.1 mice to generate congenic 
marked mice for transfer experiements. Foxp3-cre ERT2 mice were crossed with 
tdTomato mice for Treg fate-mapping studies. All mice were housed in specific 
pathogen–free conditions. 
Pathogen. Cryptococcus neoformans var. grubii strain KN99α was streaked on yeast 
peptone dextrose (YPD) agar plates and incubated for 2 days at 30°C. YPD broth was 
inoculated with colonies from the aforementioned plate and incubated for 16 hours at 
30°C with gentle agitation. The inoculum was prepared by pelleting the culture, washing 
3 times with phosphate buffered saline (PBS), and resuspending in PBS at a 
concentration of 2x106 cells/mL. 
 
Infection. 6-8 week old, sex-matched mice were anesthetized with pentobarbitol. 5x104 
cryptococcal cells in 25 μL of PBS was placed on the nares of each mouse, and the mice 
aspirated the inoculum into the lower respiratory tract. Finally, the mice were suspended 
by their incisors for 5 minutes and subsequently placed upright in their cage until 
regaining consciousness. For survival studies, ten mice per group were infected as 
described above. Animals were monitored for morbidity and sacrificed when endpoint 
criteria were reached. Endpoint criteria were defined as 20% total body weight loss, loss 
of 2 grams of weight in 2 days, or symptoms of neurological disease. 
 
Treatments. For intravital staining, 3 micrograms of anti-CD45.2 (104, BV421, 
Biolegend) was injected into the tail vein of mice or placed on the nares of sedated mice 
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(250). Foxp3-cre ERT2 tdTomato mice received 2mg/day tamoxifen IP for five 
consecutive days to induce endogenous fluorescence for Treg cell fate-mapping. For 
transfer studies, 1x106 negatively-selected CD4+ Th cells from naïve mice were injected 
via tail vein into congenic mice infected 7 days previously, and lungs were harvested at 
14 days post-infection for leukocyte isolation and flow cytometric analysis. For CCR5 
blockade experiments, mice were treated IP with 500 μg/day maraviroc (R&D Systems, 
Minneapolis, MN) from 9-14 days post-infection. Lastly, wildtype mice were treated 5 
and 10 days post-infection with 1 mg of IL-10R antibody (1B1-3A, Bio-X-Cell) to block 
IL-10 signaling. 
 
Pulmonary Leukocyte Preparation. Lung leukocytes were isolated as previously 
described (210). Briefly, lungs were excised and minced to generate approximately 1 
mm3 pieces. The lung mince was incubated in HBSS (Invitrogen, Grand Island, NY) + 
1.3 mM EDTA solution for 30 min at 37 °C with agitation, and then transferred to RPMI-
1640 (Invitrogen) medium supplemented with 5% Fetal Bovine Serum (FBS) 
(Invitrogen) and 150 U/ml type I collagenase (Invitrogen) and incubated for 1 h at 37 °C 
with agitation. The cells were passed through a 70 μm filter, pelleted, and resuspended in 
44% Percoll-RPMI medium (GE Life Sciences, Pittsburgh, PA). A percoll density 
gradient was created (44% top, 67% bottom), and the samples were centrifuged for 20 
min at 650X g. The leukocytes at the interface were removed, washed 2 times with RPMI 
medium, and resuspended in PBS + FBS at a concentration of 107 cells/ml. CD4+ T cells 
were enriched using a Dynabeads CD4+ T Cell Negative Isolation Kit (Life 
Technologies, Grand Island, NY) per manufacture’s instructions. For intracellular 
cytokine analysis, ~106 CD4+ T cells were suspended in 200 μL of restimulation buffer 
(RPMI + 10% FBS + 1% penicillin/streptomycin + 5 μg brefeldin A) without 
(unstimulated) or with (stimulated) 10 ng phorbol myristate acetate (PMA) and 50 ng 
ionomycin. After 5 hours, the cells were washed and immediately prepared for flow 
cytometry. 
 
 
   108 
Flow Cytometry. Samples were incubated for 5 minutes with CD16/32 antibody 
(Biolegend) and LIVE/DEAD Fixable Far Red stain (Invitrogen) to prevent nonspecific 
antibody binding, as well as mark dead cells. 25nM Cda2-tetramer was added to the 
sample and incubated at 25°C for 1 hour in the dark. CCR3 (J07E35, PE, Biolegend), 
CCR4 (2G12, PE, Biolegend), and CCR5 (HM-CCR5, PE, Biolegend) were added 1:50 
during tetramer staining when appropriate. Samples were surface-stained at 4°C for 30 
minutes with the following antibodies: CD4 (RM4-5, BV605, Biolegend), CD11b 
(M1/70, PE-Cy5, eBioscience, San Diego, CA), CD11c (N418, PE-Cy5, eBioscience), 
B220 (RA3-6B2, PE-Cy5, eBioscience), CD25 (3C7, BV650, Biolegend), CD44 (IM7, 
Alexa Fluor 700, Biolegend) and/or Siglec F (E50-2440, PE, BD Biosciences). When 
applicable, the cells were then incubated in Foxp3 Transcription Factor Buffer 
(eBioscience) at 4°C for 30 minutes. The cells were labeled with antibodes against the 
following intracellular antigens: Foxp3 (FJK-16s, FITC, eBioscience), IL-5 (TRFK5, 
APC, Biolegend), IL-13 (eBio13A, eFluor 450, eBioscience), GATA3 (L50-823, PE-
Cy7, BD Biosciences), and/or IRF4 (3E4, eFluor 450, eBioscience). 1:200 antibody 
concentrations were used for most surface staining, and 1:100 antibody concentrations 
were used for intracelluar staining. For data acquisition, events from the entire sample 
(500,000-1,000,000) were collected on a BD FACSCanto II flow cytometer (BD 
Biosciences, San Jose, CA), and the data were analyzed with FlowJo X (Tree Star Inc., 
Ashland, OR).  
 
Naïve Th cell Enrichment. Analysis of antigen-specific Th cells within the pre-immune 
repertoire was performed, as previously published (209). Briefly, thymi and secondary 
lymphoid organs were collected from uninfected Foxp3-GFP mice. Cell suspensions 
were labeled with Cda2-tetramer and enriched using anti-PE MACS cell isolation kits 
(Miltenyi, San Diego, CA). Flow cytometry was performed as described above. 
 
Lung Cytokines. Lungs from naïve mice or mice 14-days post-infection were excised, 
snap frozen in liquid nitrogen, and homogenized in 3 mL of T-PER (Thermo Fisher 
Scientific) with Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN). The lung 
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homogenate was pelleted, and the supernatant was collected and stored at -80°C until 
analysis. Samples were diluted 1:4 in assay buffer immediately before processing. 
Cytokines were quantified using Luminex technology according to manufacturer 
instructions (Bio-Rad, Hercules, CA). 
 
Lung Histology. Lungs were removed from mice 14 days post-infection, perfused via the 
right ventricle with cold PBS, inflated with 10% formalin (Thermo Fisher Scientific, 
Rockford, IL), and placed in a container of 10% formalin. Tissues were dried with 
organic solvent, embedded in parafin, sectioned, and stained with hematoxylin and eosin, 
before images were captured. 
 
Statistics. P-values for pairwise comparisions were by Mann-Whitney U with Bonferroni 
adjustments for multiple comparisons. Global tests were by Kruskal-Wallis ANOVA. 
Surival curves were compared with log-rank tests. Power calculations were performed to 
assess appropriate sample size for all experiments. P-values ≤ 0.05 were considered 
statistically significant. All statistics and graphs were processed with Prism 6 (GraphPad 
Software, La Jolla, CA). 
Study Aproval. All animal experiments were done in concordance with the Animal 
Welfare Act, U.S. federal law, and NIH guidelines. Mice were handled in accordance 
with guidelines defined by the University of Minnesota Institutional Animal Care and 
Use Committee (IACUC) protocol numbers 1010A91133 and 1207A17286. 
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Figure 1. Antigen-specific Treg and effector Th cells colocalize in the lung 
parenchyma. (A) Flow plots (left) and composite graph (right) of antigen-specific 
Cda2+ CD4+ Treg and effector Th cells in naïve and infected mice. (B) Cytometry plots 
of CD4+ Th cells in peripheral blood (left) or whole lung (center), and antigen-specific 
CD4+ Th cells in whole lungs (right) all treated with intravital/intravenous (IV) 
fluorescent CD45 antibody. (C) Cytometry plots of CD4+ polyclonal Th cells (left) and 
antigen-specific Th cells (right) from whole lung digests after intravital/intranasal (IN) 
instillation of fluorescent CD45 antibody. Plots are representative of 2 independent 
experiments. 
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Figure 2. Lymph node priming is dispensable for Treg cell accumulation in the 
lungs. (A) Foxp3+ Treg cells as a proportion of total CD4+ Th cells in the lungs and 
mediastinal lymph nodes (MLN). (B) Histogram of CD44 expression by CD4+ Th cells 
from lymph nodes of wildtype and CCR7 -/- mice 14 days post-infection. (C) MLN of 
naïve wildtype, as well as 14 days post-infection wildtype and chemokine receptor 7 
(CCR7) deficient mice Scale bar = 2 mm. (D) Cytometry plot (left) and composite graph 
(right) of Foxp3+ Treg cells from lungs of naïve wildtype and 14 days post-infection 
wildtype and CCR7 -/- mice. Pairwise comparisons were made by Man-Whitney U with 
Bonferoni adjustments for multiple comparisons. *** = P<0.0005, n.s. = non-significant. 
All data are presented as the mean +/- standard error of the mean and represent 2 
independent experiments. 
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Figure 3. Treg cells in the preimmune repertoire are not the dominant source of 
Treg cells that accumulate in the lungs of fungal infected mice. (A). Foxp3+ Treg 
cells as a proportion of Th cells in the thymus or secondary lymphoid tissue of naïve 
mice. Representative cytometry plots of polyclonal and antigen-specific Th cells (left) 
and composite graph of antigen-specific Th cells (right). (B) In vivo genetic fate-mapping 
strategy of Treg cells using Foxp3-cre ERT2 x Rosa26 stop-floxed tdTomato mice (left). 
Cytometry plots of fluorescent reporter activity in antigen-specific Treg cells from lungs 
with or without tamoxifen (Txfn) (right). All data are presented as the mean ± standard 
error of the mean and represent 2 independent experiments. 
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Figure 4. IRF4 is required by Treg cells to efficiently suppress the detrimental Th2 
cell response to pulmonary cryptococcal infection. (A) Flow cytometry histogram 
(left) and composite graphs (right) of Interferon Regulatory Factor 4 (IRF4) expression in 
CD44 low naïve, Cda2+ Foxp3+ Treg, Cda2+ Foxp3- effector cells collected from the 
lungs of mice. (B) Histogram of IRF4 expression by lung Treg cells in wildtype and 
Foxp3-cre IRF4 fl/fl mice 14 days post infection. (C) Antigen-specific Th2 cells 
producing interleukin-5 (IL-5) and/or IL-13 in the lungs of wildtype, Foxp3-cre, and 
Foxp3-DTR mice 14 days post-infection. (D) Total IL-5 and IL-13 secreted in lung 
homogenates from wildtype, Foxp3-cre, and Foxp3-DTR mice 14 days post-infection. 
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(E) Photograph of gross-level pathology of lungs from mice infected 14 days previously 
(top). Hematoxylin and eosin staining of lung sections from Foxp3-cre mice 14 days 
post-infection (bottom). Bar = 200 µm. (F) Survival curve of IRF4 fl/fl and Foxp3-cre 
IRF4 fl/fl infected mice (top). Survival curves of naïve Foxp3-DTR, as well as infected 
wildtype and Foxp3-DTR mice – all groups treated every other day with 200 ng DT 
beginning at 5 days post-infection (bottom). Survival curves include 10 mice per group, 
and P-values calculated by log rank test. Pairwise comparisons were made by Man-
Whitney U with Bonferoni adjustments for multiple comparisons. *** = P<0.0005, ** = 
P<0.005, * = P<0.05, n.s. = non-significant. All data are presented as the mean ± 
standard error of the mean and represent 2 independent experiments. 
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Figure 5. Pulmonary retention of Treg cells is maintained by IRF4. (A) Frequency of 
Foxp3+ Treg cells in the lungs of naïve wildtype mice and wildtype, Foxp3-cre, and 
Foxp3-DTR mice 14 days post-infection. (B) (C) Flow cytometry plots and composite 
graphs of Foxp3-IRF4 fl/fl or widltype donor Th cells collected from lungs of wildtype or 
Foxp3-cre IRF4 mismatched recipients at 14 days post-infection. (D) Flow plots and 
composite graphs of pulmonary Treg cells from wildtype and Foxp3-cre IRF4 mice 
infected 14 days previously and treated with intravenous anti-CD45 antibody. Pairwise 
comparisons were made by Man-Whitney U with Bonferoni adjustments for multiple 
comparisons. *** = P<0.0005, n.s. = non-significant. All data are presented as the mean 
± standard error of the mean and represent 3 independent experiments. 
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Figure 6. Treg cell accumulation is mediated by CCR5 via IRF4. (A) Chemokine 
Ligands (CCL) measured in lung homogenates from wildtype mice 14 days post-
infection. (B) Cytometry histograms of Chemokine Receptor (CCR) expression on CD44 
low naïve cells, as well as Treg cells from wildtype and Foxp3-cre IRF4 fl/fl mice 14 
days post-infection. (C) Flow plots (left) and composite graphs (right) of Treg cells in the 
lungs of mice 14 days post-infection with and without maraviroc treatment. (D) 
CD45.2/CD90.1 wildtype and CD45.2/CD90.2 CCR5 -/- naïve Th cells transferred into a 
CD45.1/ CD90.2 Foxp3-DTR mouse infected and Treg cell-depleted 7 days previously. 
Pairwise comparisons were made by Man-Whitney U. All data are presented as the mean 
± standard error of the mean and represent 2 independent experiments. 
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Figure S1. IL-10 is dispensable for suppression of Th2 cells produced in response to 
pulmonary cryptococcal infection. (A) Interleukin (IL)-10 measured in lung 
homogenates from wildtype, Foxp3-IRF4 fl/fl, and Foxp3-DTR mice 14 days post-
infection. (B) Cda2+ Th2 cells quantified in the lungs of infected mice treated with IL-10 
receptor blocking antibody or isotype control. (C). IL-5 (left) and IL-13 (right) measured 
in lung homogenates from infected mice treated with IL-10 receptor blocking antibody or 
isotype control. Pairwise comparisons were made by Man-Whitney U with Bonferoni 
adjustments for multiple comparisons. All data are presented as the mean ± standard error 
of the mean.   
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Figure S2. IRF4-deficient Treg cells differentiate normally in secondary lymphoid 
tissues. Flow cytometry plots and composite graphs of Th cells of mediastinal lymph 
nodes (MLN) and spleens from wildtype and Foxp3-cre IRF4 fl/fl mice infected 14 days 
prior. Plots are representative of 2 independent experiments. 
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Figure S3. Anti-CCR3 (J07E35) readily detects eosinophils in the blood and lungs of 
cryptococcal infected mice. Flow plots of total leukocytes in blood (left) and lungs 
(right) 14 days post-infection. Siglec F+, CCR3 + cells are eosinophils. Plots are 
representative of 2 independent experiments.
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CHAPTER 4 
 
Lymphocyte Competition Determines Granulocyte Responses to Pulmonary Fungal 
Infection. 
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SUMMARY 
 
Immunity to pulmonary fungal infection often involves a complex orchestration 
of an array of lymphocytes that instruct eosinophil and neutrophil differentiation. 
Interleukin-5 production by type-2 innate lymphoid cells and CD4+ T cells induces and 
sustains eosinophilia. Type-3 innate lymphoid cells, CD4+ T cells, CD8+ T cells, and γδ 
T cells coordinate neutrophil accumulation via secretion of interleukin-17. However, the 
relative contribution of each lymphocyte subset that ultimately determines a dichotomous 
eosinophil or neutrophil response remains enigmatic. Here, we use a murine model of 
pulmonary fungal infection to show that distinct lymphocyte lineages engage in 
competition to direct eosinophil or neutrophil responses, and we further establish a 
hierarchical relationship between these lymphocytes based on their ability to organize 
granulocytes in the lungs. Finally, we show that lymphocyte-derived IL-5 functions to 
promote eosinophilia, as well as intrinsically suppress neutrophil accumulation. Our data 
collectively address a fundamental question of lymphocyte regulation. We demonstrate 
that  competition between  lymphocyte subsets can determine the functional 
consequences of an immune response, leading to eosinophilia or neutrophilia and 
exacerbated disease. 
 
 
  
   123 
INTRODUCTION 
 
Fungi belong to a unique class of pathogens where the host both relies on 
lymphocytes to confer protection from disease, as well as suffers the unfortunate 
consequence of lymphocyte-mediated pathology. A selective elimination of T cells due to 
HIV infection results in more frequent and severe mycosis, revealing a potent, beneficial 
role for lymphocytes in preventing invasive disease (53). Conversely, most cases of 
allergic asthma in otherwise healthy individuals directly result from inappropriate 
lymphocyte responses to fungal exposure (90). This dichotomy highlights the 
heterogeneity among lymphocytes responding to fungal infection, and further draws 
attention to the delicate balance of immune homeostasis. Thus, pulmonary fungal 
infections are an optimal model to study lymphocyte regulation. 
Eosinophils and neutrophils are granulocyte subsets that originate from the same 
myeloblast progenitor in the bone marrow. IL-5 is a key regulator of eosinophil 
maturation, whereas IL-17/IL-22 leads to systemic release of G-CSF and neutrophil 
differentiation (251, 252). Upon differentiating into eosinophils or neutrophils, each of 
these granulocytes acquires unique functional capabilities. Eosinophils expel toxic 
products from granules into the inflammatory milieu (253). While this is an effective 
strategy to ward off parasitism, it causes host damage and when dysregulated, contributes 
to allergic airway disease (254). Neutrophils also produce toxic granules, yet the 
additional ability to produce extracellular traps and phagocytose microbes make 
neutrophils particularly useful in immunity to some fungal and bacterial pathogens (255, 
256).  
Among other important functions, lymphocytes secrete cytokines that coordinate 
eosinophil and neutrophil responses. Type-2 CD4+ T (Th2) cells along with type-2 innate 
lymphoid cells produce interleukin (IL)-5 that sustains and induces eosinophil production 
under homeostatic and inflammatory conditions (97, 193). Additionally Th17 cells, 
CD8+ T (Tc17) cells, γδ T cells, and ILC3 promote neutrophil maturation through 
secretion of IL-17 and/or IL-22 (257-259). Some pulmonary pathogens elicit neutrophilic 
responses (260, 261) while other pulmonary pathogens prompt eosinophil responses (262, 
   124 
263). Moreover, a mixture of these responses is most advantageous for protection against 
parasitic and fungal infections (264, 265). Finally, the loss of eosinophils often 
accompanies neutrophil accumulation and vice versa (69, 70, 266). Thus, a dynamic 
interaction between the host and microbe can fundamentally influence the immune 
response. This spurs the question of how is downstream granulopoiesis regulated by a 
complex mixture of lymphocytes.  
To investigate lymphocyte and granulocyte responses, we utilized a well-
established murine model of experimental cryptococcosis. A highly virulent strain of the 
fungus, Cryptococcus neoformans (KN99α), was instilled into the lungs of C57BL6/J 
mice. We analyzed lymphocyte and granulocyte composition in the bone marrow, blood, 
and lungs with flow cytometry at regular intervals following infection. Genetic 
deficiencies in lymphocyte subsets revealed an intricate competition among lymphocytes 
that had polarizing effects on the downstream eosinophil and neutrophil responses. 
Through these genetic manipulations we were able to define a hierarchy of lymphocytes 
regarding their ability to determine neutrophil or granulocyte accumulation in the lungs. 
Furthermore, we uncovered a duality in the role of IL-5; IL-5 functions to positively 
regulate eosinophilia, as well as inhibit neutrophil accumulation. Taken, together these 
findings offer unique insights into the dynamic regulation of lymphocyte and granulocyte 
responses to pulmonary fungal infection that have profound impacts on disease.  
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RESULTS 
 
We used flow cytometry to identify eosinophils and neutrophils in the bone 
marrow, blood, and lungs. Siglec F is expressed by eosinophils upon commitment to the 
eosinophil lineage (272). Chemokine receptor 3 (CCR3) binds to eotaxin, and this 
interaction is required for eosinophil chemotaxis from the bone marrow to the tissues 
(273). Thus, mature eosinophils are defined by the expression of CCR3 and Siglec F in 
the bone marrow and blood. However, in the lungs, eosinophils and alveolar 
macrophages express CCR3 and Siglec F, yet only alveolar macrophages have CD11c on 
their surface (Figure 1). Consequently, lung eosinophils are denoted as Siglec F+ 
CD11c- cells. Neutrophils are uniquely identified as Ly6G+ CD11b+ in the bone 
marrow, blood, and lungs (274). 
 
Progressive production of granulocytes in response to cryptococcal infection 
Eosinophils and neutrophils develop in the bone marrow, travel through the blood 
stream, and enter the tissues (267, 268). More specifically, granulocytes can arrive at a 
site of insult along two trajectories. First, mature granulocytes are distributed throughout 
the body in vascular pools, and upon “emergency” response, the granulocytes can be 
acutely recruited to the inflamed tissues in a process known as demargination (269-271). 
Alternatively, immature granulocytes in the bone marrow can receive cytokine and 
chemokine cues from lymphocytes and other cells in the tissues that lead to de novo 
eosinophil and neutrophil differentiation and recruitment (251). The kinetics of the 
granulocyte response is a key difference between these pathways. Demargination occurs 
on the order of hours to a day, while lymphocyte-induced production of granulocytes 
occurs over the course of days to weeks. 
To understand whether granulocytes accumulated in the lungs due to 
demargination or a lymphocyte-mediated process, we measured eosinophils and 
neutrophils throughout the course of pulmonary infection with C. neoformans. CCR3+ 
Siglec F+ eosinophils progressively increased in the bone marrow (Figure 2A), and these 
cells were steadily released into the bloodstream (Figure 2B). Siglec F+ CD11c- 
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eosinophils accumulated in the lungs and accounted for an overwhelming majority of the 
pulmonary leukocytes at later time points of infection (Figure 2C). Ly6G+ CD11b+ 
neutrophils were continuously produced in the bone marrow (Figure 2A) and represented 
a large, increasing population in the blood (Figure 2B). However, neutrophils stayed a 
minor proportion of leukocytes in the lungs of infected mice (Figure 2C). Thus, both 
granulocyte types were produced upon infection, but predominantly eosinophils 
accumulated in the lungs. The long duration and progressive nature of granulocyte 
responses to pulmonary fungal infection also suggested that granulocytes are induced by 
a lymphocyte-dependent process, not demargination. 
 
Lung-resident lymphocytes fully govern eosinophil responses and partially influence 
neutrophil responses to pulmonary fungal infection 
Lymph nodes are conventional locations for lymphocyte priming. However, C. 
neoformans elicits a Th2 cell response that is not dependent on lymph node responses 
(222). Therefore, we tested the hypothesis that granulocyte recruitment does not require 
lymphocyte induction in the mediastinal lymph node. FMS-like tyrosine kinase 3 ligand 
(Flt3L) is required for dendritic cell maturation (275), and CCR7 mediates lymphocyte 
entry into lymph nodes (276). Thus, genetic deficiency in each of these molecules 
significantly impairs lymph node responses. Eosinophil and neutrophil recruitment to the 
lungs were not decreased by Flt3L or CCR7 ablation (Figure 3), indicating the 
mediastinal lymph node is not a primary location for priming of granulocyte-inducing 
lymphocytes in this model. This finding prompted us to focus our attention on 
lymphocytes in the lungs. 
To identify which lymphocytes induce eosinophils, we screened an array of 
lymphocyte-deficient mice and monitored the effect this had on eosinophil accumulation 
in the lungs upon infection. Lymphocytes were identified as lineage- (CD19, CD11b, 
CD11c, CD49b, CD161, F4/80, FcεRIα, B220) and CD90.2+. Lymphocytes increased 
>25-fold in infected wildtype mice at an intermediate time point of infection (i.e. 14 
days) compared to naïve controls (Figure 4A). Two lineages of lymphocytes are known 
to be involved in eosinophil recruitment: Th2 cells and ILC2. Only Th cells are major 
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histocompatibility complex II (MHCII) restricted. Therefore, MHCII-deficiency inhibits 
the development and function of Th cells, but not other lymphocytes. As predicted, 
MHCII -/- mice had a defective TCRβ+ CD4+ Th cell response (Figure 4A). The loss of 
Th cells through MHCII-deficiency also abrogated pulmonary eosinophil accumulation 
(Figure 4B). Notably, eosinophil production was evident in the bone marrow, blood, and 
lungs early in the response (<5 days) of infected MHCII -/- mice, but eosinophil 
production subsided at the onset of the adaptive immune phase (>9 days) (Figure 5A-C). 
Recombination-activating gene 2 (Rag2) knockout mice have ILC but no peripheral T 
cells (i.e. TCRβ+ CD4+ Th cells, TCRβ+ CD8+ T cells, or γδ T cells) (Figure 4A). In 
striking contrast to the MHCII -/- response, Rag2 -/- mice experienced robust 
eosinophilia in the lungs (Figure 4B). To assess whether eosinophil recruitment is 
limited to lymphocytes, we utilized Rag2 -/- IL-2Rγ -/- mice that have a complete 
lymphocyte deficiency (Figure 4B). These mice exhibited a dramatic reduction of lung 
eosinophils (Figure 2B), and as a result, pulmonary lymphocytes govern eosinophil 
responses to fungal infection. Taken together, Th cells are the main drivers of eosinophil 
recruitment during fungal infection, and ILC are only sufficient to drive eosinophilia 
early in the response or in the absence of T lymphocytes. 
With specific elimination of Th cells in MHCII knockout mice, we observed a 
dramatic increase in CD8 T cells upon cryptococcal infection (Figure 4A). This 
correlated with a massive accumulation of neutrophils in the lungs (Figure 4B). 
Conversely, T lymphocyte-deficient Rag2 -/- mice did not exhibit a compensatory 
neutrophilic response (Figure 4B). Finally, total lymphocyte-lacking Rag2 -/- IL-2Rγ -/- 
mice recruited fewer neutrophils to the lungs than infected wildtype mice, yet the loss of 
lymphocytes in these mice did not completely abrogate neutrophil recruitment (Figure 
4B). Therefore, lymphocytes influence neutrophil recruitment in response to pulmonary 
fungal infection, especially with a dearth of Th cells. However, lymphocytes are not 
completely required for neutrophil accumulation. 
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Lymphocyte-derived cytokines regulate granulocyte responses 
Next, we investigated the regulation of granulocytes by lymphocyte cytokines. 
Increased quantities of IL-5, eotaxin, granulocyte-colony stimulating factor (G-CSF), and 
to a lesser extent, IL-17A were found in lung homogenates of infected wildtype mice 
compared to naïve controls (Figure 6A). IL-5, eotaxin, and G-CSF were also abundant in 
the plasma of infected mice (Figure 6A). Thus, these cytokines were released into the 
bloodstream where they can instigate bone marrow granulopoiesis. IL-5 secretion, but not 
eotaxin, in Th cell-deficient MHCII -/- mice was knocked down to near naïve levels in 
the lungs and plasma. Instead, local IL-17A and G-CSF, as well as peripheral G-CSF, 
dramatically increased in fungal infected MHCII -/- mice compared to wildtype 
counterparts (Figure 6A). Thus, Th2 cells are required for IL-5 production. Eotaxin is 
produced by a Th cell-independent source and eotaxin is not sufficient to drive eosinophil 
accumulation in the lungs. Finally, local IL-17A and G-CSF, as well as systemic G-CSF, 
increase in the absence of Th cells and this correlates with the neutrophilia experienced 
by infected MHCII -/- mice. 
IL-5 signaling is a canonical pathway of eosinopoiesis with no known role in 
neutrophil development (251, 277). The observations that neutrophils increase in the 
absence of IL-5 or IL-17-producing lymphocytes, led us to test the hypothesis that IL-5 
promotes eosinophil responses while simultaneously inhibiting neutrophils. Mepolizumab 
(GlaxoSmithKline) is an anti-IL-5 antibody therapy that recently concluded clinical trials 
for the treatment of eosinophilic asthma in humans (278, 279). The drug functions by 
blocking IL-5 binding to the alpha chain of the IL-5 receptor (IL-5Rα) (280). Treatment 
of infected wildtype mice with a murine equivalent anti-IL-5 antibody (TRFK5) 
reciprocally decreased eosinophils and increased neutrophils (Figure 6B). Infected IL-
17Rα -/- mice experienced a reduced, though incomplete elimination of neutrophil 
accumulation (Figure 6B), which is consistent with the lymphocyte-independent 
neutrophil production previously observed in Rag2 -/- IL-2Rγ -/- mice (Figure 2). Thus, 
abrogation of IL-5 enhances neutrophil accumulation. 
 Lymphocytes do not express IL-5Rα (Figure 6C), which rules out the possibility 
that IL-5 directly cues lymphocytes to coordinate indirect suppression of neutrophil 
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recruitment. In contrast, neutrophils are the highest IL-5α-expressing hematopoietic cells 
in bone marrow, blood, and lungs of infected mice (Figure 6C). This raises the 
possibility that IL-5 signals intrinsically on neutrophils. In support of this idea, 
exogenous IL-5 treatment of mice incapable of producing IL-5+ Th2 cells (MHCII -/- 
mice) inhibited neutrophils in a dose-dependent manner (Figure 6D). Taken together, IL-
5 mediates intrinsic suppression of neutrophils. 
 
Lymphocyte competition determines eosinophil or neutrophil polarity and impacts 
lethal fungal disease 
The unexpected lymphocyte compensation observed in the preceding experiments 
prompted us to dissect the hierarchy of lymphocytes in coordinating granulocyte 
recruitment. Infection of wildtype mice elicited production of IL-5 by both Th2 cells and 
ILC2 (Figure 7, Table 1). However, the specific loss of Th cells in MHCII -/- mice 
concomitantly reduced IL-5+ lymphocytes and eliminated eosinophilia (Figure 7, Table 
1). Thus, ILC2 are either impotent without Th2 cells or Th2 cells are the main 
determinant of the eosinophil response.  
Next, we evaluated the position of IL-17+ lymphocytes in the hierarchy. Signal 
transducer and activator 6 (STAT6) is a regulator of the type-2 effector phenotype (281), 
and STAT6 -/- mice had a defective Th2 cell and ILC2 response to fungal infection 
(Figure 7). Accordingly, a potent neutrophil response coincided with Th17 cells that 
outnumbered Tc17 cells, γδ T cells, and ILC3 in STAT6 -/- mice (Figure 7&8, Table 1). 
Upon anti-CD4 treatment of infected STAT6 -/- mice, Tc17 cells compensated for the 
loss of Th17 cells (Figure 7, Table 1), establishing Tc17 cells as subordinate to Th17 
cells but dominant to γδ T cells and ILC3.  
We next isolated γδ T cells and ILC using TCRα -/- mice that have CD4+ and 
CD8+ T cell deficiencies. γδ T cells outpaced the ILC subsets to drive a neutrophilic 
response in infected TCRα -/- mice (Figure 7&8, Table 1). Finally, T lymphocyte-
deficient Rag2 -/- mice experienced eosinophilia instigated by a large population of ILC2 
(Figure 7&8, Table 1). In summary, Th2 cells command the eosinophil response seen in 
mice with a full complement of lymphocytes. In their absence, an expansion of IL-17A+ 
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lymphocytes correlates with a neutrophilic switch. Within these IL-17A+ lymphocytes, 
Th17 cells are the main inducers of neutrophil recruitment, followed in order by Tc17 
cells and γδ T cells. Finally, without T lymphocyte participation, ILC2 outcompete ILC3 
to incite eosinophilia. 
Balanced eosinophil and neutrophil responses are more beneficial than strongly 
polarized responses to some fungal and parasitic infections (264, 265). Consequently, we 
sought to determine how extreme eosinophil or neutrophil polarization would affect 
lethal cryptococcal disease compared to the mildly balanced wildtype granulocyte 
response. IL-2/IL-2 antibody complex treatment strongly amplifies type-2 responses, and 
this significantly exacerbates disease in wildtype mice (222). Conversely, STAT6 -/- 
mice experienced neutrophilia (Figure 8), and this shift in neutrophil response correlated 
with significantly accelerated disease. Thus, eosinophil or neutrophil polarization is 
detrimental during pulmonary fungal infection. 
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DISCUSSION 
 
Herein, we aimed to dissect the complex regulation of lymphocytes with regard to 
their ability to coordinate pulmonary granulocyte accumulation. CD4+ Th cells were long 
believed to be the main coordinators of granulopoiesis through production of IL-5 and 
IL-17A (282). However, the realization that other lymphocyte subsets, like Tc17 cells, γδ 
T cells and ILC, could perform similar functions challenges this understanding (283, 
284). Thus, a systematic evaluation of the potency of each subset in determining 
downstream responses (e.g. granulocytes) is warranted. 
We showed through systematic elimination of lymphocyte subsets that 
lymphocytes engage in fierce competition to guide granulocyte induction (Figure 10). 
Fei and colleagues observed a similar phenomenon where BALB/c or C57BL/6 mice 
mounted disparate neutrophil or eosinophil responses to repeated exposure to Aspergillus 
conidia, and the loss of TNFα in Aspergillus treated BALB/c mice caused a neutrophil-
to-eosinophil transition (266). This granulocyte switch observation was further 
corroborated in a model system of pulmonary inoculation with purified chitin (69). Chitin 
is a polysaccharide that elicts a CD4/8 T cell-independent, ILC2 allergic response (100), 
and depletion of IL-5+ ILC2 in chitin treated mice resulted in a compensatory increase in 
γδ T cell-driven neutrophil recruitment (69). Methodical examination of lymphocyte 
responses to bacterial and viral infections could reveal an equally interesting lymphocyte 
dynamic.  
In recent years, ILC have emerged as main players in a variety of processes, 
including maintenance of tissue homeostasis, inflammation, and tissue damage repair 
(284). The standard model for investigating the sufficiency of ILC to coordinate these 
processes involves the use a RAG -/- mouse and examination of the effect CD90 antibody 
depletion or use of Rag -/- IL-2Rγ -/- mice has on a defined outcome (69, 285-287). In 
the case of pulmonary cryptococcal infection, T cells, not ILC, are the main propagators 
of granulocyte responses. The inclusion of MHCII -/- mice in our comparisons revealed 
that T cells reign supreme. Perhaps, a lack of competition with other lymphocytes for 
shared growth factors, like IL-2 and IL-7, exaggerates the effect of ILC2 on driving 
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eosinophilia in Rag2 -/- models. With the emergence of methods to specifically ablate 
ILC (189, 288), a more accurate description of the roles  ILC have to play in 
inflammation may follow. 
Eosinophil and neutrophil responses are traditionally thought be induced by 
distinct IL-5 and IL-17 modules. While IL-5 is clearly required for eosinophilia, 
neutrophil responses are only partially dependent on IL-17. Additionally, the reciprocal 
switch from eosinophil dominated response to one dominated by neutrophils when IL-5-
producing lymphocytes were removed from the system led us to test the hypothesis that 
IL-5 also negatively regulates neutrophils. This hypothesis is supported by the 
observation of IL-5 receptor expression on neutrophils, as well as the IL-5 dose-
dependent loss of neutrophils in Th2 cell deficient infected mice. However, the definitive 
test of the hypothesis will come from studies using IL-5Rα -/- (289); wildtype mixed 
bone marrow chimeras to determine the cell-intrinsic effect of IL-5 on neutrophil 
inhibition. 
Allergic asthma is traditionally viewed as a type-2-driven eosinophilic disorder. 
However, neutrophils have an underappreciated role in allergic airway disease (290). IL-
17-induced neutrophil responses are paradigmatically credited for protection against 
fungal infections (52). While true in some cases, as evidenced by enhanced susceptibility 
to mucocutaneous candidiasis in humans with IL-17-deficiencies (291), there are 
instances where IL-17 responses to fungal infection are deleterious, particularly in the 
lungs (292). As a result, the protection afforded by IL-17 against some pathogens should 
be weighed in the context of IL-17-associated immunopathology. 
Next generation therapies will simultaneously utilize antimicrobials and immune 
modulators (104, 293). As a result, understanding the individual contributions of 
lymphocyte subsets informs important targets, predicts problematic compensation, and 
thereby, affords rational design of clinical interventions that modulate lymphocyte-
dependent granulocyte responses. Moreover, IL-5 blockade with FDA approved therapies 
raises the exciting possibility of shunting detrimental IL-5/eosinophilia towards more 
beneficial, balanced IL-17/neutrophil responses to pulmonary fungal infections.  
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MATERIAL AND METHODS: 
 
Host.  All mice used in this study were derived from a C57BL/6 background. 
B6.129P2(C)-Ccr7tm1Rfor/J, B6.PL-Thy1a/CyJ, B6.129S2-H2dlAb1-Ea/J, B6.129S7-
Rag1tm1Mom/J, B6.129S2(C)-Stat6tm1Gru/J, and B6.129S2-Tcratm1Mom/J mice were 
purchased from Jackson Laboratories (Bar Harbor, ME). C57BL/6-flt3Ltm1Imx and 
B10;B6-Rag2tm1Fwa II2rgtm1Wjl mice were purchased from Taconic. IL-17Rα -/- were 
provided by Amgen. Mice were housed in specific pathogen–free conditions and were 
fed ad labitum. 
Infection. 6-8 week old, sex-matched mice were anesthetized with pentobarbitol. 5x104 
Cryptococcus neoformans var. grubii (KN99α) cells in 25 µL of PBS were placed on the 
nares of each mouse, and the mice aspirated the inoculum into the lower respiratory tract. 
 
Treatments. Mice received 1 mg anti-IL-5 (TRFK5, Bio X Cell, West Lebanon, NH) or 
500 µg anti-CD4 (GK1.5, Bio X Cell) injected into the peritoneal cavity on -1, 5, and 10 
days post-infection. 
 
Leukocyte Preparation. Leukocytes were isolated from lung digests as previously 
described (222). For bone marrow cells, femurs were harvested from euthanized mice, 
pulverized in RPMI. ~250 µL of blood was collected from anesthetized mice via retro-
obrital bleeding. Red blood cells were lysed in whole blood and bone marrow by 
incubating the samples in ACK buffer for 15 minutes at room temperature. Cell solutions 
were filtered, washed several times, and resuspended in PBS staining buffer at 5x106 
cells/mL. For intracellular cytokine analysis, ~106 CD4+ T cells were suspended in 200 
µL of restimulation buffer (RPMI + 10% FBS + 1% penicillin/streptomycin + 5 µg 
brefeldin A) without (unstimulated) or with (stimulated) 10 ng phorbol myristate acetate 
(PMA) and 50 ng ionomycin. After 5 hours, the cells were washed and immediately 
prepared for flow cytometry. 
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Flow Cytometry. Samples were incubated for 15 minutes with CD16/32 antibody 
(Biolegend) and LIVE/DEAD Fixable Near Infrared stain (Invitrogen) to prevent 
nonspecific antibody binding, as well as mark dead cells. Samples were surface-stained at 
4°C for 30 minutes with the following antibodies: Granulocytes – CCR3 (J07E35, PE, 
Biolegend, San Diego, CA), Ly6G (1A8, PE-Cy7, Biolegend), CD11b (M1/70, BV650, 
eBioscience, San Diego, CA), CD11c (N418, PE-Cy5, eBioscience), Siglec F (E50-2440, 
PE, BD Biosciences, San Jose, CA), IL-5Rα (T21, FITC, BD Biosciences), CD45 (30-
F11, AF700, Biolegend), and Erithroid Cells (TER-119, Percp-Cy5.5, Biolegend); 
Lymphocytes – CD90.2 (30-H12, APC, Biolegend), CD4 (RM4-5, e450, eBioscience), 
CD8 (BV650, Biolegend), TCRβ (H57-597, PE-Cy7, Biolegend), TCRγδ (GL3, AF488, 
Biolegend), CD11b (M1/70, Percp-Cy5.5, Biolegend), CD11c (N418, Percp-Cy5.5, 
Biolegend), F4/80 (BM8, Percp-Cy5.5, Biolegend), CD49b (DX5, Percp-Cy5.5, 
Biolegend), Ly6G (1A8, Percp-Cy5.5, Biolegend), CD19 (6D5, Percp-Cy5.5, Biolegend), 
FcεRIα (MAR1, Percp-Cy5.5, Biolegend), CD161 (PK136, Percp-Cy5.5, eBioscience), 
and B220 (RA3-6B2, Percp-Cy5.5, eBioscience). When applicable, the cells were then 
incubated in Foxp3 Transcription Factor Buffer (eBioscience) at 4°C for 30 minutes.  The 
cells were labeled with antibodes against the following intracellular antigens: IL-5 
(TRFK5, PE, Biolegend) and IL-17A (BL168, BV605, Biolegend). For data acquisition, 
events from the entire sample (500,000-1,000,000) were collected on a BD FACSCanto 
II flow cytometer (BD Biosciences), and the data were analyzed with FlowJo X (Tree 
Star Inc., Ashland, OR).  
 
Lung Cytokines.  Lungs from naïve mice or mice 14-days post-infection were excised, 
snap frozen in liquid nitrogen, and homogenized in 3 mL of T-PER (Thermo Fisher 
Scientific) with Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN). 
Cytokines were quantified using Luminex technology according to manufacturer 
instructions (Bio-Rad, Hercules, CA). 
 
Statistics.  P-values for pairwise comparisions were by Mann-Whitney U with 
Bonferroni adjustments for multiple comparisons. Global tests were by Kruskal-Wallis 
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ANOVA. Power calculations were performed to assess appropriate sample size for all 
experiments. P-values ≤ 0.05 were considered statistically significant.  All statistics and 
graphs were processed with Prism 6 (GraphPad Software, La Jolla, CA). 
Study Aproval. All animal experiments were done in concordance with the Animal 
Welfare Act, U.S. federal law, and NIH guidelines. Mice were handled in accordance 
with guidelines defined by the University of Minnesota Institutional Animal Care and 
Use Committee (IACUC) protocol numbers 1010A91133 and 1207A17286.  
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Figure 1. Eosinophils express Siglec F and CCR3, not CD11c in the lungs. Leukocyte 
suspension collected from lung digests of uninfected C57BL6/J mice. Flow cytometric 
analysis showing alveolar macrophages (blue) or eosinophils (black) as a proportion of 
CD45+ TER119+ hematopoietic cells. Alv = alveolar, CCR3 = chemokine receptor 3. 
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Figure 2. Pulmonary eosinophil accumulation does not require lymph node priming. 
Wildtype, Fms-related tyrosine kinase 3 ligand (Flt3L) -/-, and chemokine receptor 7 
(CCR7) -/- mice were analyzed 14 days post-infection with Cryptococcus neoformans. 
Composite graph of eosinophil (black) and neutrophil (red) numbers from the lungs of 
infected mice. Pairwise comparisons were made by Man-Whitney U with Bonferoni 
adjustments for multiple comparisons. * = P<0.05 relative to wildtype. All data are 
presented as the mean ± standard error of the mean and represent 2 independent 
experiments. 
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Figure 3. Granulocyte Response to Pulmonary Fungal Infection. C57BL6/J mice 0-18 
days post-infection with Cryptococcus neoformans. Flow cytometric analysis (left) and 
composite graphs (right) showing granulocytes as a proportion of CD45+ TER119+ 
hematopoietic cells. (A) Siglec F+ CCR3+ eosinophils and CD11b+ Ly6G+ neutrophils 
contained in the bone marrow. (B) Siglec F+ eosinophils and Ly6G+ neutrophils from 
peripheral blood. (C) Siglec F+ CD11c- eosinophils and CD11b+ Ly6G+ neutrophils 
collected from lung digests. All data are presented as the mean ± standard error of the 
mean and represent 2 independent experiments. 
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Figure 4. Lymphocytes mediate eosinophil and neutrophil accumulation. 
Wildtype, Major histocompatibility (MHCII) -/-, Recombinase activating gene 2 (Rag2) -
/-, or Rag2 -/- Interelukin-2 receptor γ (IL-2Rγ) -/- mice 0 or 14 days post-infection with 
Cryptococcus neoformans. Flow cytometric analysis (left) and composite graphs (right) 
showing (A) CD90+ Lineage - lymphocytes. T cell receptor (TCR)β+ CD4+ helper T 
(Th) cell, TCRβ+ CD8+ T cells, γδ T cells, and TCRγδ- TCRβ- innate lymphoid cells 
(ILC) (B) Siglec F+ CD11c- eosinophils and CD11b+ Ly6G+ neutrophils as a proportion 
of CD45+ TER119+ hematopoietic cells collected from lung digests. Pairwise 
comparisons were made by Man-Whitney U with Bonferoni adjustments for multiple 
comparisons. * = P<0.05 relative to wildtype. All data are presented as the mean ± 
standard error of the mean and represent 2 independent experiments. Lineage = B220, 
CD11b, CD11c, CD19, CD49b, CD161, F4/80, FcεRIα. 
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Figure 5. Eosinophils are produced early, not late, in MHCII -/- infected mice. 
MHCII -/- mice 0-14 days post-infection with Cryptococcus neoformans. Flow 
cytometric analysis (left) and composite graphs (right) showing granulocytes as a 
proportion of CD45+ TER119+ hematopoietic cells. (A) Siglec F+ CCR3+ eosinophils 
and CD11b+ Ly6G+ neutrophils contained in the bone marrow. (B) Siglec F+ eosinophils 
and Ly6G+ neutrophils from peripheral blood. (C) Siglec F+ CD11c- eosinophils and 
CD11b+ Ly6G+ neutrophils collected from lung digests All data are presented as the 
mean ± standard error of the mean and represent 2 independent experiments. 
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Figure 6. IL-5 positively regulates eosinophils and inhibits neutrophils. Wildtype, 
Major Histocompatibility Class II (MHCII) -/-, and Interleukin-17 receptor α (IL-17α) -/- 
mice were left unifected (naïve) or infected with Cryptococcus neoformans. Lungs were 
harvested 14 days post-infection and analyzed. (A) Cytokines measured in naïve wildtype 
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mice, as well as infected wildtype and MHCII -/- mice. (B) Eosinophils (black) and 
neutrophils (red) from wildtype mice, wildtype mice treated with anti-IL-5 antibody 
(TRFK), and IL-17Rα -/- mice. (C) IL-5Rα expression on pulmonary CD90+ Lineage- 
lymphocytes or neutrophils in the bone marrow, blood, and lungs. (D) Eosinophils 
(black) and neutrophils (red) quantified from IL-5 treated MHCII -/- , as wells as 
untreated wildtype and MHCII -/- mice. Pairwise comparisons were made by Man-
Whitney U with Bonferoni adjustments for multiple comparisons. * = P<0.05 relative to 
wildtype. All data are presented as the mean ± standard error of the mean and represent 2 
independent experiments. G-CSF = granulocyte-colony stimulating factor.  
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Figure 7. Lymphocyte subset definition by intracellular cytokine detection. 
Wildtype, Major histocompatibility (MHCII) -/-, Signal transducer and activator 6 
(STAT6) -/-, T cell receptor α (TCRα) -/-, Recombinase activating gene 2 (Rag2) -/-, or 
Rag2 -/- Interelukin-2 receptor γ (IL-2Rγ) -/- mice 14 days post-infection with 
Cryptococcus neoformans. Flow cytometric analysis (top) and composite graphs (bottom) 
showing interleuking (IL)-5 or IL-17A production by CD90+ Lineage – lymphocytes: 
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TCRβ+ CD4+ helper T (Th) cell, TCRβ+ CD8+ T cells, γδ T cells, and TCRγδ- TCRβ- 
innate lymphoid cells (ILC). Pairwise comparisons were made by Man-Whitney U with 
Bonferoni adjustments for multiple comparisons. * = P<0.05 relative to wildtype. All 
data are presented as the mean ± standard error of the mean and represent 2 independent 
experiments. Lineage = B220, CD11b, CD11c, CD19, CD49b, CD161, F4/80, FcεRIα. 
αCD4 indicates anti-CD4 antibody (GK1.5) treatment. 
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Figure 8. Granulocyte responses detected in lymphocyte deficient mice. Signal 
transducer and activator 6 (STAT6) -/-, T cell receptor α (TCRα) -/-, Recombinase 
activating gene 2 (Rag2) -/-, or Rag2 -/- Interelukin-2 receptor γ (IL-2Rγ) -/- mice 14 
days post-infection with Cryptococcus neoformans. Flow cytometric analysis (left) and 
composite graphs (right) showing granulocytes as a proportion of CD45+ TER119+ 
hematopoietic cells. (A) Siglec F+ CCR3+ eosinophils and CD11b+ Ly6G+ neutrophils 
contained in the bone marrow. (B) Siglec F+ eosinophils and Ly6G+ neutrophils from 
peripheral blood. (C) Siglec F+ CD11c- eosinophils and CD11b+ Ly6G+ neutrophils 
collected from lung digests. αCD4 indicates anti-CD4 antibody (GK1.5) treatment.   
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Figure 9. Neutrophil polarization is detrimental. Survival curve includes 10 mice per 
group. P-value calculated by log rank test. STAT6 = signal transducer and activator 6.  
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Figure 10. Model of lymphocyte competition and granulocyte regulation. Eos = 
eosinophil, G-CSF = granulocyte-colony stimulating factor, IL = interleukin, ILC = 
innate lymphoid cell, Neu = neutrophil, Tc = CD8+ T cell, Th = helper T cell.  
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Table 1. Summary of Lymphocyte and Granulocyte Responses to Pulmonary 
Fungal Infection. 
 
 TH2 ILC2 TH17 ILC3 Tc17 γδ T Outcome 
WT +(***) + (**) + (*) + (*) + (*) + (*) Eos 
MHCII -/- − + (*) − + (*) +(***) + (*) Neu 
STAT6 -/- − − +(***) + (*) + (*) + (*) Neu 
STAT6 -/- + αCD4i − − − + (*) +(***) + (*) Neu 
TCRα -/- − + (*) − + (*) − +(***) Neu 
Rag1 -/- − +(***) − + (*) − − Eos 
Rag2 -/- IL-2Rγ -/- − − − − − − Neu 
 
+/- = present/absent 
*<*** = relative amount of lymphocyte subset 
i αCD4 = antibody depletion of CD4+ Th cells 
Eos = eosinophil, Neu = neutrophil
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CONCLUDING REMARKS 
 
Research Summary 
Cryptococcus neoformans is a fungal pathogen that infects greater than one 
million people per annum and is the most common cause of lethal meningitis worldwide. 
Upon inhalation, C. neoformans establishes a pulmonary infection that eventually 
disseminates to the central nervous system to cause cryptococcal meningitis. Persons with 
CD4 T cell deficiencies are at high risk of developing cryptococcal meningitis. However, 
not all immunodeficient individuals with pulmonary cryptococcosis acquire cryptococcal 
meningits. Moreover, people with infections that progress to meningitis exhibit a wide 
range of clinical outcomes after effective antifungal therapies. These include full 
recovery, relapse infection, paradoxical reaction to latent antigen, or death. The varying 
quality of the CD4 T cell response is a likely explanation, but the exact cause of this 
clinical heterogeneity is currently unknown. In this dissertation, I provide a 
comprehensive investigation of fungal intrinsic factors and host determinants that 
influence the induction, suppression, and downstream consequences of Th2-mediated 
fungal disease (Figure 1). 
I investigated the association between cryptococcal strain genotype and virulence 
of isolates collected from a cohort of HIV/AIDS patients with cryptococcal meningitis. 
Using multilocus sequence typing, I demonstrated that patients infected with 
evolutionarily related strains were shown to have similar disease presentation and 
outcome. I developed an ex vivo assay using  cryptococcal antigens and found  that 
virulent genotypes elicited type-2 characteristic immune responses. Contrary to the 
dogma that the genetics of the host determines their response to infection, these data 
show that the genotype (and subsequent phenotype) of the infecting cryptococcal strain 
also has profound affects on the host response to infection and ultimately outcome of 
disease. Thus, endogenous (host) and exogenous (pathogen) factors contribute 
concurrently to disease and need to be taken into account during disease treatment. 
I used a mouse model of pulmonary infection with the fungal pathogen C. 
neoformans to better understand lymphocyte responses to fungal infection. Upon 
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inhalation, C. neoformans establishes a robust lung infection that disseminates and 
ultimately leads to mortality. To differentiate T cell responses to the C. neoformans 
infection from non-specific T cell responses, I created a reagent that enables 
identification of T cells with C. neoformans-specific receptors. Infection with C. 
neoformans resulted in a progressive accumulation of antigen-specific T cells in the lungs 
that produced molecules associated with Th2 cells, but not Th1 or Th17 cells. To 
understand whether these Th2 cells responding to pulmonary fungal infection are a cause 
or consequence of disease severity, I specifically induced expansion of the Th2 cells. 
Mice with increased numbers of Th2 cells had greatly reduced survival time compared to 
control infections or uninfected mice. These data show that Th2 cells directly cause 
fungal disease. 
My findings alter a longstanding paradigm, where susceptibility to lethal fungal 
disease is traditionally viewed as a breakdown in protective immunity. This idea is 
supported by the higher prevalence of invasive fungal disease in immunosuppressed 
individuals, including people living with HIV/AIDS, cancer patients undergoing 
chemotherapy, and solid organ transplant recipients. However, I propose that in addition 
to the lack of a protective immune response, independent development of a harmful Th2 
cell response further exacerbates disease. 
While pathologic Th2 cells are generated during fungal infection, how Th2 cells are 
induced remained unknown. One aim of my thesis project was to delineate the pathway 
of Th2 cell induction during pulmonary fungal infection. A forward genetic screen in 
mice allowed me to identify a specific subset of lung resident dendritic cells (DC) as the 
dominant antigen-presenting cell for Th2 cell induction. Existing evidence shows that 
these lung resident DC are capable of inducing both Th17 and Th2 cell responses; 
therefore, this DC subset is not inherently programmed to specify a single Th cell lineage 
during pulmonary fungal infection. Consequently, determination of Th2 cell fate by lung 
resident DC requires higher order detection of specific features of the infection (e.g. 
pattern recognition). 
Since parasites and fungi elicit Th2 cell responses, I hypothesized that chitin, a 
molecule produced by both organisms, leads to Th2 cell production. To explore the role 
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of chitin in Th2 cell production, I exploited a natural property of C. neoformans based on 
previous descriptions of thickened cell walls in titan cells. Since chitin is a prominent 
component of the fungal cell wall, I compared chitin content of typical sized cells and 
titan cells. In fact, titan cells had more chitin, at a higher density, in the cell wall. Using 
various C. neoformans mutants, I found chitin abundance, not cell size influenced Th2 
cell accumulation and disease severity. Next, I tested whether purified chitin was 
sufficient to increase Th2 cells. I treated infected mice with chitin particles, and this 
expanded the Th2 cell response. Therefore, chitin promotes Th2 cell accumulation during 
fungal infection. Chitin is a defining structural feature of all fungal cells , thus this 
mechanism of chitin-induced inflammation could potentially explain disease associated 
with an entire kingdom of pathogens. 
I next investigated how the host responds to chitin and influences detrimental Th2 
cell responses to fungal infection. Chitin is found deep within the fungal cell wall, thus 
chitin is not readily available to host surveillance. Enzymes that degrade chitin, termed 
chitinases, are a pivotal component of host recognition of chitin-containing organisms. 
Mammals encode two functional chitinases, chitotriosidase-1 (Chit1) and acidic 
mammalian chitinase. I determined that both enzymes are abundantly produced in 
response to pulmonary fungal infection. However, infection of mice with separate genetic 
deletions in each of these enzymes revealed that only Chit1 was necessary during 
cryptococcal infection for Th2 cell induction and subsequent disease. Furthermore, I used 
chitin particles and highly purified chitin fragments to understand the effect of Chit1-
mediated enzyme degradation of chitin on Th2 cell accumulation. Though Chit1-deficient 
mice were resistant to the effects of chitin particles, the mice had a robust increase of Th2 
cells in response to small chitin fragments. Therefore, Chit1 degradation of chitin is an 
early step in the host response, resulting in the production of chitin fragments that 
promote Th2 cell development. 
My thesis also addressed whether the host has evolved ways to counterbalance the 
detrimental Th2 cell response. One suppressive mechanism could be Treg cells. I 
determined that Treg cells represent a large proportion of the T cell repertoire in the lungs 
of mice infected with C. neoformans. I further showed that Treg cell induction occurs 
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outside the thymus and Treg cells accumulate in proximity to Th2 effector cells in the 
lung parenchyma. I additionally demonstrated that Treg cells utilize a Th2 transcription 
factor to drive expression of chemokine receptors, which allows the Treg cells to 
colocalize with and suppress detrimental Th2 effector cells. Collectively, these data 
provide a logical connection between the hitherto disjointed observations of 
extrathymically induced Treg cells, chemokine-mediated localization, and Th2-specific 
inhibition. 
Eosinophils are normally associated with allergic airway disease, and neutrophils 
assist in protection against fungal infections like candidiasis and aspergillosis. The 
immune response to cryptococcal infection elicits a striking accumulation of eosinophils 
in the lungs of infected mice. The last chapter of my thesis focused on lymphocyte 
regulation of eosinophil and neutrophil responses to pulmonary cryptococcal infection 
with the goal of understanding how this eosinophil response could be diminished. I 
showed lymphocytes are required for the IL-5 production that stimulates eosinophil 
differentiation in the bone marrow and recruitment to the lung. Furthermore, Th2 cells 
were the dominant source of IL-5, and ILC2 could only produce sufficient IL-5 to induce 
eosinophilia in the absence of other lymphocyte subsets. Th17 cells, IL-17-producing 
CD8+ T cells, γδ T cells, and ILC3 produced IL-17A in situations where Th2 cells were 
lacking, and lymphocyte expression of IL-17A correlated with neutrophilia in 
cryptococcal infected mice. Although neutrophils were dependent on IL-17A, IL-17A 
was not fully required for neutrophils to accumulate in the lungs. The eosinophil-to-
neutrophil switch in the absence of IL-5 and the abundant expression of IL-5R on 
neutrophils led to the hypothesis that IL-5 negatively regulates neutrophils. Treatment of 
mice experiencing neutrophilia with exogenous IL-5 caused a dose-dependent reduction 
in neutrophils in the lungs, which affirmed the hypothesis. Taken together, a complex 
network of lymphocytes governs eosinophil and neutrophil accumulation in the lungs of 
infected mice through the production of IL-5 and IL-17A. 
In conclusion, I have elucidated a complete mechanism for how fungal pathogens 
and host immune responses both contribute to cause disease. Upon fungal exposure, 
mammalian chitinases enzymatically digest full-length fungal chitin to produce chitin 
   153 
fragments, and this leads to potent induction of pathologic Th2 cells. Furthermore, the 
host attempts to mitigate these detrimental effects by producing Treg cells that are 
induced and retained in the lungs. Finally, Th2 cells and other lymphocytes engage in 
fierce competition to drive eosinophil or neutrophil accumulation in the lungs. 
 
 
Future Directions 
Chitin receptor – I have identified chitin as an important fungal PAMP that is recognized 
by mammalian immune system. Moreover, my work and others showed that chitin 
promotes type-2 immunity (100). Yet, I failed to determine how this signal can be 
recognized by the host. Identification of the chitin receptor in mammals could go a long 
way in targeted therapies aimed at alleviating the allergic responses associated with chitin  
exposure.   
Plants and animals are similarly confronted with the challenge of preventing 
fungal infection. Fungal diseases in plants affect millions of people and cost hundreds of 
billions of dollars per year due to famine and crop loss (294). As a result, plant 
pathologists have intensely investigated host-pathogen interactions between plants and 
fungi. The outer surface of microbes often contains the first exogenous molecules that 
contact immune recognition components. The fungal cell wall contains mannans, 
glucans, and chitin (295). Each of these molecules is recognized by the plant immune 
system as a pathogen/microbe-associated molecular pattern (296). The pathways 
describing mannan and glucan recognition are well understood in both plants and animals 
(297). However, mammalian immunologists can learn from decades of plant research on 
mechanisms for host recognition of chitin.  
The chitin receptor is known in plants (298, 299). Chitin-elicitor binding protein 
(CERK1) is composed of a Lysin motif (LysM) and a receptor-like kinase domain 
(RLK). Upon ligation with a chitin oligomer, CERK1 forms a homodimer (182). The 
dimerization initiates a signaling cascade and results in anti-fungal immunity. The RLK 
domain is unique among plants so comparative genome searches do not identify a 
homologous receptor in mammals. However, the LysM ectodomain is highly conserved 
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across kingdoms (300). A mammalian chitin receptor could have several components in 
common with the plant chitin receptor. Systematic and reductionist approaches could be 
used to identify the elusive mammalian receptor for chitin. 
 
Non-lymph node priming in BALT - I observed that Treg and Th2 cells are induced in 
substantial quantities during cryptococcal infection, even in the absence of CCR7-
mediated entry of naïve Th cells into the MLN or Flt3L-dependent dendritic cell priming 
in lymph nodes (222). This begs the question as to the precise location of T cell priming 
during cryptococcal infection. Bronchus-associate lymphoid tissue (BALT) is comprised 
of stochastically distributed clusters of lymphocytes in proximity to high endothelial 
venules and tissue-resident dendritic cells (301). These structures exist under homeostatic 
conditions and readily increase in size and number (known as “inducible” BALT) in 
individuals with chronic inflammatory conditions (302, 303).  
BALT sufficiently supports T cell priming in the absence of canonical lymphoid 
responses (304, 305). It is plausible that the BALT is responsible for T cell priming to 
cryptococcal infection. Fungi may not freely diffuse through the lymphatics to reach the 
lymph nodes due to the relatively large size of individual fungal cells. Consequently, 
during  early cryptococcal infection in mice, an overwhelming majority of antigen is 
contained in the lungs. The lung is a high blood flow organ so circulating naïve Th cells 
have consistent access to the depot of cryptococcal antigen. Naïve Th cells could be 
coaxed into the lungs via high endothelial venules in a chemokine/integrin-mediated 
process, and the BALT could direct naïve Th cell activation, proliferation, and 
differentiation. 
 
Mechanism of Treg cell suppression by IL-2 starvation – Treg cells are required for the 
suppression of Th2 cells in this model of pulmonary cryptococcal infection. However, the 
mechanism of Treg cell-mediated  suppression is unknown. IL-10 production by Treg 
cells is a well-known pathway by which Treg cells inhibit pulmonary Th cell responses 
(306). IL-10 signaling reduces the proliferative potential of Th cells (307), as well as 
amplifies the suppressive potency of Treg cells (308). However, IL-10 blockade had 
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minimal impact on Th2 cell responses to cryptococcal infection. Previous studies have 
shown IL-10-independent Treg cell suppression of effector Th cells involves close 
contact (309). Thus, mechanistically, the colocalization of Treg cells with effector Th2 
cells during cryptococcal infection is an important observation, and the ability of Treg 
cells to inhibit effector Th cell niches affords unique functional opportunities.  
Perhaps, the most interesting regulatory pathway concerns the potential ability of 
Treg cells to mediate suppression by starving Th cells of local growth factors. In 
particular, Treg cells scavenge IL-2 via their high affinity IL-2 receptor (310). This 
competition limits IL-2 growth factor availability and restricts Th cell proliferation (311). 
There is some evidence to suggest this might occur in the context of pulmonary 
cryptococcal infection. First, IL-2 complexes administered to infected mice massively 
augment Th2 cell accumulation (222). Thus, IL-2 is not only an important signal for Th2 
cell proliferation, but IL-2 is also recognized as a limited resource in this setting. 
Additionally, Signal Transducer and Activator 6 (STAT6) and IRF4 are each individually 
required for Th2 cell generation during cryptococcal infection (unpublished 
observations). However, the requirement for these transcription factors can be bypassed 
by treating infected knockout mice with IL-2 complexes (unpublished observations). 
Local IL-2 starvation by Treg cells leading to Th2 cell suppression is an intriguing, but 
still untested hypothesis in this model of pulmonary fungal infection. 
 
 
Significance 
Pulmonary fungal diseases are an enormous economic burden and global health 
threat. Chronic and subclinical infections, as well as repeated, low level exposures of 
environmental fungi evoke asthma and allergy in a multitude of otherwise healthy 
individuals. In addition, billions of dollars are spent annually to prevent or treat invasive 
fungal infections that affect millions of immunosuppressed people. Combined, most 
people worldwide are susceptible to mycoses. Current therapies and prophylaxes are 
expensive, ineffective, and consequently, unsustainable. Improvement of these remedies 
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is limited by our incomplete understanding of the how host responses to pulmonary 
fungal pathogens trigger type-2 immune responses. 
CD4+ Helper T (Th) cells are central mediators of the host response to fungal 
exposure. Th cell subsets coordinate both protective and detrimental responses to fungal 
pathogens. Th1 and Th17 responses protect against fungal disease, yet many fungi elicit 
pathologic Th2 responses that cause asthma/allergy. The cellular and molecular 
mechanisms underlying this Th2 cell polarization during pulmonary fungal exposure are 
not well defined.  
 My investigations of Th2 cell responses to cryptococcal infection aim to 
overcome this critical gap in fundamental knowledge. Moreover, my findings suggest 
that blocking chitin recognition, promoting Treg suppression of Th2 cells, and 
manipulating lymphocyte subsets to balance eosinophil and neutrophil responses could be 
fruitful avenues of therapeutic intervention in patients experiencing fungal disease. 
Collectively, this information could guide the development of novel treatment strategies 
that attempt to reduce Th2 cell-mediated disease in response to fungal encounters. 
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Figure 1. Model of Th2-mediated Cryptococcal Disease. CCR, chemokine receptor; 
cDC, classical dendritic cell; Foxp3, forkhead box P3; gd T cell, gamma delta T cell; 
ILC, innate lymphoid cell; IRF4, interferon regulatory factor 4; IL, interleukin; Treg, 
regulatory T cell; Tc17, CD8+ IL-17A+ T cell; Th, helper T cell; TSLP, thymic stromal 
lymphopoietin;
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What is Cryptococcus? 
 
Cryptococcus is a yeast that is surrounded by a thick coating of polysaccharides, called a 
capsule. For this reason Cryptococcus is often referred to as “the sugar yeast”. 
 
A sugar yeast?! Sounds great for making beer, bread and wine! 
 
No, that’s not Cryptococcus. “Yeast” is a catch-all term for any single-celled fungus, so 
many unrelated fungi can be called yeasts. The common kitchen yeast exploited by 
humankind for millennia to ferment the sugars in food into alcohol and CO2 is actually 
Saccharomyces cerevisiae, an ascomycete. The Cryptococcus species were initially 
misclassified as Saccharomyces when two scientists independently discovered the fungus 
at the end of the 19th century. Sanfelice, a Sardinian, serendipitously isolated yeasts from 
aging peach juice. Yet his discovery was not the early precursor to the Bellini cocktail, 
because the German scientist Busse simultaneously isolated the encapsulated yeast from 
a patient presenting with an unknown mycosis. Cryptococcus is actually a basidiomycete 
yeast, more closely related to the mushrooms on your pizza than the yeast used to leaven 
the crust or to ferment the beer you drink with it. The early work by Busse suggesting 
that Cryptococcus could be a novel fungal pathogen were confirmed by subsequent 
animal pathogenesis experiments proving Koch’s postulates that set the foundation for a 
century of productive research. 
 
 
Thick hair, tanned flesh, buxom body, and a robust libido… a 21st century popular 
icon? 
 
The above description is surprisingly not referring to the latest reality TV star. These 
traits in fact represent known virulence factors of Cryptococcus, such as: polysaccharide 
capsule, melanin, cell enlargement, and sexual reproduction. The thick sugary 
polysaccharide capsule allows the yeast to evade the host immune response by resisting 
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cellular uptake and subsequent degradation by phagocytes. Polysaccharide that has 
dissociated from the cell also inhibits T cell and cytokine responses, and this curious 
property has prompted investigation into using purified Cryptococcus capsule as a 
potential therapy for some forms of autoimmunity. Embedded in the cell wall directly 
below the sugar coat resides a pigment, melanin, that is capable of scavenging oxygen 
radicals deployed by host cells, thereby preventing oxidative damage and promoting 
survival inside phagocytes. The pigment can also bind to conventional fungicides and 
reduce drug efficacy. When the yeast is growing in the environment, melanin confers a 
fitness advantage by permitting the fungus to grow at wide temperature ranges, survive in 
high concentrations of toxic metals, and resist ionizing radiation. Cryptococcus also 
forms gigantic cells dubbed “titan cells” that are too large for phagocytes to engulf, are 
able to protect normal cryptococcal cells from the host immune response, and play a key 
role in establishment of disease. Finally, one of the sexes (the α mating type) is more 
prevalent in both the environment and the clinic. The α cells are bisexual – not only do 
they undergo heterosexual mating with the opposite mating type, but they are also 
homosexual, able to propagate by same-sex mating. These traits collectively distinguish 
Cryptococcus from other human pathogens. 
 
Can Cryptococcus make you sick? 
 
Yes and no. Cryptococcus is found in the environment, in and on things we are exposed 
to often. Been to a city park? You’ve probably been exposed to Cryptococcus. 
Cryptococcus can live in pigeon droppings, in soil, on trees, and in other environmental 
reservoirs not yet fully defined. Normally, your immune system fights the cryptococcal 
infection and you may never know you have been exposed. But… Cryptococcosis is 
recognized as an emerging infectious disease. Cryptococcus gattii is capable of infecting 
and causing disease in otherwise healthy individuals. More than 200 people have 
acquired C. gattii infections in the North American Pacific Northwest in an outbreak that 
is spreading south down the Pacific coast. In addition, Cryptococcus neoformans 
significantly burdens immunocompromised populations - mainly solid organs transplant 
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patients and persons living with HIV/AIDS. More than 1 million new cases of C. 
neoformans are reported annually in persons infected with HIV, and even with the 
availability of anti-retroviral and anti-fungal therapies, the rate of survival is less than 
40%. Cryptococcal meningitis has surpassed tuberculosis as the most lethal opportunistic 
infection of AIDS patients in Africa. Roughly half the people that survive this meningitis 
are often confronted with additional complications during immune recovery. Patients can 
experience a clinical relapse of aseptic meningitis and non-central nervous system 
inflammation that can result in death. By and large, the general public need not fear 
infection, but cryptococcosis remains an important public health concern in specific 
regions of the world.  
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Figure 1. Micrograph of Cryptococcus cells stained with india ink. The 
polysaccharide capsule is visible as a zone of clearing around the cell body. Two normal 
sized cryptococcal cells have been phagocytosed by host cells. In contrast, the titan cells 
are too large to be phagocytosed. 
